company_name,website_timestamp,preclinical_stage,drug_molecule,target,therapeutic_area,target_type,development_stage,small_molecules,small_molecules_keyword,small_molecules_source_url,peptides,peptides_keyword,peptides_source_url,proteins,proteins_keyword,proteins_source_url,antibodies,antibodies_keyword,antibodies_source_url,antibody_conjugates,antibody_conjugates_keyword,antibody_conjugates_source_url,fusion_proteins,fusion_proteins_keyword,fusion_proteins_source_url,nucleic_acid_therapeutics,nucleic_acid_therapeutics_keyword,nucleic_acid_therapeutics_source_url,gene_cell_therapies,gene_cell_therapies_keyword,gene_cell_therapies_source_url,vaccines,vaccines_keyword,vaccines_source_url,protein_degraders,protein_degraders_keyword,protein_degraders_source_url,other_modalities,other_modalities_keyword,other_modalities_source_url
foundation for health research and training in the region of murcia,"Error: Connection failed - HTTPSConnectionPool(host='www.nanemiar.eu', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
national center for research resources,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",Yes,Zolgensma; Evrysdi; Spinraza; AIT-102; WNTinib; MTX-531; TRC102; TAK-243; PEPDG278D; ATX101; hJAA-F11; STEAP1,"SMN1, Survival Motor Neuron 1; SMN2, Survival Motor Neuron 2; PI3K, Phosphoinositide 3-kinase; EGFR, Epidermal Growth Factor Receptor; CTNNB1, Catenin Beta-1; HER2, Human Epidermal Growth Factor Receptor 2; GPC2, Glypican-2; STEAP1, Six Transmembrane Epithelial Antigen of Prostate 1",neurology; oncology,enzyme; other; other; other; other; other; other; other,Approved; Phase 2; Preclinical,Yes,Small Molecules,https://techtransfer.cancer.gov/investigators/research-tools,Yes,Peptides/Proteins,https://techtransfer.cancer.gov/investigators/research-tools,Yes,Peptides/Proteins,https://techtransfer.cancer.gov/investigators/research-tools,Yes,Antibodies,https://techtransfer.cancer.gov/investigators/research-tools,No,,,No,,,Yes,Nucleic Acids/Vectors,https://techtransfer.cancer.gov/investigators/research-tools,No,,,No,,,No,,,No,,
the scripps research institute,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
instituto de investigacion sanitaria marques de valdecilla,"Error: Connection failed - HTTPSConnectionPool(host='es.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
fondazione telethon,2022-03-30 00:00:00,Yes,etuvetidigene autotemcel; AAVB-081; AAVB-039,"NKCC1, Sodium-Potassium-Chloride Cotransporter 1; ABCA4, ATP-Binding Cassette Subfamily A Member 4; WAS gene",rare diseases; brain disorders; inherited retinal disorders; immunology,ion channels; other; other,Preclinical; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,advancing gene therapy,https://www.fondazionetelethon.it/en/,No,,,No,,,No,,
indian council of medical research,Error: Connection failed - HTTPSConnectionPool(host='www.indiascienceandtechn,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,drug research (including traditional remedies),https://in.linkedin.com/company/icmrorganization,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"research on specific health topics like tuberculosis, leprosy, cholera and diarrhoeal diseases, viral diseases including AIDS, malaria, kala-azar",https://in.linkedin.com/company/icmrorganization,No,,,Yes,"food & drug toxicology, reproduction, immuno-haematology, oncology",https://in.linkedin.com/company/icmrorganization
fundacio institut d''investigacio en ciencies de la salut germans trias i pujol,"Error: Connection failed - HTTPSConnectionPool(host='es.linkedin.com', port=4",Yes,VPM1002; MTBVAC,Not specified,infectious diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"During the preclinical stage, the Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), a strategic project of the Germans Trias i Pujol Research Institute (IGTP), supported the project by providing its expertise and high-risk biosafety infrastructure for the evaluation of the vaccine using comparative models.",https://es.linkedin.com/company/igtp,No,,,No,,
cellular biomedicine group inc,Error: Connection failed - HTTPSConnectionPool(host='www.oncologypipeline.com,Yes,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR-T and TIL therapies,https://www.abelzeta.com/,No,,,No,,,No,,
cellular biomedicine group ltd,Error: Connection failed - HTTPSConnectionPool(host='www.oncologypipeline.com,Yes,Tafasitamab,"CD19, Cluster of Differentiation 19",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"CAR-T​ Chimeric Antigen Receptor (CAR)-T Cell, Tumor Infiltrating Lymphocytes (TIL)",https://www.abelzeta.com/,No,,,No,,,No,,
palisade bio inc,2025-10-16 00:00:00,Yes,PALI-210,Not specified,gastrointestinal disorders,Not specified,Clinical,Yes,"PALI-2108, our first-in-class, ileocolonic-targeted PDE4 B/D inhibitor",https://www.linkedin.com/company/palisadebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"palisade bio, inc",2025-10-16 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"PALI-2108, our first-in-class, ileocolonic-targeted PDE4 B/D inhibitor",https://www.linkedin.com/company/palisadebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunotech biopharm ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,CAR-T-19 Injection,"CD19, Cluster of Differentiation 19",oncology,immune checkpoint,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,immune cell products for treatments of cancers; chimeric antigen receptor T (CAR-T) cell product pipeline,https://www.cnbc.com/quotes/6978-HK,No,,,No,,,No,,
mirror biologics inc,"Error: Connection failed - HTTPSConnectionPool(host='srfc.law', port=443): Ma",No,AlloStim,Not specified,oncology; infectious diseases; aging-related diseases,other,Phase 3,No,,,No,,,No,,,Yes,monoclonal antibody-coated microparticles,https://www.linkedin.com/company/mirror-biologics-inc,No,,,No,,,No,,,Yes,"non-genetically manipulated, living immune cell therapies",https://www.linkedin.com/company/mirror-biologics-inc,Yes,pan-viral vaccine to prevent elderly adults from any type of respiratory viral infection,https://www.mirrorbio.com/,No,,,Yes,living immune cells as active ingredients,https://www.linkedin.com/company/mirror-biologics-inc
shanghai bioray laboratory inc,2025-08-29 06:05:25,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,Yes,ROR1-Targeting Dual-Epitope ADC,https://www.linkedin.com/company/bioraypharm,No,,,No,,,No,,,No,,,No,,,No,,
estrella biopharma inc,2023-10-02 00:00:00,Yes,EB103; EB104; CF33-CD19t,"CD19, Cluster of Differentiation 19; CD22, Cluster of Differentiation 22",oncology; autoimmune diseases,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors,https://www.winston.com/en/experience/estrella-biopharma-inc-closes-business-combination-with-tradeup-acquisition-corp-68701101,No,,,No,,,No,,
athenex inc,2022-09-11 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule or Orascovery business,https://www.wgrz.com/article/money/business/athenex-assets-sold-in-bankruptcy-auction-top-executives-dismissed/71-9cbc0f76-6419-4d03-bb6b-1c482de85ac6,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
23 century clinic,2025-10-16 05:36:35,Yes,Capivasertib; Tusamitamab ravtansine; Zenocutuzumab; Zolbetuximab; Revumenib; Denileukin diftitox; Icotrokinra,"AKT, Protein Kinase B; CEACAM5, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; NRG1, Neuregulin 1; Claudin 18.2; KMT2A, Lysine Methyltransferase 2A; IL-2 Receptor; IL-23, Interleukin-23",oncology; hematology; immunology; gastrointestinal diseases,kinases; other; other; other; other; cytokine; cytokine,Approved; Phase 2; Phase 1/2; Phase 3; Phase 1/2; Phase 3; Phase 2,No,,,No,,,No,,,Yes,antibody,https://23chealthcare.com/,No,,,No,,,No,,,Yes,"stem cell therapy, MCAR-T Cells, MCAR-NK cell therapies",https://23chealthcare.com/,No,,,No,,,Yes,"immune cell engagers, advanced immune cell therapy technology",https://23chealthcare.com/
nexcella inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cirm.ca.gov', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,chimeric antigen receptor T-cell (CAR-T) therapy,https://www.cgtlive.com/view/immix-nexcella-make-progress-us-trial-light-chain-amyloidosis-car-t-nxc-201,No,,,No,,,No,,
targazyme inc,"Error: Connection failed - HTTPSConnectionPool(host='www.targazyme.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small molecule products (TZ101 and TZ102),https://www.linkedin.com/company/targazyme,No,,,Yes,clinical-grade fucosyltransferase enzymes,https://www.linkedin.com/company/targazyme,No,,,No,,,No,,,No,,,Yes,"cell therapy, gene therapy",https://www.linkedin.com/company/targazyme,No,,,No,,,No,,
shenzhen pregene biopharma co ltd,2022-04-06 08:30:00,No,CD19/CD22-targeted CAR-T therapy,"CD19, Cluster of Differentiation 19; CD22, Cluster of Differentiation 22",oncology,immune checkpoint,Preclinical,No,,,No,,,No,,,Yes,single domain antibody-based anti-BCMA chimeric antigen receptor T cell (CAR-T) program,https://www.prnewswire.com/news-releases/pregene-enters-into-innovative-partnership-with-cellpoint-to-develop-anti-bcma-car-t-cell-therapy-in-europe-and-the-us-301518944.html,No,,,No,,,No,,,Yes,CAR-T cell therapy,https://www.prnewswire.com/news-releases/pregene-enters-into-innovative-partnership-with-cellpoint-to-develop-anti-bcma-car-t-cell-therapy-in-europe-and-the-us-301518944.html,No,,,No,,,No,,
biotherapy services ltd,2025-09-24 00:00:00,No,CT-P13; SB2; SB4; ABP 501; GP2015; ABP 215; BCD-021; PF-06439535; RPH-001; BCD-022; CT-P6; FTMB/ABP 980; PF-05280014,"TNF-alpha, Tumor Necrosis Factor-alpha; VEGF, Vascular Endothelial Growth Factor; HER2, Human Epidermal Growth Factor Receptor 2",oncology; chronic inflammatory diseases,cytokine; other,Approved; Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Regenerative biological therapies,https://www.foresight.group/news/innovative-biopharmaceutical-company-biotherapy-services-ltd-secures-30-million-investment-from-foresight
carsgen therapeutics ltd,2025-08-14 20:15:00,Yes,Zevor-cel; Satri-cel; CT071; CT011; CT0590; CT0596; KJ-C2219; KJ-C2320; KJ-C2114; KJ-C2526,"BCMA, B-cell Maturation Antigen; Claudin18.2, Claudin18.2; GPRC5D, G-protein Coupled Receptor Class 5 Member D; GPC3, Glypican-3; BCMA, B-cell Maturation Antigen; BCMA, B-cell Maturation Antigen; CD19/CD20, Cluster of Differentiation 19 and 20; CD38, Cluster of Differentiation 38; Undisclosed; NKG2DL, Natural Killer Group 2 Member D Ligand",oncology; hematologic malignancies; solid tumors; autoimmune diseases,immune checkpoint; other; gpcr; other; immune checkpoint; immune checkpoint; other; other; Not specified; other,Approved; Phase 2; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1; Preclinical; Preclinical,No,,,No,,,No,,,Yes,antibody development,https://www.linkedin.com/company/carsgen-therapeutics,No,,,No,,,No,,,Yes,CAR T-cell therapies,https://www.carsgen.com/,No,,,No,,,No,,
dc prime bv,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,PM359; PDC*mel,"p47 phox, NCF1 gene mutation; Disease Name",hematology; oncology; immunology,other,Phase 1/2; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"allogeneic, off-the-shelf cell-based therapies",https://www.inderes.dk/en/releases/immunicum-ab-publ-completes-business-combination-with-dcprime,Yes,"relapse vaccines, a new class of oncology vaccines",https://www.inderes.dk/en/releases/immunicum-ab-publ-completes-business-combination-with-dcprime,No,,,No,,
abelzeta inc,Error: Connection failed - HTTPSConnectionPool(host='www.oncologypipeline.com,Yes,C-CAR168; C-CAR039,"CD20, Cluster of Differentiation 20; BCMA, B-cell Maturation Antigen; CD19, Cluster of Differentiation 19",inflammatory and immunological diseases; oncology; hematological malignancies,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"CAR-T therapies, TIL (Tumor Infiltrating Lymphocytes), CD19/CD20 bi-specific CAR-T therapy",https://www.prnewswire.com/news-releases/abelzeta-announces-promising-long-term-outcomes-for-c-car039-a-novel-cd19cd20-bi-specific-car-t-therapy-in-patients-with-rr-b-nhl-at-eha-2025-302482119.html,No,,,No,,,No,,
mana therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,MANA-312; MANA-412; MANA-512,"Disease Name, AML; Disease Name, Solid Tumors",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,DNA and RNA-based therapeutics,https://www.mana.bio/,Yes,"off-the-shelf, allogeneic cell therapies targeting multiple tumor-associated surface and intracellular antigens",https://www.locustwalk.com/mana-therapeutics/,Yes,vaccines,https://www.mana.bio/,No,,,Yes,lipid nanoparticles drug delivery systems,https://www.mana.bio/
discgenics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell-based regenerative therapies for musculoskeletal degeneration,https://www.prnewswire.com/news-releases/peer-reviewed-article-reporting-discgenics-cell-therapy-phase-iii-study-results-receives-international-journal-of-spine-surgery-best-paper-award-302424175.html,No,,,No,,,No,,
huadao shanghai biomedical co ltd,2025-09-19 00:00:00,No,Not specified,"CD-19, Cluster of Differentiation 19; BCMA, B-cell Maturation Antigen",oncology,immune checkpoint,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
avenge bio inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.decibio.com', port=4",No,AVB-001,"IL-2, Interleukin-2",oncology,cytokine,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell therapy biotech,https://www.linkedin.com/posts/timospapagatsias_avenge-bio-a-cell-therapy-biotech-from-rice-activity-7229511637773258752-x082,No,,,No,,,No,,
kronos bio inc,2025-05-01 00:00:00,No,KB-7898; KB-0742; Entospletinib; Lanraplenib; Istisociclib,"p300, Lysine Acetyltransferase; MYC-driven cancers; BTK, Bruton's Tyrosine Kinase; SYK, Spleen Tyrosine Kinase; CDK9, Cyclin-Dependent Kinase 9",autoimmune diseases; oncology; hematologic malignancies,enzyme; other; kinases,Preclinical; Phase 1/2; Phase 2,Yes,small molecule therapeutics,https://www.globenewswire.com/news-release/2025/05/01/3072392/0/en/Kronos-Bio-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-0-57-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clinical research unit of nanoro,No timestamp found,No,artefenomel; ferroquine; lumefantrine; KAF156; sevuparin; tafenoquine; primaquine; arterolane; cipargamin; OZ439,Plasmodium falciparum; Plasmodium vivax; kelch gene mutations,infectious diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"RTS,S phase 3 malaria vaccine candidate trial",https://www.pamafrica-consortium.org/crun,No,,,No,,
institute for developing science & health initiatives,No timestamp found,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,HPV vaccination awareness campaigns aimed at preventing cervical cancer,https://ideshi.org/about-us/,No,,,No,,
indiana nanotech llc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pure biologics sa,2025-02-27 13:38:32,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,"protein production, purification and analysis",https://www.linkedin.com/company/pure-biologics/,Yes,selection and characterisation of antibodies,https://www.linkedin.com/company/pure-biologics/,No,,,No,,,Yes,aptamers,https://www.linkedin.com/company/pure-biologics/,No,,,No,,,No,,,No,,
seagen inc,2020-10-14 00:00:00,No,SEA-CD40,"CD40, Cluster of Differentiation 40",oncology,immune checkpoint,Not specified,Yes,bosutinib bosulif.com Prescribing Information,https://www.pfizer.com/seagen,No,,,Yes,pegfilgrastim-apgf nyvepria.com Prescribing Information,https://www.pfizer.com/seagen,Yes,Monoclonal antibody-based therapies for cancer,https://www.linkedin.com/company/seagen,Yes,Antibody-Drug Conjugates (ADCs),https://www.pfizer.com/seagen,No,,,No,,,No,,,No,,,No,,,No,,
cynata therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='au.linkedin.com', port=4",Yes,CYP-004; CYP-001,Disease Name,musculoskeletal diseases; immunology,other,Phase 3; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,clinical-stage stem cell and regenerative medicine company,https://www.cnbc.com/quotes/CYP,No,,,No,,,Yes,"Cymerus, which is a therapeutic stem cell platform technology",https://www.cnbc.com/quotes/CYP
human immunology biosciences inc,2025-07-03 00:00:00,No,felzartamab; izastobart; HIB210,"CD38, Cluster of Differentiation 38; C5aR1, Complement Component 5a Receptor 1",immunology; rare diseases,cytokine; other,Phase 3; Phase 1,No,,,No,,,No,,,Yes,"felzartamab, a fully human anti-CD38 monoclonal antibody",https://www.goodwinlaw.com/en/news-and-events/news/2024/05/announcements-lifesciences-hi-bio-acquired-by-biogen,No,,,No,,,No,,,No,,,No,,,No,,,No,,
flatley discovery lab,"Error: Connection failed - HTTPSConnectionPool(host='www.whoi.edu', port=443)",Yes,FDL169,"CFTR, Cystic Fibrosis Transmembrane Conductance Regulator",respiratory diseases,enzyme,Phase 1,Yes,discovering small molecules that help restore CFTR protein,https://www.linkedin.com/company/flatleydiscoverylab,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
avid bioservices inc,2024-11-06 00:00:00,Yes,Not specified,Not specified,oncology; respiratory; cell therapy,Not specified,Not specified,No,,,No,,,Yes,"Recombinant Proteins, Enzymes",https://www.linkedin.com/company/avid-bioservices,Yes,"mAbs, Biosimilars",https://www.linkedin.com/company/avid-bioservices,Yes,ADC program from early phase development through commercial manufacturing,https://www.linkedin.com/company/avid-bioservices,No,,,No,,,No,,,No,,,No,,,No,,
dermira inc (inactive),2020-01-10 06:30:00,No,Dupilumab; Tralokinumab; Baricitinib,"IL-4Ra, Interleukin-4 Receptor Alpha; IL-13, Interleukin-13; JAK1/2, Janus Kinase 1/2",immunology; dermatology,cytokine; cytokine; kinases,Approved,No,,,No,,,No,,,Yes,"lebrikizumab, a monoclonal antibody for atopic dermatitis",https://www.foresitecapital.com/portfolio/dermira-copy/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vertex pharmaceuticals inc,2025-10-16 14:44:21,Yes,VX-993; Journavx,"NaV1.8, Voltage-Gated Sodium Channel Subtype 1.8",pain; diabetes-related chronic nerve pain,ion channels,Phase 2,Yes,bridging medicinal chemistry scale-up with process chemistry to enable the progression of key programs into preclinical and clinical development,https://www.linkedin.com/company/vertex-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,Yes,advancing cell and genetic therapies,https://www.linkedin.com/company/vertex-pharmaceuticals,No,,,No,,,No,,
palatin technologies inc,2025-05-08 22:20:24,Yes,Not specified,Melanocortin Receptor,retinal diseases,gpcr,Preclinical,Yes,oral small molecule PL7737 MC4R agonist in preclinical studies,https://www.linkedin.com/company/palatin-technologies,Yes,long-acting peptide MC4R agonists,https://www.linkedin.com/company/palatin-technologies,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
first wave biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
center for study of stem cells,"Error: Connection failed - HTTPSConnectionPool(host='stemcell.nd.edu', port=4",Yes,ANPD001; bemdaneprocel; FT522; FT819; Omisirge; GDA-201; Orca-T,Parkinson's disease; Dopamine-producing neurons; B-cell lymphomas; Hematologic malignancies; Follicular lymphoma; Diffuse large B-cell lymphoma; High grade B-cell lymphoma; Severe aplastic anemia; CD34+ stem cells,neurology; oncology; hematology; immunology,other; cytokine; other; other; other,Phase 1/2a; Phase 2; Phase 1; Phase 3; Approved; Phase 1/2; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,use of human stem cells in drug discovery,https://www.mskcc.org/research-programs/stem-cell-biology,No,,,No,,,Yes,"induced pluripotency, directed differentiation, genetic modification",https://www.mskcc.org/research-programs/stem-cell-biology
faculty of medicine thammasat university,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
3sbio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.pfizer.com', port=44",No,SSGJ-707,"PD-1, Programmed Death-1; VEGF, Vascular Endothelial Growth Factor",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,Yes,bispecific antibody targeting PD-1 and VEGF,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio,No,,,No,,,No,,,No,,,No,,,No,,,No,,
forward pharma as,"Error: Connection failed - HTTPSConnectionPool(host='www.annualreports.com', ",No,Daraxonrasib,"RAS, Rat Sarcoma Protein",oncology,kinases,Phase 3,Yes,proprietary formulation of DMF for the treatment of inflammatory and neurological indications,https://www.linkedin.com/company/forward-pharma-a-s,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
marinomed biotech ag,"Error: Connection failed - HTTPSConnectionPool(host='at.linkedin.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
samsung biologics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Not specified,Not specified,Not specified,Not specified,Preclinical,No,,,No,,,Yes,biologics products,https://www.linkedin.com/company/samsung-biologics,Yes,Ab Cell Purification PD,https://www.linkedin.com/company/samsung-biologics,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Samsung Organoids,https://www.linkedin.com/company/samsung-biologics
bhi therapeutic sciences,2023-03-15 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,32 human cytokines and growth factors obtained from our own human stem cell cultures,https://www.bluehorizoninternational.com/bhi-therapeutic-sciences/,No,,,No,,,No,,,No,,,Yes,stem cell therapies to patients who may benefit from these treatments,https://www.bluehorizoninternational.com/bhi-therapeutic-sciences/,No,,,No,,,Yes,cancer immunotherapy using the patient’s own expanded dendritic and killer T-cells,https://www.bluehorizoninternational.com/bhi-therapeutic-sciences/
winsantor inc,No timestamp found,No,JOURNAVX; Adezunap; Cebranopadol; Suzetrigine,"NaV1.8, Voltage-Gated Sodium Channel 1.8; CB1, Cannabinoid Receptor 1; NOP, Nociceptin/Orphanin FQ Peptide Receptor; MOP, Mu-Opioid Peptide Receptor",CNS; chronic pain; diabetic neuropathy,ion channels; gpcr; other; other,Phase 3; Phase 3; Phase 2/Phase 3; Phase 3,Yes,discovery and development of treatments for peripheral neuropathies,https://p2pmarketdata.com/companies/winsantor/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
iqure pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,iQ-007,"EAAT2, Excitatory Amino Acid Transporter 2",CNS,enzyme,Phase 1,Yes,"iQ-007, a first-in-class, orally available small molecule",https://www.linkedin.com/company/iqurepharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gammacan international inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Not specified,Neoantigens,oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"tularik, inc. (inactive)","Error: Connection failed - HTTPSConnectionPool(host='investors.amgen.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,technology meant to treat cancer and inflammation by regulating genes,https://www.nbcnews.com/id/wbna4623678,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
orbsen therapeutics ltd,2017-08-26 00:00:00,Yes,ORBCEL-M,Disease Name,metabolic diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"mesenchymal stromal cell immunotherapy, ORBCEL",https://www.labiotech.eu/trends-news/orbsen-therapeutics-interim-diabetic-kidney-disease-study-results/,No,,,No,,,Yes,"stem cell therapy, stem cell isolation, cell therapy",https://ie.linkedin.com/company/orbsen-therapeutics-limited
oncosec medical inc,2023-06-16 00:00:00,Yes,TAVO; Tavokinogene Telseplasmid,"IL-12, Interleukin-12",oncology,cytokine,Phase 2,No,,,No,,,Yes,"interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions",https://www.prnewswire.com/news-releases/oncosec-announces-closing-of-1-33-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-301829063.html,No,,,No,,,No,,,Yes,DNA-based interleukin-12 (IL-12),https://www.linkedin.com/company/oncosec-medical-inc,No,,,No,,,No,,,Yes,Oncolytic viruses,https://pmc.ncbi.nlm.nih.gov/articles/PMC5084990/
kazia therapeutics ltd,2025-10-08 20:33:53,Yes,GDC-0084; Paxalisib; EVT801,"PI3K, Phosphatidylinositol 3-Kinase; VEGFR3, Vascular Endothelial Growth Factor Receptor 3",oncology; CNS; Parkinson's disease,kinases; other,Phase 3; Phase 1,Yes,small-molecule inhibitor of VEGFR3,https://au.linkedin.com/company/kaziatx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,PD-L1 protein degrader,https://au.linkedin.com/company/kaziatx,No,,
perseus proteomics inc,2020-12-30 00:00:00,Yes,PPMX-T004; PPMX-T003; PPMX-T002,"CDH3, Cadherin-3; TfR1, Transferrin Receptor 1",oncology; hematology,other; other,Non-clinical; Phase 1/2; Preclinical,No,,,No,,,No,,,Yes,antibody drug discovery utilizing its unique antibody technologies,https://www.ppmx.com/en/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gut-brain axis therapeutics llc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,MTT,Disease Name,CNS; gastrointestinal; rare diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Microbiota Transplant Therapy (MTT),https://gutbrainaxistherapeutics.com/
arrevus inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"oral, small molecule treatment",https://globalgenes.org/raredaily/aceragen-acquires-arrevus-expands-late-stage-rare-disease-pipeline/,No,,,Yes,recombinant human acid ceramidase (rhAC),https://globalgenes.org/raredaily/aceragen-acquires-arrevus-expands-late-stage-rare-disease-pipeline/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eclipse life sciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.inknowvation.com', p",No,OCS-01; 4D-150; D-4517.2; OCU200; AIV007,"VEGF, Vascular Endothelial Growth Factor; Integrin, Integrin Receptors; TGFβ1, Transforming Growth Factor Beta 1",ophthalmology,cytokine; other,Phase 3; Phase 2; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neovac ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,UBT251,"GLP-1, Glucagon-Like Peptide-1; GIP, Gastric Inhibitory Polypeptide; Glucagon",metabolic diseases; obesity,gpcr,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA-based drug delivery,https://www.neovac.co.uk/,No,,,Yes,mRNA vaccines,https://www.neovac.co.uk/,No,,,Yes,Lipid Nanoparticles (LNP),https://www.neovac.co.uk/
"aliada therapeutics, inc",Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,Yes,ALIA-1758,"3pE-Aβ, Pyroglutamate Amyloid Beta",CNS; Alzheimer's disease,other,Phase 1,No,,,No,,,No,,,Yes,anti-pyroglutamate amyloid beta (3pE-Aβ) antibody,"https://news.abbvie.com/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline",No,,,No,,,Yes,genetic medicines such as siRNA,"https://news.abbvie.com/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline",No,,,No,,,No,,,Yes,novel blood-brain barrier (BBB)-crossing technology,"https://news.abbvie.com/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline"
ganymed pharmaceuticals gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.astellas.com', port=",Yes,IMAB362,"Claudin 18.2, Claudin 18 isoform 2",oncology,other,Phase 3,No,,,No,,,No,,,Yes,Antibodies Specific for Claudin 6 (Cldn6),"https://www.northdata.com/Ganymed%20Pharmaceuticals%20GmbH,%20Mainz/HRB%2047318",No,,,No,,,No,,,No,,,No,,,No,,,No,,
"point therapeutics, inc. (inactive)",2023-10-03 13:04:12,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,radioligand therapies,https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html
keybioscience ag,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,"Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments",https://www.prnewswire.com/news-releases/keybioscience-announces-extension-of-strategic-collaboration-with-lilly-302271654.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
antria inc,2013-03-01 00:00:00,No,APX3330,"Ref-1, Reduction Oxidation Effector Factor-1",ophthalmology,enzyme,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,innovative cellular therapies,https://www.linkedin.com/company/antria-inc-,No,,,No,,,No,,
bexion pharmaceuticals inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,BXQ-350,"GCase, Glucocerebrosidase",oncology; neurodegenerative diseases,enzyme,Preclinical,No,,,No,,,Yes,"BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid",https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-announces-completion-of-enrollment-in-open-label-portion-of-phase-1b2-asist-study-in-mcrc-302307807.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need",https://www.prnewswire.com/news-releases/bexion-pharmaceuticals-inc-announces-completion-of-enrollment-in-open-label-portion-of-phase-1b2-asist-study-in-mcrc-302307807.html
bexion pharmaceuticals llc,2025-05-28 20:43:06,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,"BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid",https://www.linkedin.com/company/bexion-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
meridian bioscience inc,2022-07-07 07:17:00,No,Not specified,Mycobacterium abscessus,infectious diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sarkana pharma inc,No timestamp found,Yes,AT-019; AAT-008,"EP4, Prostaglandin E2 receptor 4",pain; inflammation; cancer,gpcr,Not specified,No,,,No,,,Yes,anti-inflammatory biologic,https://www.cbinsights.com/company/sarkana-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
the hospital for sick children,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",No,paxalisib,PI3K/AKT/mTOR pathway,oncology,kinases,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biomarin pharmaceutical inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ose immunotherapeutics sa,2025-10-03 06:28:07,Yes,Docetaxel; Ose2101; Ose-279 100Mg; Ose-279 300Mg; Ose-279 500Mg; Covepit; Ose-127; Bi 765063; Bi 754091; Fr104; Pemetrexed,Not specified,oncology; immunology; infectious diseases; gastrointestinal diseases; transplantation,Not specified,Phase III; Phase I/II; Phase I; Phase II; Phase I; Phase I; Phase I,No,,,No,,,No,,,Yes,"monoclonal antibody (mAb), anti-PD1, anti-CD28 mAb, anti-SIRPα mAb",https://www.linkedin.com/company/ose-immunotherapeutics/,No,,,Yes,BiCKI® - bispecific fusion protein platform,https://www.linkedin.com/company/ose-immunotherapeutics/,Yes,mRNA Therapeutic platform,https://www.linkedin.com/company/ose-immunotherapeutics/,No,,,Yes,Tedopi® (therapeutic cancer vaccine),https://www.linkedin.com/company/ose-immunotherapeutics/,No,,,No,,
lixte biotechnology holdings inc,2025-08-08 00:00:00,Yes,LB-100,"PP2A, Protein Phosphatase 2A",oncology,enzyme,Phase 1b/2,Yes,designed compounds that can safely target them in animal models,https://www.linkedin.com/company/lixte-biotechnology-holdings-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation,https://www.linkedin.com/company/lixte-biotechnology-holdings-inc-,No,,
african institute of biomedical science and technology,No timestamp found,Yes,Acoziborole; Bedaquiline; Emodepside; Flubentylosin; Fexinidazole; Fosravuconazole; JNJ-64281802; Moxidectin; Oxantel pamoate; Oxfendazole,Not specified,infectious diseases,enzyme,Phase 2,Yes,drug discovery and development,https://www.aibst.org/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,vaccines,https://www.aibst.org/,No,,,No,,
aqualung therapeutics corp,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,ALT-100,"eNAMPT, Extracellular Nicotinamide Phosphoribosyltransferase",respiratory diseases; inflammatory diseases; fibrotic diseases,cytokine,Phase 2,No,,,No,,,No,,,Yes,human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT),https://www.linkedin.com/company/aqualung-therapeutics-corp.,No,,,No,,,No,,,No,,,No,,,No,,,No,,
curemark llc,2025-05-20 08:53:11,No,SCI-210; JAG201,"SHANK3, SH3 and Multiple Ankyrin Repeat Domains Protein 3; Autism Spectrum Disorder",CNS; rare diseases,other,Phase 1,No,,,No,,,Yes,key enzyme deficiencies associated with autism,https://www.linkedin.com/company/curemark-llc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
censa pharmaceuticals inc,2025-07-28 21:21:35,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"CNSA-001 (sepiapterin), a clinical-stage investigational therapy",https://www.prnewswire.com/news-releases/ptc-therapeutics-to-acquire-censa-pharmaceuticals-301054298.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
canadian cancer trials group,"Error: Connection failed - HTTPSConnectionPool(host='www.ctg.queensu.ca', por",No,CX-2051; CX-801,"EpCAM, Epithelial Cell Adhesion Molecule; IFN-α2b, Interferon Alpha-2b",oncology,enzyme; cytokine,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
australasian myeloma research consortium,Error: Connection failed - HTTPSConnectionPool(host='clinicaltrialsalliance.o,Yes,Teclistamab; Talquetamab; Daratumumab; Iberdomide; Isatuximab; Selinexor; Belantamab mafodotin; Carfilzomib; Dexamethasone; Venetoclax; Bortezomib; Cyclophosphamide; KappaMab; Lenalidomide; Ixazomib; Thalidomide,"BCMA, B-cell maturation antigen; Disease Name, Multiple Myeloma",oncology,immune checkpoint,Approved; Phase 2; Phase 1/II; Phase II; Phase IIb,Yes,"trialing new treatment regimens, biologics and drug products",https://www.amarconline.org/about-amarc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
trius therapeutics inc (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
novavax inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Nuvaxovid,SARS-CoV-2 Spike Protein,infectious diseases,other,Approved,No,,,No,,,Yes,Protein-based nanoparticles are made of engineered proteins of the target pathogen used to trigger immune system recognition.,https://www.novavax.com/,No,,,No,,,No,,,No,,,No,,,Yes,"Nuvaxovid ™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S.",https://www.novavax.com/,No,,,Yes,"Combining Novavax’s protein-based nanoparticles with our Matrix-M® adjuvant achieves strong, long-lasting and broad immune responses.",https://www.novavax.com/
biomedical advanced research and development authority,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,ERVEBO,Disease Name,infectious diseases,other,Approved,Yes,testing antivirals for the treatment of hospitalized influenza infections,https://medicalcountermeasures.gov/barda/,No,,,Yes,developing new therapeutics for the treatment of acute respiratory distress syndrome,https://medicalcountermeasures.gov/barda/,Yes,Emergency Use Authorizations for 10 therapeutics,https://medicalcountermeasures.gov/barda/,No,,,No,,,No,,,No,,,Yes,developing vaccines against and therapeutics for pandemic and seasonal influenza,https://medicalcountermeasures.gov/barda/,No,,,No,,
orgenesis inc,2024-04-13 00:00:00,Yes,ORGCAR19; MOTC; DUVAC; ORGCAR19.22; CAR-NK; RanTop; SVF-COV; AutoVac; Kyslecel; Bioxome; MSCP,"CD19, Cluster of Differentiation 19; CD19.22, Cluster of Differentiation 19 and 22; Tumor Cell Antigens; Double-Stranded RNA; miRNA Precursors; Disease Name",oncology; viral diseases; metabolic diseases; autoimmune diseases,immune checkpoint; cytokine; enzyme; other,Preclinical; IND Enabling Studies; Clinical Trials; Clinical Use,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Personalized cell and gene therapies (CGTs),https://orgenesis.com/,No,,,No,,,No,,
personalized stem cells inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,ANPD001; bemdaneprocel; FT522; FT819; KYV-101; Orca-T; Remestemcel-L; REVASCOR; MPC-06-ID; MPC-300-IV; MPC-25-IC,"Disease Name, Parkinson’s disease; CD19, Cluster of Differentiation 19; Disease Name, B-cell malignancies; Disease Name, Hematologic malignancies; Disease Name, Autoimmune disorders; Disease Name, Acute graft versus host disease; Disease Name, Chronic heart failure; Disease Name, Degenerative disc disease; Disease Name, Rheumatoid arthritis; Disease Name, Diabetic nephropathy; Disease Name, Acute myocardial infarction",neurology; oncology; immunology; cardiovascular; hematology; autoimmune diseases,other; immune checkpoint; other; other; other; other; other; other; other; other; other,Phase 1/2a; Phase 2; Phase 1; Phase 1; Phase 2; Phase 3; Phase 3; Phase 3; Phase 2; Phase 2; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Stem cell therapy, stem cell storage, culture-expanded stem cells",https://sdomg.com/personalized-stem-cells/,No,,,No,,,Yes,"Regenerative medicine, adipose-derived stem cells",https://sdomg.com/personalized-stem-cells/
idp discovery pharma sl,2016-06-18 00:00:00,Yes,IDP-023; SNK01; SAR443579; NKX019,CD-19; Not specified,oncology; autoimmune disorders,immune checkpoint; other,Phase 2; Phase 1,Yes,new chemical entities,https://startupshub.catalonia.com/startup/barcelona/idp-pharma/1835,Yes,anticancer peptides,https://patents.justia.com/assignee/idp-discovery-pharma-s-l,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sinapis pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,BAT2506,"TNF-alpha, Tumor Necrosis Factor-alpha",immunology,cytokine,Phase 3,Yes,"methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models",https://www.prnewswire.com/news-releases/sinapis-pharma-completes-phase-i-trial-125343133.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hangzhou jiuyuan gene engineering co ltd,2025-05-01 13:21:44,Yes,Semaglutide; Exenatide; Liraglutide,"GLP-1R, Glucagon-Like Peptide-1 Receptor",metabolic diseases,gpcr,Approved,Yes,"Drug pipeline mainly includes Liraglutide, Fulvestrant, Fosaprepitant",https://www.linkedin.com/company/hangzhou-jiuyuan-gene-engineering-co-ltd-/,No,,,Yes,"Filgrastim (rhG-CSF), Interleukin-11, Recombinant Human Bone Morphogenetic Protein-2",https://www.jiuyuangene.net/about-us,Yes,SIRPα-Specific Monoclonal Antibody,https://www.jiuyuangene.net/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alios biopharma inc,2025-07-17 17:40:32,Yes,AL-8176; AG-181; AG-236,"RSV, Respiratory Syncytial Virus; Phenylketonuria; TMPRSS6, Transmembrane Protease Serine 6",infectious diseases; rare diseases,other; enzyme; other,Phase 2; Preclinical; Preclinical,Yes,small molecule compounds,https://www.cbinsights.com/company/alios-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
inhibrx biosciences inc,2024-05-30 00:00:00,No,INBRX-106; INBRX-109,Not specified,oncology,Not specified,Phase 2,No,,,No,,,Yes,SAR447537 is a human recombinant protein,https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-30-13-01-38-2890833,Yes,single domain antibody platform technology,https://www.linkedin.com/company/inhibrx,No,,,No,,,No,,,No,,,No,,,No,,,No,,
inhibrx inc,2024-01-23 00:00:00,No,INBRX-101; INBRX-109; INBRX-106; INBRX-105,"AAT, Alpha-1 Antitrypsin; Not specified",rare diseases; oncology,enzyme; Not specified,Phase 2; Not specified,No,,,No,,,Yes,INBRX-101 is a recombinant human AAT-Fc fusion protein,https://www.sanofi.com/en/media-room/press-releases/2024/2024-01-23-06-30-00-2813696,Yes,single domain antibody platform technology,https://www.linkedin.com/company/inhibrx,No,,,Yes,INBRX-101 is a recombinant human AAT-Fc fusion protein,https://www.sanofi.com/en/media-room/press-releases/2024/2024-01-23-06-30-00-2813696,No,,,No,,,No,,,No,,,No,,
regulus therapeutics inc,2025-05-08 16:05:40,Yes,Farabursen; RGLS8429,"miR-17, MicroRNA-17",renal diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,microRNA therapeutics,https://www.prnewswire.com/news-releases/regulus-therapeutics-reports-first-quarter-2025-financial-results-and-recent-updates-302449287.html,No,,,No,,,No,,,No,,
demerx inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,neuroplastogen therapy designed to repair neural circuits damaged by chronic heavy drinking,https://www.linkedin.com/company/demerx-inc.
poltreg sa,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"autologous TREG cells, CAR-TREG, allogeneic TREG, antigen-specific TREG, TCR-TREG therapies",https://www.globenewswire.com/news-release/2025/07/31/3125327/0/en/PolTREG-and-U-S-Subsidiary-Immuthera-Secure-Positive-FDA-Opinion-Paving-the-Way-for-a-Registrational-Pre-Symptomatic-Type-1-Diabetes-Trial.html,No,,,No,,,No,,
provirex genome editing therapies gmbh,2025-07-29 07:31:44,Yes,Casgevy,CD34+ haematopoietic stem cells,genetic diseases,other,Approved,No,,,No,,,No,,,Yes,nanobodies,https://www.linkedin.com/company/provirex,No,,,No,,,No,,,Yes,"lentiviral vectors, AAV, gene therapy, CAR-T cancer therapy",https://www.linkedin.com/company/provirex,No,,,No,,,Yes,"nanoparticles for drug delivery, exosome-based therapeutics",https://www.linkedin.com/company/provirex
synact pharma ab,2025-10-10 12:33:09,No,Resomelagon; TXP-11,"MC1R, Melanocortin Receptor 1; MC3R, Melanocortin Receptor 3",autoimmune diseases; inflammatory diseases,gpcr,Phase 2,Yes,AP1189 is an immunomodulatory small molecule delivered as a once-daily tablet,https://se.linkedin.com/company/synact-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pharma holdings as,2025-09-25 12:27:37,Yes,ABRYSVO; CTB+AVP (PF-07612577); Dekavil; PADCEV; PF-06414300; PF-06835375; PF-06940434; PF-07054894; PF-07248144 + atirmociclib (PF-07220060); PF-07248144,"Respiratory Syncytial Virus Infection; Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis; Rheumatoid Arthritis; BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer; Ulcerative Colitis; Lupus; Advanced Solid Tumors; Breast Cancer Metastatic",vaccines; inflammation & immunology; oncology,Not specified,Phase 1,No,,,Yes,Our new generation cationic peptide is the result of world-class research in the field of lytic peptides.,https://www.linkedin.com/company/pharma-holdings-as/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cytodyn inc,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cincor pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.astrazeneca.com', po",No,Baxdrostat (CIN-107),Aldosterone Synthase,cardiovascular,enzyme,Phase 2,Yes,baxdrostat (CIN-107),https://www.globenewswire.com/search/organization/CinCor%2520Pharma%2520Inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
izana bioscience ltd,2018-01-14 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
maggie's pearl llc,"Error: Connection failed - HTTPSConnectionPool(host='www.inknowvation.com', p",No,epalrestat,"PMM2, Phosphomannomutase 2",rare diseases,enzyme,Phase 3,Yes,epalrestat,https://www.maggiespearl.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
liminal biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='ca.linkedin.com', port=4",Yes,LMNL6511; OXER1 Antagonist,"GPR84, G Protein-Coupled Receptor 84; OXER1, Oxoeicosanoid Receptor 1",inflammatory diseases; fibrotic diseases; metabolic diseases; eosinophilic driven diseases,gpcr,Preclinical,Yes,focused on discovering and developing novel and distinctive small molecule therapeutics,https://www.prnewswire.com/news-releases/liminal-biosciences-announces-completion-of-the-plan-of-arrangement-with-structured-alpha-lp-301938815.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rin institute inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
camino pharma llc,2023-12-07 10:30:00,Yes,SBP-9330,"mGlu2, Metabotropic Glutamate Receptor 2",CNS; addiction,gpcr,Phase 1,Yes,discover novel mechanisms for modulating these targets with small molecule drugs,https://www.linkedin.com/company/camino-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
five prime therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.amgen.com', port=443",Yes,PM359,"p47 phox, NADPH Oxidase Subunit",hematology; immunology; oncology,enzyme,Phase 1/2,No,,,No,,,No,,,Yes,Bemarituzumab (anti-FGFR2b) is a first-in-class targeted antibody,https://www.prnewswire.com/news-releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash-301240358.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zogenix inc (inactive),2022-01-19 01:03:08,No,FINTEPLA,"5-HT1D, 5-Hydroxytryptamine Receptor 1D; 5-HT2A, 5-Hydroxytryptamine Receptor 2A; 5-HT2C, 5-Hydroxytryptamine Receptor 2C; Sigma1R, Sigma-1 Receptor",CNS; rare diseases,gpcr; other,Approved,Yes,FINTEPLA® (fenfluramine) oral solution,https://www.prnewswire.com/news-releases/ucb-to-acquire-zogenix-301463511.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies,https://www.prnewswire.com/news-releases/ucb-to-acquire-zogenix-301463511.html,No,,,No,,,No,,
flamingo therapeutics nv,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Danvatirsen; FLM-7523,"STAT3, Signal Transducer and Activator of Transcription 3; MALAT1, Metastasis Associated Lung Adenocarcinoma Transcript 1",oncology,other,Phase 2; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA-targeted therapies,https://www.linkedin.com/company/flamingo-therapeutics,No,,,No,,,No,,,No,,
okyo pharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cnn.com', port=443):",No,Urcosimod,"ChemR23, Chemerin Receptor 23",ophthalmology,gpcr,Phase 2,No,,,Yes,lipid conjugated chemerin peptide agonist,https://www.globenewswire.com/news-release/2025/10/16/3167912/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
exonate ltd,"Error: Connection failed - HTTPSConnectionPool(host='uk.linkedin.com', port=4",No,EXN407,"SRPK1, Serine-Arginine Protein Kinase 1",ophthalmology,kinases,Phase 2,Yes,small-molecule therapeutics,https://www.news-medical.net/news/20240305/Exonate-first-in-class-eye-drop-Phase-IbIIa-trial-data-demonstrate-safety-and-biological-activity-in-treatment-of-diabetic-retinopathy-and-diabetic-macular-oedema.aspx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biocon ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Nimotuzumab; Insulin Tregopil; Itolizumab,Not specified,oncology; diabetes; autoimmune diseases; inflammatory diseases,other,Marketed,No,,,No,,,Yes,"insulins, monoclonal antibodies and conjugated recombinant proteins",https://www.bioconbiologics.com/,Yes,monoclonal antibodies,https://www.bioconbiologics.com/,Yes,conjugated recombinant proteins,https://www.bioconbiologics.com/,No,,,No,,,No,,,No,,,No,,,No,,
lytix biopharma as,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunogen inc,2023-11-30 00:00:00,No,OBT076,Not specified,oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,Yes,antibody-drug conjugate (ADC),"https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio",No,,,No,,,No,,,No,,,No,,,No,,
biora therapeutics inc,2024-12-30 00:00:00,Yes,BT-600; BT-001; BT-200; BT-002,"GLP-1, Glucagon-Like Peptide-1 Receptor; TNF-alpha, Tumor Necrosis Factor-alpha",type 2 diabetes; autoimmune conditions; inflammatory bowel disease; ulcerative colitis,gpcr; cytokine,Clinical; Preclinical,Yes,tofacitinib,https://www.bioratherapeutics.com/,Yes,GLP-1 receptor agonist,https://www.bioratherapeutics.com/,Yes,large molecules,https://www.linkedin.com/company/biora-therapeutics,No,,,No,,,No,,,Yes,nucleic acids,https://www.stocktitan.net/news/BIOR/biora-therapeutics-successfully-completes-restructuring-nskn45dbk6jr.html,No,,,No,,,No,,,Yes,ingestible injectable device,https://www.stocktitan.net/news/BIOR/biora-therapeutics-successfully-completes-restructuring-nskn45dbk6jr.html
eradivir inc,"Error: Connection failed - HTTPSConnectionPool(host='www.purdue.edu', port=44",Yes,EV25,Influenza Infection,infectious diseases,other,Phase 2,Yes,"Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules.",https://www.linkedin.com/company/eradivir,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Eradivir is developing drugs that bind to diseased cells, serving as a beacon to guide the immune system.",https://www.linkedin.com/company/eradivir
interna technologies bv,"Error: Connection failed - HTTPSConnectionPool(host='interna.bio', port=443):",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,microRNA (miRNA)-based therapeutics,https://www.prnewswire.com/news/interna-technologies-b.v./,No,,,No,,,No,,,No,,
orfagen sas,"Error: Connection failed - HTTPSConnectionPool(host='www.orphagen.com', port=",Yes,TALZENNA; XTANDI; PADCEV; mevrometostat; disitamab vedotin; sasanlimab,"HRR, Homologous Recombination Repair; PD-1, Programmed Death-1; EZH2, Enhancer of Zeste Homolog 2; HER2, Human Epidermal Growth Factor Receptor 2",oncology; genitourinary cancers; prostate cancer; bladder cancer,enzyme; immune checkpoint; other,Phase 3; Approved; Marketed; Phase 1; Phase 2,Yes,Orphagen discovers and develops small molecules to drug targets,https://www.linkedin.com/company/orphagenpharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
adocia sas,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,tirzepatide; semaglutide; setmelanotide; NN-9932; cagrilintide; maridebart cafraglutide; orforglipron calcium; retatrutide; survodutide,"GLP-1, Glucagon-Like Peptide-1; GIP, Glucose-Dependent Insulinotropic Polypeptide; MC4R, Melanocortin Receptor 4; LEPR, Leptin Receptor; POMC, Proopiomelanocortin; PCSK1, Proprotein Convertase Subtilisin/Kexin Type 1",metabolic diseases; obesity,gpcr; other,Pre-registration; Phase 3; Approved,No,,,Yes,Oral formulation of peptides,https://www.linkedin.com/company/adocia/,Yes,"Therapeutic proteins, Ultra-rapid Insulin, Glucagon, Insulin, GLP-1, Amylin",https://www.linkedin.com/company/adocia/,No,,,No,,,No,,,No,,,Yes,"Cell therapy, Transplantation of Islets of Langherans, Stem cell-derived islets",https://www.linkedin.com/company/adocia/,No,,,No,,,No,,
calcimedica subsidiary inc,2023-03-20 00:00:00,No,Auxora,"CRAC, Calcium Release-Activated Calcium Channel",inflammatory diseases; immunologic diseases,ion channels,Phase 2,Yes,small molecule calcium release-activated calcium (CRAC) channel inhibitor,https://www.globenewswire.com/news-release/2023/03/20/2630834/0/en/CalciMedica-Announces-Closing-of-Merger-with-Graybug-Vision-and-Concurrent-Private-Placement.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
grace therapeutics inc,2025-09-22 17:50:49,No,GTx-104; GTX-102; GTX-101,"Disease Name, Aneurysmal Subarachnoid Hemorrhage; Disease Name, Ataxia Telangiectasia; Disease Name, Postherpetic Neuralgia",rare diseases; CNS,other,Phase 3,Yes,novel injectable formulation of nimodipine,https://www.home.saxo/markets/stocks/grce-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
causeway therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,TenoMiR,"miR29a, MicroRNA-29a",musculoskeletal disorders,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
eureka therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cirm.ca.gov', port=4",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,fully-human antibodies against intracellular cancer antigens,https://www.linkedin.com/company/eureka-therapeutics-inc,No,,,No,,,No,,,Yes,"CAR-T, Engineered T cell therapy, Cell Therapy",https://www.linkedin.com/company/eureka-therapeutics-inc,No,,,No,,,No,,
metro international biotech llc,"Error: Connection failed - HTTPSConnectionPool(host='www.alzdiscovery.org', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
imgt co ltd,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances,https://www.marketscreener.com/quote/stock/IMGT-CO-LTD-157133376/company/
prometheus biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
trethera corp,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",Yes,TRE-515,"dCK, Deoxycytidine Kinase; PSMA, Prostate-Specific Membrane Antigen",oncology; autoimmune diseases,enzyme; other,Phase 1,Yes,"TRE-515, a novel dCK inhibitor",https://www.globenewswire.com/news-release/2025/06/03/3092853/0/en/Trethera-Secures-New-License-Strengthening-TRE-515-Intellectual-Property-Portfolio-and-Extending-Market-Exclusivity-to-2045.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunimed inc,No timestamp found,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,polyclonal antibodies against key proteins of the intestinal parasite Cryptosporidium,https://gcgh.grandchallenges.org/grant/development-safe-and-effective-oral-immunotherapy,No,,,No,,,No,,,No,,,No,,,No,,,No,,
altor bioscience llc,No timestamp found,Yes,ALT-801,Not specified,oncology,Not specified,Not specified,No,,,No,,,No,,,Yes,therapeutic antibodies,https://www.linkedin.com/company/altor-bioscience-corporation_2,Yes,antibody-like STAR™ fusions which function as therapeutics,https://www.linkedin.com/company/altor-bioscience-corporation_2,Yes,STAR™ fusions with cytokines and antibody-like STAR™ fusions,https://www.linkedin.com/company/altor-bioscience-corporation_2,No,,,Yes,engineer single chain T cell receptors to deliver immunotherapies,https://www.gatesfoundation.org/about/committed-grants/2008/10/opp52092,No,,,No,,,Yes,"novel targets on virus-infected or cancerous cells, including intracellular antigens",https://www.linkedin.com/company/altor-bioscience-corporation_2
sustained therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Iberdomide; Mezigdomide,"CRBN, Cereblon E3 Ligase",oncology,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,sustained-release drug delivery platform,https://ca.linkedin.com/company/sustained-therapeutics
ocugenix corp,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,OCU410,"hRORA, Retinoic Acid Receptor-Related Orphan Receptor Alpha",ophthalmology,nuclear receptors,Phase 2,No,,,Yes,targeted peptide fragments of these proteins,https://blog.innovation.pitt.edu/startup-check-in-ocugenix,Yes,synthetic proteins that act as switches to turn off the wound healing process,https://blog.innovation.pitt.edu/startup-check-in-ocugenix,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rich pharmaceuticals inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,L1-79; AJA001; SCI-210; AST-001; ML004; NV01-A02; ARD-501; ALA-002,Not specified,CNS,Not specified,Phase 2,Yes,12-O-tetradecanoylphorbol-13-acetate (RP-323),https://www.marketscreener.com/quote/stock/RICH-PHARMACEUTICALS-INC-111314014/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
apeiron biologics ag,2024-07-08 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,QARZIBA is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2),https://investor.ligand.com/news-and-events/press-releases/news-details/2024/Ligand-to-Acquire-APEIRON-Biologics-AG-for-100-Million/default.aspx,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cabaletta bio inc,2025-10-14 12:00:56,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Engineered T cell therapies designed for the treatment of patients with autoimmune diseases,https://www.linkedin.com/company/cabalettabio,No,,,No,,,No,,
gracell biotechnologies inc,2025-09-22 01:28:10,Yes,GC012F,"BCMA, B-Cell Maturation Antigen; CD19, Cluster of Differentiation 19",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,novel autologous and allogeneic cell therapies for cancer and autoimmune diseases,https://www.linkedin.com/company/gracellbio,No,,,No,,,No,,
kousai bio co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.kousai.vip', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,dendritic cell-based vaccines (KSD-101) against EBV-associated,https://library.ehaweb.org/eha/2024/eha2024-congress/419526/chunrui.li.dendritic.cell-based.vaccines.%28ksd-101%29.against.ebv-associated.html,No,,,No,,
radiomedix inc,2024-09-12 00:00:00,Yes,AlphaMedix,Somatostatin receptor,oncology; rare diseases,gpcr,Phase 2,No,,,Yes,somatostatin receptor-targeting peptide complex,https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceuticals for PET imaging and targeted alpha therapy (TAT),https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919
piqur therapeutics ag (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",Yes,PQR309; bimiralisib,"PI3K/mTOR, Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin",oncology; dermatology,kinases,Phase 2,Yes,"bimiralisib, a potent and balanced pan-PI3K/mTOR inhibitor",https://www.linkedin.com/pulse/swiss-rockets-ag-acquired-assets-intellectual-property-piqur-?trk=public_post_main-feed-card_feed-article-content,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nkarta inc,2025-03-27 10:55:00,Yes,NKX019,Disease Name,autoimmune disorders; oncology,Not specified,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"allogeneic, off-the-shelf engineered natural killer (NK) cell therapies",https://www.cnbc.com/quotes/NKTX,No,,,No,,,No,,
bright minds biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,BMB-201; BMB-101,"5-HT2, Serotonin 2 receptor family",CNS; neurological disorders; neuropsychiatric disorders; chronic pain,gpcr,Phase 2,Yes,developing novel serotonergic drugs,"https://www.linkedin.com/company/bright-minds-biosciences#:~:text=Bright%20Minds%20Biosciences%20is%20clinical,Website%20http%3A%2F%2Fbrightmindsbio.com",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
theseus pharmaceuticals inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,No,THE-630; THE-349,"KIT, Receptor Tyrosine Kinase; EGFR, Epidermal Growth Factor Receptor",oncology,kinases,Phase 1,Yes,selective epidermal growth factor receptor inhibitor,https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-enters-into-agreement-to-be-acquired-by-concentra-biosciences-for-between-3-90-and-4-05-in-cash-per-share-plus-a-contingent-value-right-302021402.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aadi bioscience inc,2025-03-04 16:05:29,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,Yes,antibody-drug conjugates (ADCs),https://www.linkedin.com/company/aadi-bioscience-inc,No,,,No,,,No,,,No,,,No,,,No,,
whitehawk therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,HCW11-006; HCW9302,"PTK7, Protein Tyrosine Kinase 7; MUC16, Mucin 16; SEZ6, Seizure Related 6 Homolog",oncology; autoimmune diseases,immune checkpoint; cytokine,Preclinical,No,,,No,,,No,,,No,,,Yes,antibody drug conjugate (ADC) portfolio,https://www.cnbc.com/quotes/WHWK,No,,,No,,,No,,,No,,,No,,,No,,
mersana therapeutics inc,2025-10-08 13:59:28,No,XMT-1660; XMT-2056,"B7-H4, Not specified; HER2, Human Epidermal Growth Factor Receptor 2",oncology,immune checkpoint; other,Phase 1,No,,,No,,,No,,,Yes,antibody-drug conjugates (ADCs),https://www.mersana.com/,Yes,antibody-drug conjugates (ADCs),https://www.mersana.com/,No,,,No,,,No,,,No,,,No,,,No,,
adc therapeutics sa,2025-10-08 13:00:35,Yes,ZYNLONTA,"CD19, Cluster of Differentiation 19",oncology,other,Marketed,No,,,No,,,No,,,Yes,CD19-directed antibody drug conjugate (ADC),https://www.prnewswire.com/news-releases/adc-therapeutics-announces-60-million-private-placement-302581554.html,Yes,antibody drug conjugates (ADCs),https://www.prnewswire.com/news-releases/adc-therapeutics-announces-60-million-private-placement-302581554.html,No,,,No,,,No,,,No,,,No,,,No,,
anaptysbio inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Rosnilimab; ANB033; ANB101; ANB030,Not specified,autoimmune diseases; inflammatory diseases; alopecia areata,cytokine; other,Phase 2; Phase 1; Preclinical,No,,,No,,,No,,,Yes,Best-in-class antibodies designed to help dampen the inflammatory response and restore immune balance.,https://www.anaptysbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hutchmed china ltd,2025-10-13 07:02:48,Yes,Savolitinib; Fruquintinib; Surufatinib; Tazemetostat; Sovleplenib; Fanregratinib; Ranosidenib,"MET, Mesenchymal Epithelial Transition Factor; VEGFR, Vascular Endothelial Growth Factor Receptor; VEGFR, FGFR, CSF-1R; EZH2, Enhancer of Zeste Homolog 2; SYK, Spleen Tyrosine Kinase; FGFR, Fibroblast Growth Factor Receptor; IDH1/IDH2, Isocitrate Dehydrogenase 1/2",oncology; hematology; immunology,kinases; kinases; kinases; enzyme; kinases; kinases; enzyme,Approved; Marketed; Phase 2/3; Approved; Phase 2; Phase 2; Phase 3,Yes,discovery and global development and commercialization of targeted therapies,https://www.linkedin.com/company/hutchmed,No,,,No,,,Yes,Antibody Targeted Therapy Conjugates platform,https://www.linkedin.com/company/hutchmed,Yes,Antibody Targeted Therapy Conjugates platform,https://www.linkedin.com/company/hutchmed,No,,,No,,,No,,,No,,,No,,,No,,
entrada therapeutics inc,2025-10-15 14:14:19,Yes,ENTR-601-44; ENTR-601-45; ENTR-601-50; Exon 51; VX-670,"Disease Name, Duchenne Muscular Dystrophy; Disease Name, Myotonic Dystrophy Type 1",rare diseases,other,Phase 1,No,,,No,,,Yes,advancing a robust development portfolio of RNA- and protein-based programmes,https://stockanalysis.com/stocks/trda/company/,No,,,No,,,No,,,Yes,advancing a robust development portfolio of RNA- and protein-based programmes,https://stockanalysis.com/stocks/trda/company/,No,,,No,,,No,,,No,,
context therapeutics inc,2025-10-10 21:43:00,No,CLP002; BT5528; SAR408701; RAYZ-8009; 177 Lu-FAP-2286,"PD-L1, Programmed Death-Ligand 1; EphA2, Ephrin Type-A Receptor 2; CEACAM5, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5; GPC3, Glypican-3; FAP, Fibroblast Activation Protein",oncology,immune checkpoint; other; other; other; other,Phase 2; Phase 1/2; Phase 2; Phase 1; Phase 1/2,No,,,No,,,No,,,Yes,bispecific antibodies for solid tumors,https://www.linkedin.com/company/context-therapeutics,Yes,T cell engaging ('TCE') bispecific antibodies,https://www.linkedin.com/company/context-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,
nordic bioscience as,2025-10-16 06:30:08,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Endotrophin: a collagen-derived hormone,https://www.linkedin.com/company/nordicbioscience/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ECM-based biomarkers can support oncology drug development programs,https://www.linkedin.com/company/nordicbioscience/
camp4 therapeutics corp,2025-10-15 14:00:40,Yes,CMP-SYNGAP-01,"SYNGAP1, Synaptic Ras GTPase-Activating Protein 1",neurodevelopmental disorders,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,antisense oligonucleotides,https://www.linkedin.com/company/camp4-therapeutics,No,,,No,,,No,,,No,,
oncusp therapeutics inc,2024-01-04 08:11:00,Yes,CUSP06; CUSP02,"CDH6, Cadherin-6; Tumor Micro-Environment",oncology,other,Phase 1; Discovery,No,,,No,,,No,,,Yes,proprietary antibody with high CDH6 binding affinity,https://www.prnewswire.com/news-releases/oncusp-therapeutics-raises-oversubscribed-100-million-series-a-financing-to-advance-portfolio-of-assets-for-cancer-patients-302026328.html,Yes,antibody drug conjugate (ADC) targeting CDH6,https://www.prnewswire.com/news-releases/oncusp-therapeutics-raises-oversubscribed-100-million-series-a-financing-to-advance-portfolio-of-assets-for-cancer-patients-302026328.html,No,,,No,,,No,,,No,,,No,,,No,,
coherent biopharma,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,medicinal chemistry/CMC,https://www.linkedin.com/company/%E5%90%8C%E5%AE%9C%E5%8C%BB%E8%8D%AF-%E8%8B%8F%E5%B7%9E-%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/,No,,,No,,,No,,,Yes,tumor targeting ligand conjugate drugs,https://www.linkedin.com/company/%E5%90%8C%E5%AE%9C%E5%8C%BB%E8%8D%AF-%E8%8B%8F%E5%B7%9E-%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/,No,,,No,,,No,,,No,,,No,,,Yes,Bi-Engaging ligand-mediated Selective Targeting platform (BESTTM),https://www.linkedin.com/company/%E5%90%8C%E5%AE%9C%E5%8C%BB%E8%8D%AF-%E8%8B%8F%E5%B7%9E-%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/
granite bio ag,"Error: Connection failed - HTTPSConnectionPool(host='forbion.com', port=443):",Yes,GRT-001; GRT-002,"Pro-inflammatory monocytes; IL-3, Interleukin-3",immunology; inflammatory diseases; autoimmune diseases,other; cytokine,Phase 1; Preclinical,Yes,nintedanib unexpectedly modulates CCR2 immune cell infiltration,https://www.linkedin.com/company/granitebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Core competencies Therapeutics/vaccines (human),https://www.swissbiotech.org/listing/granite-bio-ag/,No,,,No,,
palleon pharmaceuticals inc,2025-10-02 14:37:34,No,E-602; E-688,"Siglecs, Sialic Acid-Binding Immunoglobulin-Like Lectins; B7H3, Not specified",oncology; autoimmune diseases,immune checkpoint; other,Phase 2; IND-Enabling,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,glyco-immunology approach,https://www.linkedin.com/company/palleon-pharmaceuticals
arctic vision shanghai biotechnology co ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,triamcinolone acetonide,https://www.linkedin.com/company/arcticvision,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,suprachoroidal space microinjection technology (SCS Microinjector®),https://www.linkedin.com/company/arcticvision
blossomhill therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,BH-30643; BH-30236,"EGFR, Epidermal Growth Factor Receptor; HER2, Human Epidermal Growth Factor Receptor 2",oncology; autoimmune diseases,kinases,Phase 2; Phase 1,Yes,focused on small molecule drug design and development,https://www.linkedin.com/company/blossomhill-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
goldfinch bio inc,2023-02-02 11:32:00,Yes,GFB-887; GFB-024,"TRPC4, Transient Receptor Potential Channel 4; TRPC5, Transient Receptor Potential Channel 5",kidney diseases; psychiatric disorders; neurological disorders,ion channels,Phase 2,Yes,discovery and development of novel compounds,https://www.gilead.com/news/news-details/2019/gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tianjin xinyi suntech biomedical technology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.tjsjkt.com', port=44",Yes,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,Yes,multi-target immuno-biopharmaceuticals,https://suntecmedical.com/,No,,,No,,,No,,,No,,,Yes,gene therapies,https://suntecmedical.com/,Yes,vaccines,https://suntecmedical.com/,No,,,Yes,Multi-target Immunotherapy Nano Complex (MINC) Technology,https://suntecmedical.com/
boundless bio inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,BBI-355; BBI-825; BBI-940,"CHK1, Checkpoint Kinase 1; RNR, Ribonucleotide Reductase; Kinesin, DNA Segregation Protein",oncology,kinases; enzyme; other,Phase 1; Preclinical,Yes,"BBI-355 is a novel, oral, and potent CHK1 inhibitor",https://www.globenewswire.com/news-release/2024/12/12/2996511/0/en/Boundless-Bio-Announces-Pipeline-and-Leadership-Updates.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ecDTx programs targeting extrachromosomal DNA (ecDNA),https://www.globenewswire.com/news-release/2024/12/12/2996511/0/en/Boundless-Bio-Announces-Pipeline-and-Leadership-Updates.html
galvanize therapeutics inc,2025-09-03 07:00:00,No,Aliya; RheOx; CENTAURI,Non-Small Cell Lung Cancer; Chronic Bronchitis; Soft Tissue Lesions,oncology; respiratory diseases,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Pulsed Electric Field (PEF) therapies,https://galvanizetx.com/
asceneuron sa,2024-07-16 07:15:00,Yes,Aducanumab; AGB101; AR1001; AVP-786; AXS-05; Blarcamesine; BPDO-1603; Brexpiprazole; Caffeine; Donanemab; Donepezil; E2814; Escitalopram; Fosgonimeton; Gantenerumab; Guanfacine; Hydralazine hydrochloride; Icosapent ethyl,"Aβ, Amyloid beta; SV2A, Synaptic Vesicle Glycoprotein 2A; Neurotransmitter receptors; Tau, Tau protein; Hepatocyte growth factor receptor; Oxidative stress; Alpha-2 adrenergic receptor",CNS; Alzheimer's disease; neuropsychiatric symptoms,other; gpcr; enzyme; cytokine; Not specified,Phase 3,Yes,clinical-stage small molecule O-GlcNAcase inhibitors,https://www.swissbiotech.org/listing/asceneuron-sa/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
autobahn therapeutics inc,2024-07-24 10:30:00,Yes,ABX-002; ABX-101; ABX-003,"TRβ, Thyroid Hormone Beta Receptor; S1P, Sphingosine-1-Phosphate Receptor",CNS; neuropsychiatry; neuroimmunology,nuclear receptors; gpcr,Phase 2; Phase 1; Preclinical,Yes,Our brain-targeting chemistry platform creates orally administered small molecule prodrugs,https://autobahntx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
siteone therapeutics inc,2025-05-27 12:30:00,Yes,STC-004,"Nav1.8, Voltage-Gated Sodium Channel Subtype 1.8; Nav1.7, Voltage-Gated Sodium Channel Subtype 1.7",pain; neuronal hyperexcitability disorders,ion channels,Phase 2,Yes,"highly selective small molecule inhibitors targeting NaV1.7, NaV1.8, and other voltage-gated ion channels",https://www.linkedin.com/company/siteone-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
umoja biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,UB-VV111,"CD19, Cluster of Differentiation 19",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,Yes,multi-target antibody discovery collaboration,https://nonabio.com/nona-biosciences-enters-into-collaboration-agreement-with-umoja-biopharma-to-advance-in-vivo-car-t-cell-therapies/,No,,,No,,,No,,,Yes,in vivo CAR T cell therapy,https://www.linkedin.com/company/umoja-biopharma,No,,,No,,,No,,
forma therapeutics inc,2020-01-19 00:00:00,No,Etavopivat,"PK, Pyruvate Kinase",rare diseases; hematology,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
avalyn pharma inc,2025-07-22 11:00:00,Yes,AP01; AP02; AP03,"Pirfenidone, Small Molecule Inhibitor with Anti-Inflammatory and Anti-Fibrotic Effects; Nintedanib, Small Molecule Inhibitor of Multiple Tyrosine Kinases",rare diseases; respiratory diseases; pulmonary fibrosis; interstitial lung diseases,cytokine; kinases,Phase 2; Phase 1; Preclinical,Yes,optimized inhaled formulations of pirfenidone (AP01) and nintedanib (AP02),https://www.globenewswire.com/news-release/2025/07/22/3119277/0/en/Avalyn-Completes-Oversubscribed-100-Million-Series-D-Financing-to-Further-Advance-Clinical-Development-of-Novel-Inhaled-Therapies-for-Pulmonary-Fibrosis.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
f2g ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Fosmanogepix; Ibrexafungerp; Olorofim; Rezafungin,"Gwt1, Glycosylphosphatidylinositol Biosynthetic Pathway Enzyme; Dihydroorotate Dehydrogenase, Pyrimidine Synthesis Pathway",infectious diseases,enzyme,Phase 3; Approved,Yes,novel therapies to treat life-threatening invasive fungal infections; discovered and developed a completely new class of antifungal agents called the orotomides,https://www.linkedin.com/company/f2g,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
engeneic ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.forbes.com.au', port",No,PNU-159682,"EGFR, Epidermal Growth Factor Receptor",oncology,enzyme,Phase 1/Phase 2,Yes,super-cytotoxic drug PNU-159682,https://www.globenewswire.com/news-release/2025/05/13/3079706/0/en/EnGeneIC-launches-groundbreaking-new-Australian-trial-for-innovative-cancer-therapy-with-international-trial-site-in-Singapore-to-follow.html,No,,,No,,,No,,,No,,,No,,,Yes,functional nucleic acids,https://www.linkedin.com/company/engeneic,No,,,No,,,No,,,Yes,EDV nanocells form the backbone of the company's ongoing commitment to revolutionise cancer therapy by utilising advanced nanotechnology,https://www.globenewswire.com/news-release/2025/05/13/3079706/0/en/EnGeneIC-launches-groundbreaking-new-Australian-trial-for-innovative-cancer-therapy-with-international-trial-site-in-Singapore-to-follow.html
epicentrx inc,"Error: Connection failed - HTTPSConnectionPool(host='www.epicentrx.com', port",Yes,AdAPT-001,"TGF-β, Transforming Growth Factor Beta",oncology,cytokine,Phase 2,Yes,dinitroazetidine-based small molecules with anti-inflammatory/antioxidant and tumor associated macrophage stimulatory properties,https://pmc.ncbi.nlm.nih.gov/articles/PMC10054294/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"proprietary oncolytic adenoviruses, which also serve as excellent gene delivery vectors",https://pmc.ncbi.nlm.nih.gov/articles/PMC10054294/,Yes,COVID-19 nucleocapsid-based vaccine,https://pmc.ncbi.nlm.nih.gov/articles/PMC10054294/,No,,,Yes,"oncolytic viruses developed by gastrointestinal oncologist and businessman, Dr. Tony Reid",https://pmc.ncbi.nlm.nih.gov/articles/PMC10054294/
lyndra therapeutics inc.,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,LYN-005,Not specified,CNS,Not specified,Phase 3,Yes,oral weekly risperidone (LYN-005),https://www.linkedin.com/company/lyndra,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,LYNX® drug delivery platform,https://www.linkedin.com/company/lyndra
mythic therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,antibody-based therapeutics,https://www.massbio.org/members/mythic-therapeutics/,Yes,antibody-drug conjugates (ADCs),https://www.massbio.org/members/mythic-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,
cleave therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,CB-5339,"VCP/p97, Valosin-Containing Protein",oncology; neurodegenerative diseases,enzyme,Phase 1,Yes,small molecule valosin-containing protein (VCP)/p97 inhibitor,https://www.prnewswire.com/news-releases/casi-pharmaceuticals-acquires-global-intellectual-property-rights-to-cleave-therapeutics-vcpp97-inhibitor-cb-5339-301881595.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
entasis therapeutics holdings inc,Error: Connection failed - HTTPSConnectionPool(host='www.repair-impact-fund.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,novel clinical and preclinical antibacterial programs,https://www.linkedin.com/company/entasis-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sorrento therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='financhill.com', port=44",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"non-opioid pain management small molecule, resiniferatoxin (""RTX"")",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html,No,,,No,,,Yes,"fully human antibodies (""G-MAB™ library"")",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html,Yes,"antibody-drug conjugates (""ADCs"")",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html,No,,,No,,,Yes,"immuno-cellular therapies (""DAR-T™"")",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html,Yes,"vaccines against coronaviruses, including STI-1558 and COVI-MSC™",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html,No,,,Yes,"oncolytic virus (""Seprehvec™"")",https://www.prnewswire.com/news-releases/sorrento-therapeutics-inc-announces-the-consummation-of-the-previously-announced-sale-of-substantially-all-of-the-common-shares-preferred-shares-and-warrants-that-sorrento-held-in-scilex-holding-company-301936341.html
aligos therapeutics inc,2025-10-16 12:35:55,Yes,ALG-000184; Pevifoscorvir Sodium,Not specified,infectious diseases; liver diseases,other,Phase 2,Yes,oral small molecule capsid assembly modulator (CAM-E),https://www.globenewswire.com/news-release/2025/10/16/3167896/0/en/Aligos-Therapeutics-Receives-USAN-Council-Approval-for-pevifoscorvir-sodium-as-Nonproprietary-Name-for-ALG-000184.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arch oncology inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biostl.org', port=44",Yes,CBX-12; CBX-15,"TOP1, Topoisomerase 1",oncology,enzyme,Phase 2,No,,,No,,,No,,,Yes,anti-CD47 antibody therapies,https://www.globenewswire.com/search/organization/Arch%2520Oncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,
harbor therapeutics inc,2025-03-21 07:21:56,Yes,Batoclimab; HBM9378; Porustobart; HBM1020; HBM7004; HBM7020; R2006; HBM7026,"FcRn, Neonatal Fc Receptor; TSLP, Thymic Stromal Lymphopoietin; CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4; B7H7, B7 Homolog 7; B7H4, B7 Homolog 4; BCMA, B-Cell Maturation Antigen; CD19, Cluster of Differentiation 19; CD3, Cluster of Differentiation 3",autoimmune diseases; asthma; chronic obstructive pulmonary disease; oncology; solid tumors; metabolic diseases; CNS,immune checkpoint; cytokine; immune checkpoint; immune checkpoint; other; other; other; other,Phase 3; Phase 2; Phase 2; Phase 1; Preclinical; Phase 1; Preclinical; Preclinical,No,,,No,,,No,,,Yes,novel antibody therapeutics in immunology and oncology,https://www.prnewswire.com/news-releases/harbour-biomed-reports-2025-interim-results-302540099.html,Yes,antibody-drug conjugation,https://www.prnewswire.com/news-releases/harbour-biomed-reports-2025-interim-results-302540099.html,No,,,No,,,Yes,NK cell therapies,https://www.prnewswire.com/news-releases/harbour-biomed-reports-2025-interim-results-302540099.html,No,,,No,,,Yes,immune cell engagers (BiTEs),https://www.prnewswire.com/news-releases/harbour-biomed-reports-2025-interim-results-302540099.html
vedanta biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='puretechhealth.com', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Live Biotherapeutic Product consisting of a defined bacterial consortium,https://www.biopharmadive.com/news/vedanta-layoffs-ulcerative-colitis-study-results-microbiome-puretech/757650/
seven and eight biopharmaceuticals corp,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,EIK1001; PLUVICTO; LUTATHERA,"TLR, Toll-Like Receptor; PSMA, Prostate-Specific Membrane Antigen",oncology,other; other,Phase 3; Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Immunotherapies, Toll Like Receptor 7, and Toll Like Receptor 8",https://www.linkedin.com/company/seven-and-eight-biopharmaceuticals-inc
urogen pharma ltd,2025-10-16 13:00:01,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RTGel® drug delivery technology,https://www.linkedin.com/company/urogenpharma
juventas therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Juvena maps the therapeutic potential of natural secreted proteins and engineers them into biologics that restore tissue homeostasis,https://www.juvenatherapeutics.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rs research,"Error: Connection failed - HTTPSConnectionPool(host='tr.linkedin.com', port=4",No,NAMPT inhibitors; Tideglusib; Mexiletine; Metformin,"NAMPT, Nicotinamide Phosphoribosyltransferase; GSK3β, Glycogen Synthase Kinase 3 Beta",oncology; neuromuscular diseases,enzyme; kinases,Phase 2; Phase 3,No,,,No,,,No,,,No,,,Yes,biodegradable conjugation platforms,https://rsresearch.net/,No,,,No,,,No,,,No,,,No,,,Yes,smart nanomedicines,https://rsresearch.net/
nido biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,Yes,NIDO-361,"AR, Androgen Receptor",neurology; rare diseases,nuclear receptors,Phase 2,Yes,precision medicines,https://www.linkedin.com/company/nido-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,functional genomics discovery platform based on human cell lines,https://www.linkedin.com/company/nido-biosciences
tennor therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
acceleron pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,protein engineering,https://www.flagshippioneering.com/companies/acceleron-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
verona pharma plc,"Error: Connection failed - HTTPSConnectionPool(host='www.merck.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Developing life enhancing treatments for chronic respiratory diseases,https://www.linkedin.com/company/verona-pharma-plc.,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pluri inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,RC-0315,"Disease Name, Idiopathic Pulmonary Fibrosis",rare diseases; respiratory diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell-based products directed for a range of industries,https://www.cnbc.com/quotes/PLUR,No,,,No,,,Yes,researching and developing cell transformation and 3D cell expansion technologies,https://www.cnbc.com/quotes/PLUR
cellatoz therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.nature.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hookipa pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,oncology; inflammation; virology,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aortica group,"Error: Connection failed - HTTPSConnectionPool(host='evtoday.com', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bioelectron technology corp,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cascadian therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,tucatinib; CASC-578; CASC-674,"HER2, Human Epidermal Growth Factor Receptor 2; Chk1, Checkpoint Kinase 1; Not specified",oncology,kinases; kinases; other,Phase 2; Preclinical; Preclinical,Yes,"tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor",https://www.jitta.com/stock/NASDAQ:CASC,No,,,No,,,Yes,"CASC-674, an antibody against an immuno-oncology target",https://www.jitta.com/stock/NASDAQ:CASC,No,,,No,,,No,,,No,,,No,,,No,,,No,,
keryx biopharmaceuticals inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='biopharmguy.com', port=4",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
small pharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,SPL026,"Disease Name, Major Depressive Disorder",CNS,other,Phase 2,Yes,novel deuterated molecules,"https://uk.linkedin.com/company/small-pharma-inc#:~:text=Small%20Pharma%20is%20a%20biotech,option%20of%20better%20mental%20health.",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,psychedelic-assisted treatments,"https://uk.linkedin.com/company/small-pharma-inc#:~:text=Small%20Pharma%20is%20a%20biotech,option%20of%20better%20mental%20health."
pharmajet inc,2025-10-16 23:34:47,No,Not specified,Not specified,infectious diseases; COVID-19; vaccines,Not specified,Not specified,No,,,Yes,Prototypes of the subcutaneous injectors aimed at the chronic disease and metabolic peptide self-injection markets,https://www.linkedin.com/company/pharmajet-inc,No,,,No,,,No,,,No,,,No,,,No,,,Yes,PharmaJet Precision Delivery Systems provide increased vaccine effectiveness,https://www.linkedin.com/company/pharmajet-inc,No,,,No,,
vivani medical inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,NPM-139; NPM-115; NPM-133,"GLP-1, Glucagon-Like Peptide-1",obesity; chronic weight management; type 2 diabetes,gpcr,Preclinical,No,,,Yes,GLP-1 for Chronic Weight Management,https://vivani.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,NanoPortal™ implant technology,https://vivani.com/
shanghai sinobioway sunterra biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='exumabio.com', port=443)",Yes,CAB-CAR-T,Axl; Ror2,oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAB-CAR-T cell therapy,https://www.cmocro.com/company/Shanghai+Sinobioway+Sunterra+Biotechnology+Co.%2C+Ltd./index.html,No,,,No,,,No,,
ilya pharma ab,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,emilimogene sigulactibac; ILP100-Topical; ILP100-Oral,"STING, Stimulator of Interferon Genes; CXCR4, C-X-C Chemokine Receptor Type 4",rare diseases; immunology,cytokine; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Gene Therapy,https://se.linkedin.com/company/ilya-pharma,No,,,No,,,Yes,Bioengineered bacteria expressing healing chemokine,https://se.linkedin.com/company/ilya-pharma
rise therapeutics llc,2025-10-14 18:08:33,Yes,R-5780; R-2487,Not specified,oncology; immunology,Not specified,Phase 1,No,,,No,,,Yes,therapeutic proteins,https://www.linkedin.com/company/rise-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,other modalities,https://www.linkedin.com/company/rise-therapeutics
an2 therapeutics inc,2025-09-08 13:00:06,Yes,Epetraborole; AN2-502998,Disease Name,infectious diseases,Not specified,Phase 2,Yes,discovering and developing novel small molecule therapeutics derived from its boron chemistry platform,https://www.linkedin.com/company/an2-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nalagenetics pte ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,clinically validated genomic insights,https://sg.linkedin.com/company/nalagenetics,No,,,No,,,No,,,No,,
pibd-net,"Error: Connection failed - HTTPSConnectionPool(host='www.hra.nhs.uk', port=44",No,Duvakitug,"TL1A, Tumor Necrosis Factor-Like Ligand 1A",immunology; inflammatory bowel disease,cytokine,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
beijing kawin technology share-holding co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.kawin-bio.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,recombinant human interferon Î±2b,https://www.marketscreener.com/quote/stock/BEIJING-KAWIN-TECHNOLOGY--130615627/company/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biolinerx ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Motixafortide; APHEXDA; GLIX1,Not specified,oncology; rare diseases,other,Approved; Phase 2; Preclinical,Yes,"GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers",https://www.prnewswire.com/news-releases/biolinerx-issues-letter-to-shareholders-302355990.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
jiangsu qyuns therapeutics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.qyuns.net', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai mabgeek biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.mabge.com', port=443",No,MG-K10; anti-TSLP; anti-IL-33; anti-MASP-2,"IL-4Rα, Interleukin-4 Receptor Alpha; TSLP, Thymic Stromal Lymphopoietin; IL-33, Interleukin-33; MASP-2, Mannan-Binding Lectin-Associated Serine Protease 2",immunology; respiratory; dermatology; nephrology,cytokine; cytokine; cytokine; enzyme,Phase 3; Phase 1; Preclinical; IND approved,No,,,No,,,No,,,Yes,"anti-IL-4Rα monoclonal antibody, anti-TSLP, anti-IL-33, anti-MASP-2 mAb",https://informaconnect.com/bioeurope/sponsors/shanghai-mabgeek-biotech-co-ltd/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"shanghai mabgeek biotechnology co., ltd","Error: Connection failed - HTTPSConnectionPool(host='www.mabge.com', port=443",No,MG-K10; anti-TSLP; anti-IL-33; anti-MASP-2,"IL-4Rα, Interleukin-4 Receptor Alpha; TSLP, Thymic Stromal Lymphopoietin; IL-33, Interleukin-33; MASP-2, Mannan-Binding Lectin-Associated Serine Protease-2",immunology; respiratory; dermatology; nephrology,cytokine; cytokine; cytokine; enzyme,Phase 3; Phase 1; Preclinical; IND Approved,No,,,No,,,No,,,Yes,"anti-IL-4Rα monoclonal antibody, anti-TSLP, anti-IL-33, anti-MASP-2 mAb",https://informaconnect.com/bioeurope/sponsors/shanghai-mabgeek-biotech-co-ltd/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai meiji biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.mabge.com', port=443",No,Not specified,Not specified,oncology; genetic disorders,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
transcode therapeutics inc,2025-03-23 23:13:21,Yes,TTX-MC138,microRNA-10b,oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA therapeutics based on its proprietary TTX nanoparticle platform,https://www.prnewswire.com/news-releases/transcode-therapeutics-inc-announces-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-302408720.html,No,,,No,,,No,,,Yes,TTX nanoparticle platform for the transport of targeted therapeutics to cancer cells,https://www.linkedin.com/company/transcodetherapeutics
verrica pharmaceuticals inc,2025-10-07 20:05:01,No,VP-102; VP-315,Molluscum Contagiosum; Basal Cell Carcinoma,dermatology; oncology,other,Phase 3; Phase 2,No,,,Yes,oncolytic chemotherapeutic peptide immunotherapy,https://www.globenewswire.com/news-release/2025/10/07/3162943/0/en/Verrica-Pharmaceuticals-to-Present-New-Data-on-VP-315-from-its-Phase-2-Trial-in-Basal-Cell-Carcinoma-BCC-at-the-40th-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic viruses,https://www.globenewswire.com/news-release/2025/10/07/3162943/0/en/Verrica-Pharmaceuticals-to-Present-New-Data-on-VP-315-from-its-Phase-2-Trial-in-Basal-Cell-Carcinoma-BCC-at-the-40th-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
cel-sci corp,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Gedatolisib,"PAM, PI3K/AKT/mTOR Pathway",oncology,kinases,Phase 3,No,,,No,,,Yes,"Leukocyte Interleukin, Injection",https://www.linkedin.com/company/cel-sci-corporation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
reviva pharmaceuticals holdings inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,brilaroxazine; RP5063; RP1208,Not specified,CNS; inflammatory; cardiometabolic diseases,Not specified,Not specified,Yes,Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies,https://www.linkedin.com/company/reviva-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurotech international ltd,No timestamp found,Yes,NTI164,Rett Syndrome,CNS; rare diseases,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cannabinoid derived biopharmaceutical called NTI164,https://nextinvestors.com/company/asx-nti/
clearmind medicine inc,Error: Connection failed - HTTPSConnectionPool(host='www.clearmindmedicine.co,Yes,CMND-100,"AUD, Alcohol Use Disorder",CNS,other,Phase 1/2a,Yes,psychedelic-based compounds,https://www.cnbc.com/quotes/CMND,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Revolutionary Psychedelics for Treating Addiction & Mental Health,https://ca.linkedin.com/company/clearmind-medicine
everfront biotech inc,Error: Connection failed - HTTPSConnectionPool(host='www.renaissancecapital.c,No,CPI-613; Masitinib; EndoTAG-1; SM-88; Pamrevlumab; Eryaspase; AVB-500,Not specified,oncology,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
galectin therapeutics inc,2025-08-09 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,tumor vaccine enhancement,https://www.linkedin.com/company/galectin-therapeutics,No,,,Yes,carbohydrate-based candidate compounds,https://www.linkedin.com/company/galectin-therapeutics
puma biotechnology inc,2025-10-16 15:00:06,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,alisertib,https://www.linkedin.com/company/puma-biotechnology-ltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
inventiva sa,2025-10-15 14:45:02,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,development of oral small molecule therapies,https://www.linkedin.com/company/inventiva-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lifetech scientific (shenzhen) co ltd,"Error: Connection failed - HTTPSConnectionPool(host='in.linkedin.com', port=4",No,IBS Titan; IBS,Not specified,cardiovascular; peripheral vascular diseases,Not specified,Phase 2; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elicio therapeutics inc,2025-10-13 14:45:12,Yes,ELI-002 7P; ELI-002 2P; ELI-007; ELI-008,"KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog",oncology,enzyme,Phase 1,No,,,Yes,multivalent lymph node–targeted amphiphile (AMP) peptide vaccine,https://stockanalysis.com/stocks/eltx/company/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,therapeutic cancer vaccines,https://stockanalysis.com/stocks/eltx/company/,No,,,No,,
adams clinical trials llc,2025-10-10 15:59:57,No,Aducanumab; AGB101; AR1001; AVP-786; AXS-05; Blarcamesine; BPDO-1603; Brexpiprazole; Caffeine; Donanemab; Donepezil; E2814; Escitalopram; Fosgonimeton; Gantenerumab; Guanfacine; Hydralazine hydrochloride,"Aβ, Amyloid beta; SV2A, Synaptic Vesicle Glycoprotein 2A; Neurotransmitter receptors; NMDA, N-Methyl-D-Aspartate receptor; Sigma-1 receptor; Tau, Microtubule-associated protein tau; Hepatocyte Growth Factor (HGF); Alpha-2 adrenergic receptor",CNS; Alzheimer's disease,enzyme; gpcr; immune checkpoint; other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pharmactive,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,ABRYSVO; CTB+AVP (PF-07612577); Dekavil; PADCEV; PF-06414300; PF-06835375; PF-06940434; PF-07054894; PF-07248144; atirmociclib (PF-07220060),"Respiratory Syncytial Virus Infection; Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis; Rheumatoid Arthritis; BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer; Ulcerative Colitis; Lupus; Advanced Solid Tumors; Breast Cancer Metastatic",vaccines; inflammation & immunology; oncology,Not specified,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ellipses pharma ltd,2025-10-14 17:35:33,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
jaguar gene therapy llc,"Error: Connection failed - HTTPSConnectionPool(host='deerfield.com', port=443",No,Not specified,Not specified,rare diseases,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,accelerating breakthroughs in gene therapy,https://jaguargenetherapy.com/,No,,,No,,,No,,
fbd biologics ltd,Error: Connection failed - HTTPSConnectionPool(host='www.pharmaindustrial-ind,No,BND-22; BND-35; BND-67,"ILT2, Immunoglobulin-like Transcript 2; ILT3/LILRB4, Immunoglobulin-like Transcript 3/Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4; CD28",oncology; immunology,immune checkpoint; immune checkpoint; other,Phase 2; Phase 1; Preclinical,No,,,No,,,Yes,Fc fusion proteins,https://www.outsourcedpharma.com/doc/hanchorbio-and-henlius-sign-major-licensing-deal-expand-immuno-oncology-reach-0001,Yes,anti-PD-1 mAb,https://www.outsourcedpharma.com/doc/hanchorbio-and-henlius-sign-major-licensing-deal-expand-immuno-oncology-reach-0001,No,,,Yes,Fc fusion proteins,https://www.outsourcedpharma.com/doc/hanchorbio-and-henlius-sign-major-licensing-deal-expand-immuno-oncology-reach-0001,No,,,No,,,No,,,No,,,No,,
maia biotechnology inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,ateganosine; THIO,"Disease Name, Telomerase-positive cancer cells",oncology,other,Phase 2,Yes,Small Molecule,https://www.linkedin.com/company/maiabiotech,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
navifus corp,"Error: Connection failed - HTTPSConnectionPool(host='is.linkedin.com', port=4",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Focused ultrasound (FUS) solutions for clinically unmet needs,https://is.linkedin.com/company/navifus-corporation
orfan-bio,"Error: Connection failed - HTTPSConnectionPool(host='o2h.com', port=443): Max",No,ART4,"JAG1, Jagged-1",rare diseases; liver diseases; cardiometabolic diseases; CNS; kidney diseases,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pharmabcine inc,"Error: Connection failed - HTTPSConnectionPool(host='www.nature.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
provectus biopharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,PV-10; PH-10; PV-305,Not specified,oncology; dermatology; ophthalmology,other,Preclinical; Phase 2,Yes,Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer,https://www.globenewswire.com/search/organization/Provectus%2520Biopharmaceuticals%2520Inc%C2%A7,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy,https://www.globenewswire.com/search/organization/Provectus%2520Biopharmaceuticals%2520Inc%C2%A7,No,,,Yes,"PV-10, is an ablative immunotherapy under investigation in solid tumor cancers",https://www.linkedin.com/company/provectus-biopharmaceuticals
bioniz therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
digestome therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.viagetx.com', port=4",Yes,STM-01; STM-21,"HFpEF, Heart Failure with Preserved Ejection Fraction; DCM, Dilated Cardiomyopathy; ALS, Amyotrophic Lateral Sclerosis; Diabetic Neuropathy; Burns; Inflammatory Conditions of the Skin",cardiovascular; neurology; dermatology,other,Phase 1; Preclinical,Yes,a phase I small molecule for schizophrenia,https://www.prnewswire.com/news-releases/digestome-therapeutics-announces-exclusive-out-license-of-dgx-001-for-greater-china-with-zhongze-therapeutics-301490278.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
obctcd24 ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.ivc-online.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CD24 enriched exosome as a therapy,https://il.linkedin.com/company/nano24
alyra biotech pty ltd,Error: Connection failed - HTTPSConnectionPool(host='www.drsusanevans.com.au',Yes,Alyra Device,"TLR4, Toll-Like Receptor 4",reproductive health; pelvic pain; dysmenorrhea,immune checkpoint,Phase 1,Yes,levonorgestrel releasing approximately 9.6 micrograms per 24 hours and ~27 mg of amitriptyline releasing approximately 0.35 mg per 24 hours,https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384790,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,immune-modulating intrauterine device to reduce pelvic pain in women,https://alyrabiotech.com/
aptissen sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Synolis VA,Osteoarthritis,musculoskeletal diseases,other,Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,orthobiologic solutions,https://www.linkedin.com/company/aptissen/
autifony therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.uclb.com', port=443)",Yes,AUT00206; AUT00201,"Kv3, Kv3 Potassium Channels",CNS; rare diseases,ion channels,Phase 2; Phase 1,Yes,Kv3 modulator,https://autifony.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cebiotex sl,"Error: Connection failed - HTTPSConnectionPool(host='www.f6s.com', port=443):",No,CBX-12,"TOP1, Topoisomerase 1",oncology,enzyme,Phase 2,Yes,chemotherapeutic drug SN-38,https://www.linkedin.com/company/cebiotex,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,nanofiber engineering to develop new medicinal products in the form of implantable membranes,https://www.linkedin.com/company/cebiotex
indiana university research & technology corp,2022-12-13 17:21:09,No,MBX 2109; Not specified; Not specified; Not specified; Not specified; Not specified; Not specified; Not specified,Hypoparathyroidism; Pulmonary Arterial Hypertension; Pancreatic Cancer; Diabetic Retinopathy; Fragile X Syndrome; Human Papillomavirus; Lung Cancer; Breast Cancer,rare diseases; cardiopulmonary diseases; oncology; metabolic diseases; CNS; infectious diseases; regenerative medicine,other; other; other; other; other; other; other; other,Phase 2; Preclinical; Preclinical; Phase 2; Preclinical; Preclinical; Preclinical; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kaizen bioscience co,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Pharmacokinetic Comparison of Augmentin ES-600 and a Reduced Concentration Clavulanate Formulation,https://www.linkedin.com/company/kaizen-bioscience,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kyoto drug discovery & development co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.kyoto-unicap.co.jp',",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sinew pharma inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,TQ-B3234; TQB2102; LM-350; LM-2417; TQF3250; Zongertinib; TQC3721; TQC2731; TQC3403,"MEK1/2, Mitogen-Activated Protein Kinase Kinase 1/2; HER2, Human Epidermal Growth Factor Receptor 2; CDH17, Cadherin-17; NaPi2b/4-1BB, Sodium-Dependent Phosphate Transporter 2b/4-1BB; GLP-1, Glucagon-Like Peptide-1; PNPLA3, Patatin-Like Phospholipase Domain-Containing Protein 3",oncology; diabetes; metabolic diseases,kinases; immune checkpoint; nuclear receptors; other,Phase 1; Phase 2; Phase 3; Approved,Yes,"New Chemical Entity, First-in-Class Drug",https://www.linkedin.com/company/sinew-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
the therapeutic advances in childhood leukemia & lymphoma (tacl) consortium,"Error: Connection failed - HTTPSConnectionPool(host='pcrf-kids.org', port=443",Yes,Trametinib; Azacitidine; Nivolumab,Not specified,oncology,Not specified,Phase 1; Phase 2,Yes,small molecule tyrosine kinase inhibitor,https://pmc.ncbi.nlm.nih.gov/articles/PMC6122960/,No,,,Yes,pegylated asparaginase,https://pmc.ncbi.nlm.nih.gov/articles/PMC6122960/,Yes,immune checkpoint blockade,https://pmc.ncbi.nlm.nih.gov/articles/PMC6122960/,No,,,No,,,Yes,CpG oligodeoxynucleotide GNKG168,https://pmc.ncbi.nlm.nih.gov/articles/PMC6122960/,Yes,"CAR-T cell trial in which the T cells are directed against CD19, CD20 and CD22 antigens",https://www.texaschildrens.org/content/for-physicians/bringing-leukemia-research-bedside-texas-childrens-cancer-and-hematology,No,,,No,,,Yes,"epigenetic modifying agents including single agent panobinostat, azacytidine",https://pmc.ncbi.nlm.nih.gov/articles/PMC6122960/
theracryf plc,"Error: Connection failed - HTTPSConnectionPool(host='theracryf.com', port=443",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,patented sulforaphane-based medicine,https://uk.linkedin.com/company/theracryf,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
modulation therapeutics inc,2013-03-14 00:00:00,No,MTI-201; MTI-301,"SCD1, Stearoyl-CoA Desaturase-1",oncology; hepatocellular cancer; metabolic diseases,enzyme,Phase 1,Yes,early stage first in class molecules targeting the tumor microenvironment,https://www.linkedin.com/company/modulationtherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurocentrx pharma ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,NRCx-201; NRCx-201-IR; NRCx-201-AD; Keticap,"Disease Name, Treatment Resistant Depression; Disease Name, Bipolar Depression",CNS; mood disorders; depression,other,Phase 2,Yes,oral ketamine capsule,https://www.neurocentrx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pep-therapy sas,"Error: Connection failed - HTTPSConnectionPool(host='pep-therapy.com', port=4",No,PEP-010,"Caspase9 and PP2A, Caspase-9 and Protein Phosphatase 2A",oncology,enzyme,Phase 1,No,,,Yes,Cell-Penetrating Peptides,https://insights.citeline.com/SC144744/Frances-PEP-Therapy-Cell-Penetrating-Peptides-To-Teach-Cancer-Cells-How-To-Die-Again/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
innostellar biotherapeutics co ltd,Error: Connection failed - HTTPSConnectionPool(host='www.legendcapital.com.cn,No,LX101; LX102,"RPE65, Retinal Pigment Epithelium-specific Protein 65",ophthalmology,enzyme,Phase 3; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pulsesight therapeutics sas,"Error: Connection failed - HTTPSConnectionPool(host='sprim.net', port=443): M",Yes,PST-611,"Transferrin, Human Transferrin Protein",ophthalmology,other,Phase 1,No,,,No,,,Yes,"Transferrin, an endogenous glycoprotein, regulates iron homeostasis",https://www.globenewswire.com/news-release/2025/09/04/3144188/0/en/PulseSight-Therapeutics-Provides-New-Insights-into-the-Role-of-Iron-and-Transferrin-in-AMD-Supporting-its-PST-611-Vectorized-Therapy-for-Dry-AMD-Geographic-Atrophy-at-EURETINA-2025.html,No,,,No,,,No,,,Yes,non-viral vectorized therapies with minimally-invasive delivery technology,https://www.globenewswire.com/news-release/2025/02/13/3025626/0/en/PulseSight-Therapeutics-Announces-First-Close-of-its-Series-A-Financing-to-Fund-Clinical-Development-of-PST-611-in-dry-AMD.html,Yes,non-viral gene therapies with minimally-invasive delivery technology,https://fr.linkedin.com/company/pulsesight-therapeutics,No,,,No,,,No,,
suzhou huayi liangjian biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Guselkumab; Risankizumab; Mirikizumab; V565; SAR441566; Etrasimod; Zasocitinib; Brepocitinib; Ritlecitinib; VTX958; Tulisokibart; RVT-3101; Duvakitug; ABX464; MBF-118; E6011; AGMB-129; MORF-057; AZD7798,"IL-23, Interleukin-23; TNFα, Tumor Necrosis Factor-alpha; S1P1, Sphingosine-1-Phosphate Receptor 1; S1P4, Sphingosine-1-Phosphate Receptor 4; S1P5, Sphingosine-1-Phosphate Receptor 5; TYK2, Tyrosine Kinase 2; JAK1, Janus Kinase 1; TL1A, Tumor Necrosis Factor-like Cytokine 1A; MiR-124, MicroRNA-124; PPARγ, Peroxisome Proliferator-Activated Receptor Gamma; CX3CL1, Fractalkine; TGFβRI/ALK5, Transforming Growth Factor Beta Receptor I/Activin Receptor-like Kinase 5; α4β7, Alpha4 Beta7 Integrin Receptor; CCR9, C-C Chemokine Receptor 9",gastroenterology; immunology,cytokine; cytokine; gpcr; gpcr; gpcr; kinases; kinases; cytokine; other; nuclear receptors; cytokine; kinases; gpcr; gpcr,Phase 3; Phase 3; Phase 3; Phase 2; Phase 2; Phase 2/Phase 3; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vigeneron gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.bionity.com', port=4",No,VG801; VG901,"ABCA4, ATP-binding cassette sub-family A member 4",ophthalmology,other,Phase 1/Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapies based on our two unique and proprietary technology platforms,https://de.linkedin.com/company/veongentherapeutics,No,,,No,,,No,,
al-s pharma ag,"Error: Connection failed - HTTPSConnectionPool(host='tvm-capital.com', port=4",No,ANX005; ASHA-624; NX210c; CTx2000; TDP-43 small molecule condensate modulator; Tofersen; ION363; NUZ-001; PrimeC; PLL001; Pridopidine; UNC13A-targeting ASO; VTx-002; VRG50635,"C1q, Complement Component 1q; SARM1, Sterile Alpha and TIR Motif Containing 1; TDP-43, TAR DNA-binding Protein 43; TDP-43, TAR DNA-binding Protein 43; SOD1, Superoxide Dismutase 1; FUS, Fused in Sarcoma; TDP-43, TAR DNA-binding Protein 43; Multiple Mechanisms; Gut Permeability; Sigma-1 receptor; UNC13A, Unc-13 Homolog A; TDP-43, TAR DNA-binding Protein 43; PIKfyve, Phosphoinositide Kinase",neurodegenerative diseases; ALS,enzyme; other; other; other; other; other; other; other; other; other; other; other; other; kinases,Phase 2b/3; Preclinical; Phase 2; Preclinical; Not specified; Approved; Phase 3; Phase 2/3; Phase 3; Phase 1/2; Phase 3; Preclinical; Preclinical; Phase 1,No,,,No,,,No,,,Yes,AP-101 is a monoclonal antibody targeting misfolded SOD1,https://www.prnewswire.com/news-releases/al-s-pharma-announces-positive-topline-results-from-phase-2-study-of-ap-101-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-302545686.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clarametyx biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,developing immune-enabling biologic therapies,https://www.linkedin.com/company/clarametyx-biosciences,No,,,No,,,No,,,No,,,Yes,"advance CMTX-301, our anti-biofilm vaccine program",https://www.linkedin.com/company/clarametyx-biosciences,No,,,Yes,Targeting biofilms to treat chronic respiratory disease,https://www.linkedin.com/company/clarametyx-biosciences
enb therapeutics llc,"Error: Connection failed - HTTPSConnectionPool(host='www.avestria.vc', port=4",Yes,ENB-003; KEYTRUDA,"ETBR, Endothelin B Receptor; PD-1, Programmed Death-1",oncology; immunology,gpcr; immune checkpoint,Phase 1,Yes,small molecule endothelin B receptor (ETBR) inhibitor,https://www.linkedin.com/company/enb-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunesensor therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,IMSA-101,"STING, Stimulator of Interferon Genes",oncology; immunology,cytokine,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cGAS-STING pathway of the innate immune system,https://www.linkedin.com/company/immunesensor-therapeutics
kalivir immunotherapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,VET3-TGI; ASP1012,"Disease Name, Advanced Solid Tumors; Disease Name, Locally Advanced or Metastatic Solid Tumors",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,American Society of Gene & Cell Therapy (ASGCT) Annual Meeting,https://www.linkedin.com/company/kalivir-immunotherapeutics,No,,,No,,,Yes,"oncolytic viruses, oncolytic viral immunotherapy",https://kalivir.com/
pancreatic cancer research team,2021-04-05 12:54:40,Yes,Daraxonrasib,"RAS, Rat Sarcoma Protein",oncology,kinases,Phase 3,Yes,combining gemcitabine with inhibitors that target DNA repair proteins,https://www.aacr.org/professionals/research-funding/funded-research/independent-research-grants/pancreatic-cancer-collective/,Yes,radiolabeled αvβ6-targeting peptide,https://www.aacr.org/professionals/research-funding/funded-research/independent-research-grants/pancreatic-cancer-collective/,No,,,No,,,No,,,No,,,No,,,Yes,T-cell receptor (TCR) adoptive cell therapies to target mutant KRAS,https://www.aacr.org/professionals/research-funding/funded-research/independent-research-grants/pancreatic-cancer-collective/,No,,,No,,,Yes,Using Oncolytic Viruses to Improve Immunotherapy,https://www.aacr.org/professionals/research-funding/funded-research/independent-research-grants/pancreatic-cancer-collective/
peel therapeutics inc,2025-10-03 16:15:08,No,PEEL-224,Topoisomerase 1,oncology; inflammation,enzyme,Phase 1,Yes,TOP1 inhibitor PEEL-224,https://peeltx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zhejiang xinkanghe biomedical technology co ltd,"Error: Connection failed - HTTPConnectionPool(host='en.kanovabiopharma.com', ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Interleukin-25 Proteins,https://patents.google.com/patent/CN112638940A/en,Yes,anti-IL-25 antibodies,https://patents.google.com/patent/CN112638940A/en,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai rnacure biopharma co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sirnagen therapeutics corp,"Error: Connection failed - HTTPSConnectionPool(host='www.decibio.com', port=4",Yes,Inclisiran; Vutrisiran; Patisiran; Lumasiran; Givosiran; Nedosiran,"PCSK9, Proprotein Convertase Subtilisin/Kexin Type 9; GalNAc, N-Acetylgalactosamine; TTR, Transthyretin; Glycolate oxidase; ALAS1, Aminolevulinic Acid Synthase 1; LDHA, Lactate Dehydrogenase",cardiovascular; metabolic diseases; rare diseases,enzyme; other,Approved,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNAi platform products company focused on immunology and central nervous system (CNS) diseases,https://www.linkedin.com/company/sirnagen-therapeutics,No,,,No,,,No,,,No,,
myr gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.htgf.de', port=443):",Yes,Hepcludex; bulevirtide; Myrcludex B,"NTCP, Sodium Taurocholate Cotransporting Polypeptide",infectious diseases,other,Approved,No,,,Yes,"Bulevirtide, sold under the brand name HepcludexTM, is a first-in-class entry inhibitor",https://www.eu-startups.com/directory/myr-gmbh/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
allievex corp,2019-11-23 00:00:00,No,Tralesinidase alfa; TA-ERT,"NAGLU, Alpha-N-acetyglucosaminidase",rare diseases,enzyme,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alteogen inc,2025-09-23 01:17:20,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,"NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body.",https://www.linkedin.com/company/alteogen/,Yes,"NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body.",https://www.linkedin.com/company/alteogen/,Yes,optimized analytical methods to support the development of monoclonal antibody biosimilars.,https://www.linkedin.com/company/alteogen/,Yes,"proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies.",https://www.linkedin.com/company/alteogen/,Yes,"NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body.",https://www.linkedin.com/company/alteogen/,No,,,No,,,No,,,No,,,No,,
chongqing kerun biopharm r &,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"ZD2767P (4-[N,N-bis(2-iodoethyl)amino] phenoxycarbonyl L-glutamic acid)",https://pmc.ncbi.nlm.nih.gov/articles/PMC9652066/,No,,,Yes,carboxypeptidase G2 (CPG2),https://pmc.ncbi.nlm.nih.gov/articles/PMC9652066/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amazentis sa,Error: Connection failed - HTTPSConnectionPool(host='www.nestlehealthscience.,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Senior Medicinal Chemist & Drug Hunter,https://www.linkedin.com/company/amazentis,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hangzhou chance pharmaceuticals,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,AER-901; imatinib,"PDGF-Rs, Platelet-Derived Growth Factor Receptors; c-KIT, Proto-Oncogene c-KIT; BCR-ABL, Breakpoint Cluster Region-Abelson",cardiovascular,kinases,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"spray drying platform enables the transformation of biological macromolecules, low-activity drugs, and deep lung/systemic delivery drugs into highly efficient dry powder inhalation formulations",https://www.prnewswire.com/news-releases/chance-pharma-secures-new-funding-to-accelerate-development-of-innovative-inhalation-therapies-302402896.html
intezyne inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,IT-139; IT-235,"GRP78, Glucose-Regulated Protein 78",oncology,enzyme,Phase 2,Yes,Small Molecule,https://www.linkedin.com/company/intezyne-technologies,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Nanoparticles,https://www.linkedin.com/company/intezyne-technologies
landos biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='nimml.org', port=443): M",No,NX-13,"NLRX1, NOD-like Receptor X1",immunology; inflammatory bowel disease,other,Phase 2,Yes,"NX-13, a first-in-class, oral NLRX1 agonist",https://news.abbvie.com/2024-05-23-AbbVie-Completes-Acquisition-of-Landos-Biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
qingdao sino-cell biomedicine co ltd,2025-08-05 00:00:00,No,HS-IT101,"Disease Name, Advanced Non-Small Cell Lung Cancer",oncology,other,Phase 1,No,,,No,,,Yes,Drug IL-2 (interleukin 2),https://clinicaltrials.gov/study/NCT07105176,No,,,No,,,No,,,No,,,Yes,tumor-infiltrating lymphocyte (TIL) therapies,https://www.cbinsights.com/company/sino-cell-biomed,No,,,No,,,No,,
river 3 renal corp (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,bardoxolone methyl;lademirsen;sparsentan;atrasentan;hydroxychloroquine;metformin;paricalcitol,"NRf2, Nuclear Factor Erythroid 2-related Factor 2;miRNA-21, MicroRNA-21;ETAR, Endothelin Type A Receptor;Angiotensin II Type 1 Receptor;ABCA1, ATP-binding Cassette Transporter A1;DDR1, Discoidin Domain Receptor 1;Osteopontin",nephrology;rare diseases,other;enzyme;gpcr;other;other;other;other,Phase 3;Phase 2;Phase 2;Phase 2;Phase 2;Not specified;Not specified,Yes,Small molecule,https://www.globenewswire.com/news-release/2025/08/19/3135948/0/en/Focal-Segmental-Glomerulosclerosis-Clinical-Trial-Pipeline-Analysis-Demonstrates-12-Key-Companies-at-the-Horizon-Expected-to-Transform-the-Treatment-Paradigm-Assesses-DelveInsight.html,No,,,No,,,No,,,No,,,Yes,Recombinant fusion proteins,https://www.globenewswire.com/news-release/2025/08/19/3135948/0/en/Focal-Segmental-Glomerulosclerosis-Clinical-Trial-Pipeline-Analysis-Demonstrates-12-Key-Companies-at-the-Horizon-Expected-to-Transform-the-Treatment-Paradigm-Assesses-DelveInsight.html,No,,,No,,,No,,,No,,,No,,
oncostellae sl,2024-04-18 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"Novel small-molecule drugs in immunology, fibrosis and women health",https://www.linkedin.com/company/oncostellae/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vogenx inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Mizagliflozin,"GIP, Gastric Inhibitory Peptide",metabolic diseases; gastrointestinal diseases,enzyme,Phase 2,Yes,"first-in-class, oral, small molecule drug candidate",https://vogenx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
yiviva inc,2018-11-29 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
exeliom biosciences sas,2025-10-16 09:43:01,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,microbiome-based immunotherapy,https://www.eu-startups.com/2023/07/paris-based-exeliom-biosciences-completes-final-close-of-e24-million-series-a-to-further-progress-its-microbiome-based-inmunotherapy/
endevica bio,"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,Endevica Bio's lead drug candidate is a peptide therapeutic,https://www.linkedin.com/company/endevicabio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
endevica bio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.crunchbase.com', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,peptide therapeutic,https://www.linkedin.com/company/endevicabio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
suzhou jinmeng biotechnology co ltd,2024-11-05 03:19:53,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pharmeste srl,"Error: Connection failed - HTTPSConnectionPool(host='www.mp-healthcare.com', ",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,TRPV1 Antagonist,https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-study-in-healthy-males-to-investigate-a-new-pain-relief-drug-2/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
phoenix solutions as,"Error: Connection failed - HTTPSConnectionPool(host='exact-tx.com', port=443)",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai high-tech bioengineering co ltd,2014-12-24 00:00:00,Yes,CMX410,"Pks13, Polyketide Synthase 13",infectious diseases,enzyme,Preclinical,No,,,Yes,Peptide,https://www.linkedin.com/company/shanghai-hi-tech-bio-engineeing-ltd-,Yes,Enzyme,https://www.linkedin.com/company/shanghai-hi-tech-bio-engineeing-ltd-,Yes,antibodies,https://www.bioengine-global.com/company-overview,No,,,Yes,antibody fusion protein drug,https://www.bioengine-global.com/company-overview,No,,,Yes,CAR-T cells and NK cells,https://www.bioengine-global.com/company-overview,Yes,"vaccine production of Vero, HEK293, MDCK, PK15, BHK, MDBK, insect cells",https://www.bioengine-global.com/company-overview,No,,,No,,
genome & co,"Error: Connection failed - HTTPConnectionPool(host='genomecom.co.kr', port=80",Yes,Iberdomide; Mezigdomide,Not specified,oncology,enzyme,Phase 3,No,,,No,,,No,,,Yes,novel drug target antibodies,https://www.linkedin.com/company/genomeandcompany,No,,,No,,,No,,,No,,,No,,,No,,,Yes,microbiome therapeutics,https://www.linkedin.com/company/genomeandcompany
genome &,"Error: Connection failed - HTTPConnectionPool(host='genomecom.co.kr', port=80",Yes,benzoxazole propiolamide analog 243; compound 739; compound 804,"p97, Parasite Valosin-Containing Protein",infectious diseases,enzyme,Preclinical,No,,,No,,,No,,,Yes,novel drug target antibodies,https://www.linkedin.com/company/genomeandcompany,No,,,No,,,No,,,No,,,No,,,No,,,Yes,microbiome pharmaceuticals,https://www.linkedin.com/company/genomeandcompany
immvira co ltd,2022-11-26 00:00:00,Yes,cretostimogene grenadenorepvec; TAR-210; TYRA-300; UGN-301,"CAR, Coxsackievirus and Adenovirus Receptors; FGFR, Fibroblast Growth Factor Receptor; CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4",oncology,other; kinases; immune checkpoint,Phase 3; Phase 2; Phase 1,No,,,No,,,No,,,Yes,anti-PD-1Ab,https://hk.linkedin.com/company/immvira,No,,,No,,,No,,,No,,,No,,,No,,,Yes,genetically engineered viruses,https://hk.linkedin.com/company/immvira
wecare probiotics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.crunchbase.com', por",No,Wec120B; Wec300B; BL21,Gastrointestinal Microbiota,gastrointestinal diseases; metabolic diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zhongze therapeutics,Error: Connection failed - HTTPSConnectionPool(host='www.zhongzetherapeutics.,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
swanbio therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.crunchbase.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapies to deliver dramatic clinical efficacy for neurological diseases,https://www.linkedin.com/company/swanbio-therapeutics,No,,,No,,,No,,
swanbio therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapies to deliver dramatic clinical efficacy for neurological diseases,https://www.linkedin.com/company/swanbio-therapeutics,No,,,No,,,No,,
clovis oncology inc,2011-07-02 00:00:00,No,Not specified,Not specified,oncology,Not specified,Not specified,Yes,precision medicine—to deliver the right drug to the right patient at the right time,https://www.linkedin.com/company/clovis-oncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nectin therapeutics ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,NTX1088,"PVR, CD155",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,Yes,novel monoclonal antibodies,https://www.prnewswire.com/news-releases/nectin-therapeutics-licenses-novel-antibodies-to-immunome-302206469.html,Yes,antibody drug conjugates (ADC),https://www.prnewswire.com/news-releases/nectin-therapeutics-licenses-novel-antibodies-to-immunome-302206469.html,No,,,No,,,Yes,CAR-T and -NK drivers,https://www.linkedin.com/company/nectin-therapeutics/,No,,,No,,,No,,
armagen inc,2018-03-23 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,"iduronate-2-sulfatase, an enzyme deficient in mucopolysaccharidosis II (Hunter's disease)",https://www.prnewswire.com/news-releases/jcr-pharmaceuticals-announces-completion-of-acquisition-of-armagen-inc-301047260.html,Yes,an antibody against the transferrin receptor,https://www.prnewswire.com/news-releases/jcr-pharmaceuticals-announces-completion-of-acquisition-of-armagen-inc-301047260.html,No,,,Yes,"JR-141, a fusion protein consisting of an antibody against the transferrin receptor and iduronate-2-sulfatase",https://www.prnewswire.com/news-releases/jcr-pharmaceuticals-announces-completion-of-acquisition-of-armagen-inc-301047260.html,No,,,No,,,No,,,No,,,Yes,"Blood-Brain barrier, J-Brain Cargo® technology",https://www.linkedin.com/company/armagen
pneumagen ltd,2025-09-17 11:06:48,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,NeumoBind™ extends the residence time of therapeutic proteins on nasal and other mucosal surfaces.,https://uk.linkedin.com/company/pneumagen-limited,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sl vaxigen inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
abbisko cayman limited,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,ABSK011; ABSK091; ABSK112; ABSK131; ABK-KRAS-1; Pimicotinib,"FGFR4, Fibroblast Growth Factor Receptor 4; FGFR1/2/3, Fibroblast Growth Factor Receptor Subtypes 1/2/3; EGFR exon20ins, Epidermal Growth Factor Receptor Exon 20 Insertion; PRMT5*MTA, Protein Arginine Methyltransferase 5*Methylthioadenosine; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; CSF-1R, Colony Stimulating Factor 1 Receptor",oncology,kinases; kinases; kinases; enzyme; kinases; enzyme,Phase 1; Phase 1; Preclinical; Phase 1; Preclinical; Approved,Yes,dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies,https://www.marketscreener.com/quote/stock/ABBISKO-CAYMAN-LIMITED-127830029/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
recovac consortium,"Error: Connection failed - HTTPSConnectionPool(host='www.pandemicpact.org', p",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gamaleya federal research center of epidemiology and microbiology,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",No,levonadifloxacin; alalevonadifloxacin; contezolid,Not specified,infectious diseases,enzyme,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,vector-based vaccines against Ebola fever using the adenovirus vector platform,https://sputnikvaccine.com/about-us/,No,,,No,,
midatech pharma plc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,MidaCore; MTX110; MTX210,Brain Tumors; Rare Diseases,oncology; rare diseases,other,Phase II; Preclinical,Yes,solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH),https://www.marketscreener.com/quote/stock/BIODEXA-PHARMACEUTICALS-P-19157045/news/Midatech-Pharma-plc-has-Changed-its-Name-to-Biodexa-Pharmaceuticals-PLC-42798972/,No,,,No,,,No,,,Yes,ultra-small gold nanoparticle (GNP) drug conjugates,https://www.marketscreener.com/quote/stock/BIODEXA-PHARMACEUTICALS-P-19157045/news/Midatech-Pharma-plc-has-Changed-its-Name-to-Biodexa-Pharmaceuticals-PLC-42798972/,No,,,No,,,No,,,No,,,No,,,Yes,long-acting injectables using proprietary three-dimensional (3D) printing technology,https://www.marketscreener.com/quote/stock/BIODEXA-PHARMACEUTICALS-P-19157045/news/Midatech-Pharma-plc-has-Changed-its-Name-to-Biodexa-Pharmaceuticals-PLC-42798972/
qpex biopharma inc,2024-05-31 00:00:00,Yes,xeruborbactam; S-649228; S-743229,"Beta-lactamase, Beta-lactamase enzyme",infectious diseases,enzyme,Phase 3,Yes,beta-lactamase inhibitor discovered by Qpex scientists,https://www.shionogi.com/global/en/news/2024/05/E_20240531_1.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shasqi inc,2025-10-15 15:00:11,Yes,SQ3370,Disease Name,oncology,other,Phase 1,No,,,No,,,No,,,Yes,antibody-mediated tumor-targeting agents,https://www.linkedin.com/company/shasqi-inc-,Yes,antibody drug conjugates (ADCs),https://www.prnewswire.com/news-releases/shasqi-publishes-landmark-study-in-clinical-cancer-research-first-in-human-use-of-click-chemistry-unlocks-new-opportunities-for-targeted-cancer-therapies-302482314.html,No,,,No,,,No,,,No,,,No,,,Yes,Click Activated Protodrugs Against Cancer (CAPAC®) platform,https://www.linkedin.com/company/shasqi-inc-
sun pharma advanced research company ltd,"Error: Connection failed - HTTPSConnectionPool(host='medicine.washu.edu', por",No,Enibarcimab; M6229; SNIPR001,"ADM, Adrenomedullin; Histones; E. coli",infectious diseases,cytokine; other; other,Phase 2; Phase 2; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immusoft corp,"Error: Connection failed - HTTPSConnectionPool(host='www.cirm.ca.gov', port=4",No,ISP-001,"MPS I, Mucopolysaccharidosis type I",rare diseases,other,Phase 1,No,,,No,,,Yes,sustained delivery of therapeutic proteins from a patient’s own cells,https://www.linkedin.com/company/immusoft,No,,,No,,,No,,,No,,,Yes,Immusoft has reached a major milestone in the field of cell and gene therapy,https://www.linkedin.com/company/immusoft,No,,,No,,,No,,
incyclix bio llc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,INX-315,"CDK2, Cyclin-Dependent Kinase 2",oncology,kinases,Phase 1/2,Yes,potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor,https://incyclixbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
intensity therapeutics inc,2025-08-07 16:06:00,Yes,INT230-6,Not specified,oncology,other,Phase 3,Yes,"two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate",https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update-302524797.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,direct intratumoral injection; proprietary non-covalent conjugation technology,https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update-302524797.html
bioverativ inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,hemophilia therapies,https://www.linkedin.com/company/bioverativ,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bioverativ therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,hemophilia therapies,https://www.linkedin.com/company/bioverativ,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genascence corp,2025-10-08 18:13:47,No,GNSC-001,"IL-1, Interleukin-1",musculoskeletal diseases,cytokine,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,AAV-mediated anti-interleukin-1 gene therapy,https://www.linkedin.com/company/genascence-corporation,No,,,No,,,No,,
forsight vision5 inc,2016-05-20 00:00:00,Yes,Not specified,Disease Name,ophthalmology,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,non-invasive peri-ocular product that rests on the surface of the eye (under the eyelids),https://www.prnewswire.com/news-releases/allergan-to-acquire-eye-care-company-forsight-vision5-adding-peri-ocular-ring-technology-to-companys-leading-portfolio-of-innovative-eye-health-products-300312348.html
wellmarker bio co ltd,2021-11-14 00:00:00,Yes,WM-A1-3389; KEYTRUDA,Not specified,oncology,immune checkpoint,Phase 1,Yes,Medicinal chemistry department,https://www.linkedin.com/company/wellmarkerbio/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kite pharma inc,2017-08-28 00:00:00,No,anito-cel,"BCMA, B-cell Maturation Antigen",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"CAR T-cell therapy, engineered T cell therapy, chimeric antigen receptor (CAR), T cell receptor (TCR)",https://www.kitepharma.com/,No,,,No,,,No,,
impact biotech limited,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Vascular Targeted Photodynamic (VTP) therapy,https://www.globenewswire.com/news-release/2025/04/11/3060047/0/en/ImPact-Biotech-Announces-New-Data-Presentations-at-AUA-2025-Highlighting-Safety-and-Efficacy-of-Padeliporfin-VTP.html
aptose biosciences inc,2025-10-22 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"CG-806, our oral mutation-agnostic FLT3/BTK inhibitor",https://www.linkedin.com/company/aptose-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
foundation for research and biomedical innovation of the infanta leonor university hospital,"Error: Connection failed - HTTPSConnectionPool(host='beamerproject.eu', port=",No,Capivasertib,"AKT, Protein Kinase B",oncology,kinases,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
xencor inc,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,Proteins by Design,https://www.linkedin.com/company/xencor,Yes,engineered antibodies for the treatment of cancer and autoimmune diseases,https://www.linkedin.com/company/xencor,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Bispecific antibodies,https://www.linkedin.com/company/xencor
t-knife gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.mdc-berlin.de', port",Yes,T1367,"MAGE-A1, Melanoma-Associated Antigen A1",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,T cell receptor (TCR) engineered T cell therapies (TCR-Ts),https://www.linkedin.com/company/t-knife,No,,,No,,,No,,
macrogenics inc,2025-09-04 12:33:50,Yes,Lorigerlimab; MGC026; MGC028; MGD024; MARGENZA; ZYNYZ; TZIELD,"PD-1 × CTLA-4, Programmed Death-1 × Cytotoxic T-Lymphocyte-Associated Protein 4; B7-H3, B7 Homolog 3; ADAM9, A Disintegrin and Metalloproteinase Domain 9; CD123 × CD3, Interleukin-3 Receptor Alpha × Cluster of Differentiation 3; HER2, Human Epidermal Growth Factor Receptor 2",oncology; autoimmune disorders; infectious diseases,immune checkpoint; other; enzyme; immune checkpoint; immune checkpoint,Phase 3; Phase 2; Phase 2; Phase 1; Marketed,No,,,No,,,No,,,Yes,monoclonal antibody-based therapeutics,https://macrogenics.com/,Yes,"MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC)",https://macrogenics.com/,No,,,No,,,No,,,No,,,No,,,No,,
cargo therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='cargo-tx.com', port=443)",Yes,firicabtagene autoleucel; CRG-023,"CD22, Cluster of Differentiation 22; CD19, Cluster of Differentiation 19; CD20, Cluster of Differentiation 20",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,engineering best-in-class CAR T-cell therapy,https://www.linkedin.com/company/cargo-tx-inc,No,,,No,,,No,,
foghorn therapeutics inc,2025-10-16 11:27:49,Yes,Selective ARID1B; Selective CBP; Selective EP300,"ARID1B, AT-rich interactive domain-containing protein 1B; CBP, CREB-binding protein; EP300, E1A-associated protein p300",oncology,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Selective ARID1B degrader, Selective CBP degrader, Selective EP300 degrader",https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-announces-significant-progress-for-selective-lptj4xi3h65l.html,No,,
neogene therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,ELC-301; ELC-401,"CD20, Cluster of Differentiation 20; Glioblastoma",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,next-generation engineered T cell receptor (TCR) therapies,"https://www.builtinla.com/company/neogene-therapeutics#:~:text=Neogene%20Therapeutics%20is%20a%20global,broad%20spectrum%20of%20solid%20cancers.",No,,,No,,,No,,
ribox (shanghai) therapeutics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,MSI2; SOX5,"MSI2, Musashi2; SOX5, SRY-Box Transcription Factor 5",rheumatology; osteoarthritis,other,Preclinical,No,,,No,,,Yes,"RXRG001 consists of the circular RNA coding human aquaporin 1 (hAQP1, a water channel protein of cell membranes)",https://www.prnewswire.com/news-releases/ribox-therapeutics-announces-first-patient-dosed-in-phase-iiia-clinical-trial-of-rxrg001-the-first-circular-rna-therapy-for-the-treatment-of-radiation-induced-xerostomia-and-hyposalivation-302395477.html,No,,,No,,,No,,,Yes,RiboX focuses on the discovery and development of fully engineered circular RNA therapeutics,https://www.riboxtx.com/,No,,,No,,,No,,,Yes,encapsulated in lipid nanoparticles (LNPs),https://www.prnewswire.com/news-releases/ribox-therapeutics-announces-first-patient-dosed-in-phase-iiia-clinical-trial-of-rxrg001-the-first-circular-rna-therapy-for-the-treatment-of-radiation-induced-xerostomia-and-hyposalivation-302395477.html
immpact bio usa inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,IMPT-314; LYL119,"CD19/20, Cluster of Differentiation 19 and 20",oncology; autoimmune diseases,immune checkpoint,Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,chimeric antigen receptor (CAR) T-cell therapies,https://www.linkedin.com/company/immpact-bio,No,,,No,,,No,,
intellia therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,"Nex-z, NTLA-2001","TTR, Transthyretin gene knockout using CRISPR/Cas9",Cardiovascular/Metabolic; Rare Disease; Hematology,Other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CRISPR/Cas9 genome editing systems,https://www.linkedin.com/company/intelliatx,No,,,No,,,No,,
zura bio ltd,2025-08-20 10:30:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,developing dual-pathway antibodies for autoimmune and inflammatory diseases,https://www.stocktitan.net/news/ZURA/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sagimet biosciences inc,2025-09-08 15:13:48,No,denifanstat; TVB-3567,"FASN, Fatty Acid Synthase",metabolic diseases; dermatology,enzyme,Phase 2; Phase 1,Yes,small-molecule fatty acid synthase (FASN) inhibitor,https://www.linkedin.com/company/3-v-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
castle creek biosciences inc,"Error: Connection failed - ('Connection aborted.', RemoteDisconnected('Remote",No,D-Fi; FCX-007; FCX-013; LV-FAH,"COL7, Type VII Collagen; FAH, Fumarylacetoacetate Hydrolase",rare diseases; skin and connective tissue disorders; rare liver diseases; metabolic diseases,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Developing novel gene therapies to improve lives,https://castlecreekbio.com/,No,,,No,,,No,,
avencell europe gmbh,2025-06-30 14:49:28,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Universal Switchable CAR-T cell therapy platform,https://www.linkedin.com/company/avencell,No,,,No,,,No,,
avencell therapeutics inc,2024-10-22 06:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Universal Switchable CAR-T cell therapy platform,https://www.prnewswire.com/news-releases/avencell-raises-112-million-in-series-b-funding-led-by-novo-holdings-302282924.html,No,,,No,,,No,,
profoundbio us co,2024-02-13 07:00:00,No,Rinatabart sesutecan; PRO1160; PRO1107; PRO1286,"FRα, Folate Receptor-Alpha; CD70; PTK7, Protein Tyrosine Kinase 7; Not specified",oncology,other; other; kinases; other,Phase 2; Phase 1; Phase 1; Preclinical,No,,,No,,,No,,,Yes,novel antibody-based therapeutics for patients with cancer,https://www.linkedin.com/company/profoundbio,No,,,No,,,No,,,No,,,No,,,No,,,No,,
opthea ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,VEGF-C/D ‘trap’ inhibitor,https://www.linkedin.com/company/opthea,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
trevi therapeutics inc,2025-06-05 16:30:32,No,Haduvio,Opioid Receptors,CNS; respiratory diseases,gpcr,Phase 2,Yes,oral nalbuphine extended-release,https://www.linkedin.com/company/trevi-therapeutics-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
wugen inc,2025-08-27 10:28:54,No,WU-CART-007,"CD7, Cluster of Differentiation 7",oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,off-the-shelf CAR-T therapy,https://www.biopharmadive.com/news/wugen-funding-car-t-allogeneic-off-the-shelf/758726/,No,,,No,,,Yes,memory natural killer (NK) cell therapies,https://www.globenewswire.com/news-release/2024/06/14/2898923/0/en/Phase-2-Findings-Show-Wugen-s-Investigational-Allogeneic-CAR-T-WU-CART-007-Was-Highly-Effective-and-Surpassed-Standard-of-Care-in-Treating-Hard-to-Treat-T-ALL-LBL-Data-Presented-To.html
talaris therapeutics inc,2020-11-06 00:00:00,No,FCR001; TAL-001,Not specified,organ transplantation; autoimmune diseases; non-malignant blood disorders; immune disorders; metabolic disorders,other,Phase 3; Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"cell therapy, allogeneic cell therapy",https://www.linkedin.com/company/talaris-therapeutics,No,,,No,,,No,,
y-mabs therapeutics inc,2025-09-24 14:00:19,No,DANYELZA; Omburtamab; Nivatrotamab; GD2-SADA,"GD2, Disialoganglioside GD2; B7-H3, CD276; Not specified",oncology; rare diseases,immune checkpoint; other,Approved; Phase 2; Phase 1,No,,,No,,,No,,,Yes,antibody-based therapeutic cancer products,"https://ir.ymabs.com/#:~:text=Y%2DmAbs%20is%20a%20commercial,antibody%2Dbased%20therapeutic%20cancer%20products.",Yes,radioimmunotherapy and antibody-based therapeutic cancer products,"https://ir.ymabs.com/#:~:text=Y%2DmAbs%20is%20a%20commercial,antibody%2Dbased%20therapeutic%20cancer%20products.",No,,,No,,,No,,,No,,,No,,,Yes,radioimmunotherapy,"https://ir.ymabs.com/#:~:text=Y%2DmAbs%20is%20a%20commercial,antibody%2Dbased%20therapeutic%20cancer%20products."
evommune inc,"Error: Connection failed - HTTPSConnectionPool(host='wewillcure.com', port=44",No,EVO756; EVO301,"MRGPRX2, Mas-related G-protein coupled receptor member X2; IL-18, Interleukin-18",immunology; dermatology; gastrointestinal,gpcr; cytokine,Phase 2,Yes,EVO756 is a potent and highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2),https://www.prnewswire.com/news-releases/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress-302560722.html,No,,,Yes,"EVO301 binds to IL-18, an inflammatory cytokine",https://www.biopharmadive.com/news/evommune-ipo-chronic-spontaneous-urticaria-atopic-dermatitis-MRGPRX2/802555/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sudo biosciences inc,2023-12-20 14:36:06,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,precision TYK2 (tyrosine kinase 2) inhibitors,https://www.tpg.com/news-and-insights/sudo-biosciences-raises-116m-series-b-financing-to-advance-potential-best-in-class-tyk2-therapeutics-programs-into-the-clinic,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amunix operating inc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,AMX-818,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,immune checkpoint,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amunix pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.baincapital.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
precirix nv,No timestamp found,Yes,CAM-H2,"HER2, Human Epidermal Growth Factor Receptor 2",oncology,other,Phase 1/Phase 2,No,,,No,,,No,,,Yes,radiolabelled single-domain antibodies (sdAbs),https://www.prnewswire.com/news-releases/precirix-raises-eur-80m-in-series-b-to-advance-its-pipeline-of-precision-radiopharmaceuticals-301503283.html,Yes,radiopharmaceuticals using camelid single-domain antibodies labelled with radioisotopes,https://www.prnewswire.com/news-releases/precirix-raises-eur-80m-in-series-b-to-advance-its-pipeline-of-precision-radiopharmaceuticals-301503283.html,No,,,No,,,No,,,No,,,No,,,Yes,"theragnostic approach, where patients can be selected using a low dose/imaging version of the product",https://www.prnewswire.com/news-releases/precirix-raises-eur-80m-in-series-b-to-advance-its-pipeline-of-precision-radiopharmaceuticals-301503283.html
exelixis inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Zanzalintinib; XB010; XL309,"VEGFR, Vascular Endothelial Growth Factor Receptor; MET, Mesenchymal-Epithelial Transition Factor; TAM kinases, TYRO3/AXL/MER; 5T4, Tumor Antigen 5T4; USP1, Ubiquitin-Specific Peptidase 1",oncology,kinases; other; enzyme,Preclinical,Yes,Biologics & Small Molecules,https://www.linkedin.com/company/exelixis,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
anaveon ag,2025-10-14 08:00:03,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,develops biologics to modulate the functions of cytokines,https://ch.linkedin.com/company/anaveon-ag,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alladapt immunotherapeutics inc,Error: can't compare offset-naive and offset-aware dateti,No,Not specified,Not specified,immunology,Not specified,Not specified,No,,,No,,,Yes,protein structures,https://patientsquarecapital.com/alladapt-announces-completion-of-oversubscribed-119-million-institutional-financing/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pepromene bio inc,2025-05-20 10:22:34,No,Not specified,"Disease Name, Acute Lymphoblastic Leukemia",oncology,other,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR-T cells targeting an innovative tumor antigen (BAFF-R),https://www.linkedin.com/company/pepromene-bio,No,,,No,,,No,,
pmd device solutions ab,2025-01-01 11:21:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"Genaissance Pharmaceuticals, Inc. (inactive)","Error: Connection failed - HTTPSConnectionPool(host='www.courant.com', port=4",No,Emraclidine; Tavapadon; CVL-354; Darigabat,"M4, Muscarinic M4 receptor; D1/D5, Dopamine D1/D5 receptor; KOR, Kappa Opioid Receptor; GABA A receptor",psychiatric disorders; neurological disorders; schizophrenia; Parkinson's disease; epilepsy; panic disorder; Alzheimer's disease psychosis,gpcr; gpcr; other; ion channels,Phase 2; Phase 3; Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
"genaissance pharmaceuticals, inc. (inactive)",Error: Connection failed - 403 Client Error: Forbidden for url: https://www.s,No,Emraclidine; Tavapadon; CVL-354; Darigabat,"M4, Muscarinic M4 receptor; D1/D5, Dopamine D1/D5 receptors; KOR, Kappa Opioid Receptor; GABA A, Gamma-Aminobutyric Acid A receptor",psychiatric disorders; neurological disorders; Parkinson's disease; epilepsy; mood disorders,gpcr; gpcr; other; ion channels,Phase 2; Phase 3; Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
reconnect labs ag,2025-10-14 13:35:00,No,Not specified,Not specified,mental health; insomnia; anxiety; substance use disorders,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arecor therapeutics plc,Error: Connection failed - 403 Client Error: Forbidden for url: https://areco,Yes,AT278,"Disease Name, Type 1 and Type 2 Diabetes",metabolic diseases,other,Phase 2,No,,,Yes,#GLP1 #metabolic #peptides,"https://uk.linkedin.com/company/arecor-limited#:~:text=Arecor%20Therapeutics%20plc%20is%20a,enhancement%20of%20existing%20therapeutic%20products.",Yes,High Concentration mAbs,"https://uk.linkedin.com/company/arecor-limited#:~:text=Arecor%20Therapeutics%20plc%20is%20a,enhancement%20of%20existing%20therapeutic%20products.",Yes,High Concentration mAbs,"https://uk.linkedin.com/company/arecor-limited#:~:text=Arecor%20Therapeutics%20plc%20is%20a,enhancement%20of%20existing%20therapeutic%20products.",No,,,No,,,No,,,No,,,Yes,Vaccine Stability,"https://uk.linkedin.com/company/arecor-limited#:~:text=Arecor%20Therapeutics%20plc%20is%20a,enhancement%20of%20existing%20therapeutic%20products.",No,,,No,,
vensica therapeutics,2024-10-29 12:34:37,Yes,Xeomin,Not specified,urology,enzyme,Phase 2,No,,,No,,,Yes,Botulinum toxin A (Xeomin®),https://www.prnewswire.com/il/news-releases/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder-treatment-302288449.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,needle-free catheter-based system that uses ultrasound waves,https://il.linkedin.com/company/vensica-medical
immunos therapeutics ag,2024-09-17 08:00:00,Yes,iosH2; IOS-1002,"HLA, Human Leukocyte Antigen",oncology; autoimmune diseases,immune checkpoint,Phase 2,No,,,No,,,Yes,multi-functional HLA-fusion protein,https://www.globenewswire.com/news-release/2024/09/17/2947186/0/en/ImmunOs-Therapeutics-AG-Raises-11-Million-and-Further-Strengthens-Investor-Base.html,No,,,No,,,Yes,multi-functional HLA-fusion protein,https://www.globenewswire.com/news-release/2024/09/17/2947186/0/en/ImmunOs-Therapeutics-AG-Raises-11-Million-and-Further-Strengthens-Investor-Base.html,No,,,No,,,No,,,No,,,Yes,targeting myeloid checkpoints,https://www.globenewswire.com/news-release/2024/09/17/2947186/0/en/ImmunOs-Therapeutics-AG-Raises-11-Million-and-Further-Strengthens-Investor-Base.html
national institute for research in tuberculosis,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,delamanid; bedaquiline; moxifloxacin; pyrazinamide; rifapentine; rifamycin; isoniazid,Mycobacterium tuberculosis,infectious diseases,other,Phase 3; Phase 2; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Vaccine development for complex intracellular neglected pathogens,https://www.validate-network.org/national-institute-for-research-in-tuberculosis,No,,,No,,
immunovative therapies ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,AlloStim,"Disease Name, Metastatic Colorectal Cancer",oncology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,New vaccine concept that works in over 65yo to protect against respiratory viral infection,https://il.linkedin.com/company/immunovative-therapies-ltd.,No,,,Yes,"Next Generation Immunotherapy. Off-the shelf, non-genetically altered, Neo-antigen-based, in-situ cancer vaccines",https://il.linkedin.com/company/immunovative-therapies-ltd.
lineage cell therapeutics inc,2025-10-16 15:44:38,No,TECVAYLI; DARZALEX FASPRO,"BCMA, B-cell Maturation Antigen; CD38, Cluster of Differentiation 38",oncology,immune checkpoint; immune checkpoint,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing novel cell therapies for unmet medical needs,https://www.linkedin.com/company/lineagecell,No,,,No,,,No,,
ck regeon inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,"CXXC5, Negative Regulator of WNT Pathway; Dvl, Dishevelled",metabolic diseases; CNS,enzyme,Preclinical,Yes,First-in-class small molecule drugs which could restore damaged tissues of target diseases by restorative activation of the regenerative WNT/ꞵ-catenin signaling,https://informaconnect.com/bioeurope-spring/sponsors/ck-regeon-inc/,Yes,KY19382 is a small molecule that mimics PTD-DBM peptide functions,https://dermaregeon.com/post/ck-regeon-debuts-new-scalp-and-hair-care-brands-heribon-and-hairregeon,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kezar life sciences inc,2025-08-28 20:06:23,No,Zetomipzomib; KZR-616; KZR-261,Immunoproteasome,autoimmune diseases; liver disease,enzyme,Phase 2,Yes,"Pioneering first-in-class, small-molecule therapies",https://www.linkedin.com/company/kezarlifesciences,No,,,Yes,"Kezar is developing novel, first-in-class, small molecule approaches for targeting select proteins",https://kezarlifesciences.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bergenbio asa,"Error: Connection failed - HTTPSConnectionPool(host='www.oncoinvent.com', por",Yes,Bemcentinib; Tilvestamab,"AXL, AXL receptor tyrosine kinase",oncology; infectious diseases,kinases,Phase 2,Yes,selective AXL kinase inhibitors,https://www.linkedin.com/company/bergenbio-as/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurotherapia inc,2024-08-06 08:00:00,Yes,NTRX-07,"CB2, Cannabinoid Receptor 2",CNS; neurodegenerative diseases,gpcr,Phase 2,Yes,Small molecule therapies to treat central nervous system (CNS) diseases,https://www.neurotherapia.com/,No,,,No,,,Yes,currently approved antibody therapies,https://www.neurotherapia.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neurotherpia inc,2024-08-06 08:00:00,Yes,NTRX-07,"CB2, Cannabinoid Receptor 2",CNS; neurodegenerative diseases; Alzheimer's disease,gpcr,Phase 2,Yes,"oral, small molecule therapeutics",https://www.neurotherapia.com/,No,,,No,,,Yes,therapeutic monoclonal antibodies,https://www.prnewswire.com/news-releases/neurotherapia-raises-12-3m-in-the-first-close-of-its-series-b-financing-302213518.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
faron pharmaceuticals oy,2025-10-17 05:58:02,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,anti-Clever-1 antibody,https://fi.linkedin.com/company/faron,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kineta inc,2025-06-30 08:50:00,No,TBS-2025; KVA12123,"VISTA, V-domain Ig suppressor of T cell activation",oncology; immuno-oncology,immune checkpoint,Phase 2,No,,,No,,,No,,,Yes,Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb),https://www.prnewswire.com/news-releases/tuhura-biosciences-completes-acquisition-of-kineta-302494115.html,Yes,bi-specific antibody drug conjugates,https://www.prnewswire.com/news-releases/tuhura-biosciences-completes-acquisition-of-kineta-302494115.html,No,,,No,,,No,,,No,,,No,,,No,,
oncomatryx biopharma sl,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,human-derived proteins,https://www.pharmaceutical-tech.com/suppliers/oncomatryx-biopharma-sl,Yes,therapeutic human antibodies,https://www.pharmaceutical-tech.com/suppliers/oncomatryx-biopharma-sl,Yes,antibody-drug conjugates (ADCs),https://es.linkedin.com/company/oncomatryx-biopharma,No,,,No,,,No,,,No,,,No,,,Yes,immunotoxins,https://www.pharmaceutical-tech.com/suppliers/oncomatryx-biopharma-sl
neurodegenerative disease research inc,No timestamp found,Yes,ANX005; ASHA-624; NX210c; CTx2000; PrimeC; NUZ-001; PLL001; pridopidine; VTx-002; VRG50635,"C1q, Complement Component 1q; SARM1, Sterile Alpha and TIR Motif Containing 1; TDP-43, TAR DNA Binding Protein 43; SOD1, Superoxide Dismutase 1; Sigma-1 receptor; UNC13A, Unc-13 Homolog A",CNS; neurodegenerative diseases,enzyme; other; other; enzyme; other; other,Phase 2b/3; Preclinical; Phase 2; Preclinical; Phase 3; Phase 2/3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
molecure sa,2025-10-02 06:58:00,Yes,OATD-01; OATD-02,"CHIT1, Chitinase 1; ARG1 and ARG2, Arginase 1 and Arginase 2",pulmonary diseases; oncology; metabolic diseases,enzyme; enzyme,Phase 2; Phase 1,Yes,Small Molecule Drug Discovery,https://pl.linkedin.com/company/molecure-sa,No,,,No,,,No,,,No,,,No,,,Yes,modulate underexplored protein targets and the function of RNA,https://pl.linkedin.com/company/molecure-sa,No,,,No,,,Yes,"Discovery, optimization and in vivo efficacy of novel pyrrolotriazine-based ubiquitin-specific protease 7 (USP7) inhibitors",https://pl.linkedin.com/company/molecure-sa,No,,
tolerogenixx gmbh,2023-07-07 15:18:39,Yes,MIC-Lx,Not specified,transplantation; autoimmune diseases,Not specified,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients.,https://de.linkedin.com/company/tolerogenixx-gmbh,No,,,No,,,Yes,"Through the newly developed MIC technology, donor PBMCs are modified to create a cell therapy product administered to transplant recipients.",https://www.labiotech.eu/trends-news/tolerogenixx-expands-trial-closes-financing/
geovax labs inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,GEO-CM04S1; Gedeptin; GEO-MVA,"Disease Name, COVID-19; Disease Name, Head and Neck Squamous Cell Carcinoma; Disease Name, Mpox/Smallpox",infectious diseases; oncology,Not specified,Phase 2; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR-T cell therapy,https://www.linkedin.com/company/geovax-inc-,Yes,developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform,https://www.linkedin.com/company/geovax-inc-,No,,,No,,
oncoinvent as,2025-06-18 05:27:32,Yes,Radspherin,Not specified,oncology,other,Phase 2,No,,,No,,,No,,,No,,,Yes,radioimmunotherapeutic products,https://www.linkedin.com/company/oncoinvent-as/,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceutical products,https://www.linkedin.com/company/oncoinvent-as/
applied molecular transport inc,2021-05-01 00:00:00,No,AMT-101; AMT-126,"IL-10, Interleukin 10; IL-22, Interleukin 22",autoimmune; inflammatory; metabolic diseases,cytokine,Preclinical,No,,,No,,,Yes,transformational biologic medicines,https://www.linkedin.com/company/applied-molecular-transport,No,,,No,,,Yes,investigational oral biologic fusion protein of interleukin 10 (IL-10),https://www.linkedin.com/company/applied-molecular-transport,No,,,No,,,No,,,No,,,No,,
belief biomed inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,BBM-H901; BBM-P002,"FIX, Coagulation Factor IX; Dopamine Synthesis Genes",rare diseases; neurodegenerative diseases,enzyme; other,Approved; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene therapy, AAV vector technology, adeno-associated virus (AAV) vectors",https://www.bayer.com/media/en-us/askbio-to-collaborate-with-belief-biomed-to-explore-the-potential-of-new-gene-therapies/,No,,,No,,,No,,
compass therapeutics inc,2025-08-11 11:00:00,Yes,CTX-009; CTX-471; CTX-8371; CTX-10726,"DLL4, Delta-like ligand 4; VEGF-A, Vascular Endothelial Growth Factor A; CD137, Tumor Necrosis Factor Receptor Superfamily Member 9; PD-1, Programmed Death-1; PD-L1, Programmed Death-Ligand 1",oncology,immune checkpoint; cytokine,Phase 2,No,,,No,,,No,,,Yes,developing proprietary antibody-based therapeutics,https://www.globenewswire.com/news-release/2025/08/11/3130767/0/en/Compass-Therapeutics-Reports-2025-Second-Quarter-Financial-Results-and-Provides-Corporate-Update.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
zenas biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Orelabrutinib; Obexelimab; IL-17AA/AF inhibitor; TYK2 inhibitor,"BTK, Bruton’s Tyrosine Kinase; CD19 and FcγRIIb; IL-17AA/AF; TYK2",neurology; immunology; autoimmune diseases,kinases; other; cytokine; other,Phase 3; Phase 3; Preclinical; Preclinical,No,,,No,,,No,,,Yes,monoclonal antibody candidates,https://www.nasdaq.com/articles/chairman-and-ceo-zenas-biopharma-zbio-buys-36928-shares-769948,No,,,No,,,No,,,No,,,No,,,No,,,No,,
iteos therapeutics inc,2025-05-12 14:09:24,Yes,Lung-201; EOS-215; A2A-005; Lung-301,"PD-L1, Programmed Death-Ligand 1; TREM2, Triggering Receptor Expressed on Myeloid Cells 2; A2AR, Adenosine A2A Receptor",oncology,immune checkpoint; other; gpcr,Phase 3; Phase 2; Phase 1,Yes,Small molecule immunomodulators,"https://www.linkedin.com/company/iteos-therapeutics-sa#:~:text=iTeos%20Therapeutics%20is%20a%20clinical,immuno%2Doncology%20therapeutics%20for%20patients.",No,,,No,,,Yes,anti-TREM2 antibody,"https://www.linkedin.com/company/iteos-therapeutics-sa#:~:text=iTeos%20Therapeutics%20is%20a%20clinical,immuno%2Doncology%20therapeutics%20for%20patients.",No,,,No,,,No,,,No,,,No,,,No,,,Yes,"T Cell Engagers, BiTEs","https://www.linkedin.com/company/iteos-therapeutics-sa#:~:text=iTeos%20Therapeutics%20is%20a%20clinical,immuno%2Doncology%20therapeutics%20for%20patients."
pheon therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,oncology,Not specified,Preclinical,No,,,No,,,No,,,Yes,novel and clinically validated monoclonal antibodies (mAbs),https://uk.linkedin.com/company/pheon-therapeutics,Yes,Antibody-Drug Conjugate specialist developing next generation ADCs,https://uk.linkedin.com/company/pheon-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,
nohla therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,ProTmune; KB103; BPX-501; A002; SIG-003; SGT-001; AVXS-101; ABO-202; DTX301; FCX-013; NSR-REP1,"Disease Name; COL7A1, Collagen Type VII Alpha 1 Chain; Disease Name; CNGB3, Cyclic Nucleotide-Gated Channel Beta 3; Factor IX; Dystrophin; SMN1, Survival Motor Neuron 1; Disease Name; OTC, Ornithine Transcarbamylase; MMP-1, Matrix Metalloproteinase-1; CHM, Choroideremia",oncology; rare diseases; dermatology; genetic disorders; ophthalmology; hematology; muscular dystrophy; metabolic diseases,Not specified; enzyme; Not specified; other; enzyme; other; other; Not specified; enzyme; enzyme; other,Phase 1; Preclinical; Phase 1; Phase 1/2; Preclinical; Phase 1/2; Phase 1; Preclinical; Phase 1/2; Preclinical; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,CAR progenitor and NK cell therapies,https://www.globenewswire.com/news-release/2018/07/11/1536174/0/en/Nohla-Therapeutics-Announces-Second-Closing-of-56-Million-Series-B-Financing.html,No,,,No,,,Yes,genetically-modified stem cells for gene therapy and editing,https://www.globenewswire.com/news-release/2018/07/11/1536174/0/en/Nohla-Therapeutics-Announces-Second-Closing-of-56-Million-Series-B-Financing.html
angitia biopharmaceuticals,2024-12-11 13:00:20,No,AGA111; CELZ-201-DDT; TG-C,Not specified,degenerative disc disease,Not specified,Phase 3; Phase 2; Phase 1,No,,,No,,,Yes,"AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease",https://www.globenewswire.com/news-release/2024/12/11/2995375/0/en/Angitia-Biopharmaceuticals-Announces-120-Million-Series-C-Financing.html,Yes,bispecific antibodies targeting sclerostin and DKK1,https://www.globenewswire.com/news-release/2024/12/11/2995375/0/en/Angitia-Biopharmaceuticals-Announces-120-Million-Series-C-Financing.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
angitia biopharmaceuticals ltd,2024-12-11 13:00:20,No,AGA111,Not specified,degenerative disc disease,Not specified,Phase 3,No,,,No,,,Yes,"AGA111, a biologic to promote spinal fusion",https://www.globenewswire.com/news-release/2024/12/11/2995375/0/en/Angitia-Biopharmaceuticals-Announces-120-Million-Series-C-Financing.html,Yes,bispecific antibodies targeting sclerostin and DKK1,https://www.globenewswire.com/news-release/2024/12/11/2995375/0/en/Angitia-Biopharmaceuticals-Announces-120-Million-Series-C-Financing.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cellcentric ltd,2025-10-16 12:31:38,No,Inobrodib; CCS1477,"p300/CBP, CREB-binding protein/E1A-associated protein p300",oncology; hematological malignancies; multiple myeloma,enzyme,Phase 2,Yes,Inobrodib; oral first-in-class p300/CBP small molecule inhibitor drug to treat cancer,https://www.cellcentric.com/,No,,,No,,,Yes,new combination of inobrodib with bi-specific antibodies,https://uk.linkedin.com/company/cellcentric,No,,,No,,,No,,,No,,,No,,,No,,,No,,
epimab biotherapeutics inc,2021-04-22 00:00:00,Yes,EMB-01,"EGFR, Epidermal Growth Factor Receptor; Met, Mesenchymal Epithelial Transition Factor",oncology,kinases,Not specified,No,,,No,,,No,,,Yes,developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology,https://www.linkedin.com/company/epimab-biotherapeutics/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,T-cell engager platform,https://www.globenewswire.com/news-release/2024/09/04/2940171/0/en/EpimAb-Biotherapeutics-and-Vignette-Bio-Announce-Strategic-Collaboration-to-Develop-EMB-06-a-BCMA-CD3-Bispecific-Antibody.html
virogin biotech ltd,2021-10-24 00:00:00,No,OH2 injection,Not specified,oncology,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic virus,https://ca.linkedin.com/company/viroginbiotech
phasebio pharmaceuticals inc,2023-04-18 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
st george street capital ltd,2019-09-24 00:00:00,No,GTB-3650; GTB-5550,"CD33, Cluster of Differentiation 33; B7H3, B7 Homolog 3",oncology; autoimmune diseases,immune checkpoint; other,Phase 1; Preclinical,Yes,to develop two compounds in the clinic,https://onenucleus.com/st-george-street-capital-agrees-deal-astrazeneca-drive-science-patients-need,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ngm biopharmaceuticals inc,2025-08-01 17:14:03,No,NGM120; Aldafermin,"GDF15, Growth Differentiation Factor 15; GFRAL, Glial Cell-Derived Neurotrophic Factor Family Receptor Alpha-Like",pregnancy-related disorders; oncology; gastrointestinal diseases,cytokine; other,Phase 2,No,,,No,,,No,,,Yes,GDF15/GFRAL antagonist antibody,https://www.ngmbio.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
flare therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,FX-909; FX-111,"PPARG, Peroxisome Proliferator-Activated Receptor Gamma",oncology,nuclear receptors,Phase 1,Yes,small molecule inhibitor of PPARG,https://www.linkedin.com/company/flare-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,potent and selective degrader for ARON,https://www.linkedin.com/company/flare-therapeutics,No,,
precigen inc,2025-09-03 07:00:00,No,PAPZIMEOS; PRGN-2009; PRGN-3006; PRGN-3005; PRGN-3007,"HPV 6 and HPV 11 proteins, Human Papillomavirus types 6 and 11 proteins",infectious diseases; oncology,other,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,advancing the next generation of gene and cell therapies,https://www.linkedin.com/company/precigen,No,,,No,,,No,,
maverick therapeutics inc,2025-06-04 10:46:35,Yes,TAK-186; TAK-280,"EGFR, Epidermal Growth Factor Receptor; B7-H3, B7 Homolog 3",oncology,immune checkpoint,Phase 1,No,,,No,,,Yes,"COBRA-engineered, protein-based therapies",https://www.takeda.com/newsroom/newsreleases/2021/takeda-to-acquire-maverick-therapeutics-to-advance-t-cell-engager-therapies-for-solid-tumors-and-expand-novel-immuno-oncology-portfolio/,Yes,bispecific T-cell engaging platform,https://www.takeda.com/newsroom/newsreleases/2021/takeda-to-acquire-maverick-therapeutics-to-advance-t-cell-engager-therapies-for-solid-tumors-and-expand-novel-immuno-oncology-portfolio/,No,,,No,,,No,,,Yes,T-cell therapy to solid tumor cancers,https://www.takeda.com/newsroom/newsreleases/2021/takeda-to-acquire-maverick-therapeutics-to-advance-t-cell-engager-therapies-for-solid-tumors-and-expand-novel-immuno-oncology-portfolio/,No,,,No,,,Yes,redirected T-cell targeted immunotherapies,https://www.linkedin.com/company/maverick-therapeutics
vectivbio holding ag,2023-06-26 16:01:00,No,apraglutide,"GLP-2, Glucagon-like Peptide-2",gastrointestinal diseases; rare diseases,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
surmodics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Triamcinolone Acetonide,Diabetic Macular Edema,ophthalmology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
astria therapeutics inc,2025-10-16 18:42:36,No,navenibart,"Disease Name, Hereditary Angioedema",rare diseases,other,Phase 3,No,,,No,,,No,,,Yes,monoclonal antibody inhibitor of plasma kallikrein,https://www.globenewswire.com/news-release/2025/10/14/3166038/29446/en/BioCryst-to-Acquire-Astria-Therapeutics-Strengthening-Presence-in-HAE-Transforming-Growth-Profile.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
atreca inc,2020-08-15 00:00:00,Yes,ATRC-101; ATRC-301,"Ribonucleoprotein Complex; EphA2, Erythropoietin-Producing Hepatocellular Receptor A2",oncology,other; kinases,Phase 1; Preclinical,No,,,No,,,No,,,Yes,novel cancer immunotherapeutics,https://www.linkedin.com/company/atreca-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,
deciphera pharmaceuticals inc,2025-10-16 14:00:26,Yes,vimseltinib; ripretinib,"CSF1R, Colony-Stimulating Factor 1 Receptor",oncology,kinases,Approved,Yes,proprietary switch-control kinase inhibitor platform,https://www.linkedin.com/company/deciphera-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
stoke therapeutics inc,2025-10-15 16:55:57,Yes,zorevunersen; STK-001,"Disease Name, Dravet Syndrome; Disease Name, Autosomal Dominant Optic Atrophy",CNS; rare diseases,other,Phase 3,No,,,No,,,Yes,restoring protein expression,https://www.stoketherapeutics.com/,No,,,No,,,No,,,Yes,antisense oligonucleotides (ASOs),https://www.stoketherapeutics.com/,No,,,No,,,No,,,No,,
point biopharma global inc,2022-10-13 00:00:00,Yes,PNT2002; PNT2001,"PSMA, Prostate-Specific Membrane Antigen",oncology,other,Phase 3; Preclinical,Yes,SMDC (Small Molecule…),https://www.linkedin.com/company/point-biopharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Radioligand therapies,https://point-biopharma.webflow.io/
travere therapeutics inc,2025-10-17 14:55:54,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
belite bio inc,2025-09-16 23:53:26,Yes,Tinlarebant; LBS-008,"RBP4, Retinol Binding Protein 4",degenerative retinal diseases; rare diseases,other,Phase 3,Yes,Tinlarebant is a novel oral therapy,https://www.quiverquant.com/news/Belite+Bio%2C+Inc.+Announces+NMPA+Acceptance+of+Priority+Review+for+Tinlarebant+NDA+Based+on+Phase+3+DRAGON+Interim+Analysis+Results,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
caribou biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,allogeneic CAR-T cell therapies,https://www.linkedin.com/company/caribou-biosciences,No,,,No,,,No,,
fulcrum therapeutics inc,2025-10-16 14:00:01,Yes,Losmapimod,"DUX4, Double Homeobox 4",rare diseases; neuromuscular disorders,other,Phase 2,Yes,"pociredir, a once-daily oral therapy",https://www.linkedin.com/company/fulcrum-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Improving Cell and Gene Therapy (ICGT) Education for Sickle Cell Disease Initiative,https://www.linkedin.com/company/fulcrum-therapeutics,No,,,No,,,No,,
design therapeutics inc,2021-02-27 00:00:00,No,DT-216P2; DT-168,"FXN, Frataxin; TCF4, Transcription Factor 4",rare diseases; ophthalmology,other,Phase 1/2; Phase 2,Yes,GeneTAC™ gene targeted chimera small molecules,https://www.linkedin.com/company/designtx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
oric pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='seekingalpha.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit",https://www.linkedin.com/company/oric-pharmaceuticals-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ultragenyx pharmaceutical inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,UX143; UX111; DTX401; DTX301; UX701; GTX-102,"FGF23, Fibroblast Growth Factor 23; Sclerostin; G6Pase-α, Glucose-6-Phosphatase-alpha; OTC, Ornithine Transcarbamylase; ATP7B, Copper Transporter; UBE3A-ATS",rare diseases; metabolic diseases; genetic disorders; bone disorders,cytokine; other; enzyme; enzyme; other; other,Phase 3; Phase 3; Phase 3; Phase 3; Phase 3; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,groundbreaking gene therapy,https://www.ultragenyx.com/,No,,,No,,,No,,
omega therapeutics inc,2025-02-04 12:15:00,Yes,Not specified,"Insulated Genomic Domains, Conserved 3D Structures for Genomic Control",oncology; regenerative medicine; multigenic diseases; inflammatory conditions; cardiometabolic conditions,other,Clinical-stage,No,,,No,,,No,,,No,,,No,,,No,,,Yes,programmable mRNA therapeutics for controlled epigenomic modulation,https://www.linkedin.com/company/omega-therapeutics,No,,,No,,,No,,,Yes,Epigenomic Controllers™ target specific intervention points,https://www.linkedin.com/company/omega-therapeutics
silverback therapeutics inc,2025-10-17 00:00:00,Yes,SBTX-101; SBTX-102; SBTX-103,Solid Tumors; Breast Cancer; Prostate Cancer,oncology,other,Phase 1; Preclinical,No,,,No,,,No,,,Yes,monoclonal antibodies directed at specific disease sites,https://www.nasdaq.com/press-release/silverback-therapeutics-and-ars-pharmaceuticals-announce-merger-2022-07-21,Yes,antibody-TLR agonist conjugates,https://www.marketbeat.com/stocks/NASDAQ/SBTX/,No,,,No,,,No,,,No,,,No,,,Yes,ImmunoTAC™ (tumor-activated cytokine) platform,https://www.marketbeat.com/stocks/NASDAQ/SBTX/
archigen biotech ltd (inactive),Error: Connection failed - HTTPSConnectionPool(host='www.centerforbiosimilars,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
adverum biotechnologies inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,No,Ixo-vec; ADVM-022,Not specified,ophthalmology,Not specified,Phase 3,No,,,No,,,Yes,vectorized therapeutic protein (aflibercept) treatment,https://adverum.com/,No,,,No,,,No,,,No,,,Yes,gene therapy,https://adverum.com/,No,,,No,,,No,,
amphivena therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,bivalent T-cell engagers,https://www.prnewswire.com/news-releases/amphivena-therapeutics-announces-first-patient-dosed-in-the-phase-1-dose-expansion-of-amv564-301194326.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,immune cell engagers (bivalent T-cell engagers),https://www.prnewswire.com/news-releases/amphivena-therapeutics-announces-first-patient-dosed-in-the-phase-1-dose-expansion-of-amv564-301194326.html
act biotech inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
toragen inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,TGN-S11,"E5, E5 Oncogene of HPV",oncology,other,Phase 1,Yes,Novel small molecule therapeutics targeting oncogenic viruses,https://www.linkedin.com/company/toragen-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
acurx pharmaceuticals inc,2025-08-12 07:01:00,Yes,ibezapolstat; ACX-801; ACX-375C,"DNA pol IIIC, DNA Polymerase IIIC",infectious diseases,enzyme,Phase 3,Yes,developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections,https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-reports-second-quarter-results-and-provides-business-update-302520712.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
neuexcell therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.nature.com', port=44",Yes,Not specified,Not specified,oncology; CNS; neurodegenerative diseases,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,adeno-associated virus (AAV)-based gene therapy,https://members.lifesciencespa.org/directory/Details/neuexcell-therapeutics-inc-2766910,No,,,No,,,No,,
tafalgie therapeutics,Error: can't compare offset-naive and offset-aware dateti,No,Not specified,Not specified,CNS; pain management,ion channels; gpcr; other,Not specified,No,,,Yes,TAFA4 protein peptide,https://www.eu-startups.com/2025/09/french-biotech-startup-tafalgie-therapeutics-locks-in-e12-million-to-tackle-the-opioid-crisis-with-non-opioid-drugs/,Yes,TAFA4 protein-derived compounds,https://www.eu-startups.com/2025/09/french-biotech-startup-tafalgie-therapeutics-locks-in-e12-million-to-tackle-the-opioid-crisis-with-non-opioid-drugs/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sillajen biotherapeutics,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oncolytic viruses,https://www.cmocro.com/company/SillaJen+Biotherapeutics+Inc./index.html
modag gmbh,"Error: Connection failed - HTTPSConnectionPool(host='www.izb-online.de', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
myokardia inc,"Error: Connection failed - HTTPSConnectionPool(host='news.bms.com', port=443)",Yes,danicamtiv,Cardiac Myosin,cardiovascular,other,Phase 2,Yes,targeted drugs for heart disease,https://www.statnews.com/2025/01/10/kardigan-biotech-heart-disease-myokardia/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
shanghai zerun biotechnology co ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.walvax.com', port=443",No,Not specified,Human Papillomavirus,infectious diseases; oncology,other,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"novel human vaccine and biopharmaceutical research, development and commercialization",https://www.linkedin.com/company/shanghai-zerun-biotechnology,No,,,No,,
dimerix ltd,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",Yes,DMX-200,"CCR2, C-C Chemokine Receptor Type 2; Angiotensin Type 1 Receptor",rare diseases; nephrology,gpcr,Phase 3,Yes,"Dimerix’ lead clinical asset, DMX-200",https://au.linkedin.com/company/dimerix-bioscience,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arxx therapeutics as,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,CAL101; CAL102; AX-202; 6B12,"S100A4, Damage-Associated Molecular Pattern Protein; Oxidized Phospholipids",rare diseases; dermatology; rheumatology; oncology; immunology; fibrotic diseases,other,Phase 1,No,,,No,,,No,,,Yes,first-in-class monoclonal antibody,https://www.linkedin.com/company/arxx-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cancer targeted technology llc,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
scarless laboratories inc,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",Yes,SCX-001; OLX101; INV001; TRTP-101,"Connective Tissue Growth Factor; HSP47, Heat Shock Protein 47; YAP-TEAD pathway",dermatology,enzyme; other; other,Preclinical; Phase 2; Phase 1,No,,,Yes,fibromodulin-derived peptide,https://www.uclahealth.org/news/release/researchers-may-have-found-way-mitigate-or-eliminate,Yes,protein that helps prevent excessive scarring,https://www.uclahealth.org/news/release/researchers-may-have-found-way-mitigate-or-eliminate,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pdc line pharma sas,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,PDC*lung01; PDC*neo,NY-ESO-1; MAGE-A3; MAGE-A4; Multi-MAGE-A; MUC1; Survivin,oncology,immune checkpoint,Phase 1/Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,allogeneic cellular immunotherapies for cancer,https://fr.linkedin.com/company/pdc-line-pharma,Yes,therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line),https://fr.linkedin.com/company/pdc-line-pharma,No,,,No,,
adjuvance technologies inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,Zevor-cel; Satri-cel; CT071; CT011; CT0590; CT0596; KJ-C2219; KJ-C2320; KJ-C2114; KJ-C2526,"BCMA, B-cell Maturation Antigen; Claudin18.2; GPRC5D, G-protein coupled receptor family C group 5 member D; GPC3, Glypican-3; BCMA, B-cell Maturation Antigen; BCMA, B-cell Maturation Antigen; CD19/CD20; CD38; Undisclosed; NKG2DL, Natural Killer Group 2 Member D Ligand",oncology; hematology; infectious diseases; rare diseases,immune checkpoint; other; gpcr; other; immune checkpoint; immune checkpoint; other; other; Not specified; other,Approved; Phase 2; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,therapeutic vaccines and vaccine adjuvants,https://www.linkedin.com/company/adjuvance-technologies-inc,No,,,No,,
bnh research,"Error: Connection failed - HTTPSConnectionPool(host='www.biospectator.com', p",Yes,Not specified,Not specified,CNS,Not specified,Preclinical,Yes,drug candidates with special emphasis on reopening cortical plasticity,https://www.bnhresearch.net/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spine biopharma inc,2025-08-01 13:45:26,No,SB-01; vicatertide,"TGF-β, Transforming Growth Factor Beta",CNS; chronic pain,cytokine,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
targed biopharmaceuticals bv,2025-10-13 07:47:43,Yes,KarXT; RAP 219; ABBV-932; ABX-002; ALTO-100; CB03-154; 4MT 2001; AL001; RP5063; NRX-101; LB 102; Aripiprazole 2-month injectable,Muscarinic M1 receptor; Muscarinic M4 receptor; AMPA receptor; Dopamine D2 receptor; Dopamine D3 receptor; Thyroid hormone receptor beta; Brain-derived neurotrophic factor; KCNQ2 potassium channel; KCNQ3 potassium channel; Glycogen synthase kinase 3 beta,CNS; neuropsychiatric conditions,gpcr; ion channels; nuclear receptors; other,Phase 3; Phase 2; Phase 1,No,,,No,,,Yes,MICROLYSE enzymatically breaks down blood clots,https://nl.linkedin.com/company/targedbiopharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biothera pharmaceutical inc,2018-04-15 00:00:00,Yes,STARJEMZA; BAT2206,"IL-12, Interleukin-12; IL-23, Interleukin-23",dermatology; immunology; gastroenterology,cytokine,Approved,No,,,No,,,No,,,Yes,anti-angiogenic antibodies,https://www.linkedin.com/company/biothera,No,,,No,,,No,,,No,,,No,,,No,,,Yes,innate immune modulator,https://www.linkedin.com/company/biothera
anhui biomec biopharmaceutical co ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.lcywhx.com', port=443",No,REGN1908-1909; IRL201104,"Fel d 1, Cat Allergen; Not specified",allergy; respiratory diseases,immune checkpoint; other,Phase 3; Phase 2,No,,,No,,,Yes,genetically recombinant products,https://www.linkedin.com/company/anhui-zhifei-longcome-bio-pharmaceutical-co.-ltd./?trk=ppro_cprof,No,,,No,,,No,,,No,,,No,,,Yes,vaccines,https://www.linkedin.com/company/anhui-zhifei-longcome-bio-pharmaceutical-co.-ltd./?trk=ppro_cprof,No,,,No,,
kangpu biopharmaceuticals ltd,2023-09-30 00:00:00,No,KPG-121,Not specified,oncology,Not specified,Phase 2/Phase 3,Yes,discovery and development of innovative small molecules,https://www.linkedin.com/company/kangpu,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,targeted protein ubiquitination and degradation,https://www.linkedin.com/company/kangpu,No,,
shanghai kangabio co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",Yes,KGX101,"IL-12, Interleukin-12",oncology,cytokine,Phase 1,No,,,No,,,No,,,Yes,monoclonal antibody drug,https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-and-kangabio-established-strategic-collaboration-to-accelerate-antibody-drug-development-and-innovation-301611386.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,multi-specific biologics,https://www.prnewswire.com/news-releases/sanyou-biopharmaceuticals-and-kangabio-established-strategic-collaboration-to-accelerate-antibody-drug-development-and-innovation-301611386.html
cartesian bio llc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Descartes-08; Descartes-15,"BCMA, B-cell maturation antigen",autoimmune diseases; multiple myeloma,immune checkpoint,Phase 3; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,mRNA cell therapies,https://www.linkedin.com/company/cartesian-therapeutics,Yes,mRNA CAR-T,https://www.linkedin.com/company/cartesian-therapeutics,No,,,No,,,No,,
"cartesian bio, llc","Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,Descartes-08; Descartes-15,"BCMA, B-cell maturation antigen",autoimmune diseases,other,Phase 3; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,mRNA cell therapies,https://www.linkedin.com/company/cartesian-therapeutics,Yes,mRNA CAR-T,https://www.linkedin.com/company/cartesian-therapeutics,No,,,No,,,No,,
changchun bcht biotechnology co ltd,"Error: Connection failed - HTTPConnectionPool(host='www.bchtpharm.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
evopoint bioscience co ltd,2025-10-18 00:18:29,No,XNW27011,"CLDN18.2, Claudin 18.2",oncology,other,Phase 1; Phase 2,No,,,No,,,No,,,Yes,"Monoclonal antibodies (mAbs - human, humanized, chimeric)",https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html,Yes,antibody-drug conjugate (ADC),https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html,No,,,No,,,No,,,No,,,Yes,targeted protein degradation (TPD),https://www.prnewswire.com/news-releases/astellas-enters-exclusive-license-agreement-with-evopoint-biosciences-for-xnw27011--a-novel-clinical-stage-antibody-drug-conjugate-targeting-cldn18-2--302469022.html,No,,
ossium health inc,2025-10-15 20:54:14,Yes,"OssiGraft; HPC, Marrow; MSCs; Selected CD34+ Cells",Hematologic malignancies; Graft-versus-host Disease (GVHD); Organ Transplant Rejection; Musculoskeletal Defects,hematologic diseases; immunology; musculoskeletal defects,other,Phase 2; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"cell therapy development, stem cell biology, stem cell therapy, stem cell transplant",https://ossiumhealth.com/,No,,,No,,,Yes,"bone marrow banking, cryopreserved bone marrow banking platform, organ donor derived bone marrow",https://ossiumhealth.com/
protagonist therapeutics inc,2025-10-09 13:15:03,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,peptide-based new chemical entities (NCEs),https://www.linkedin.com/company/protagonist-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
glycotope gmbh,2025-01-13 00:00:00,Yes,Not specified,Not specified,oncology,other,Preclinical,No,,,No,,,No,,,Yes,developing antibodies against proteins carrying tumor-specific carbohydrate structures,https://www.globenewswire.com/news-release/2024/04/08/2858888/0/en/Glycotope-to-present-platform-approach-for-development-of-anti-GlycoTarget-antibodies-at-2024-AACR-Meeting.html,Yes,antibody-drug-conjugates,https://www.globenewswire.com/news-release/2024/04/08/2858888/0/en/Glycotope-to-present-platform-approach-for-development-of-anti-GlycoTarget-antibodies-at-2024-AACR-Meeting.html,Yes,fusion-proteins,https://www.globenewswire.com/news-release/2024/04/08/2858888/0/en/Glycotope-to-present-platform-approach-for-development-of-anti-GlycoTarget-antibodies-at-2024-AACR-Meeting.html,No,,,No,,,No,,,No,,,No,,
endeavor biomedicines inc,2024-04-24 15:40:56,No,ENV-101,"Hedgehog, Hedgehog Signaling Pathway",respiratory diseases,other,Phase 2,Yes,"ENV-101, once known as taladegib, blocks a cellular pathway dubbed 'hedgehog'",https://www.biopharmadive.com/news/endeavor-john-hood-series-c-idiopathic-pulmonary-fibrosis-adc-her3/714060/,No,,,No,,,Yes,ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC),https://www.linkedin.com/company/endeavor-biomedicines,Yes,ENV-501 is a human epidermal growth factor 3 (HER3)-targeted antibody-drug conjugate (ADC),https://www.linkedin.com/company/endeavor-biomedicines,No,,,No,,,No,,,No,,,No,,,No,,
baili-bio (chengdu) pharmaceutical co ltd,2025-08-27 23:34:22,Yes,SI-B001,"EGFR, Epidermal Growth Factor Receptor; HER3, Human Epidermal Growth Factor Receptor 3",oncology,other,Phase 2,Yes,generic drug production operations,https://systimmune.com/news-biokin,No,,,No,,,Yes,innovative antibody-based therapeutics,https://systimmune.com/news-biokin,Yes,antibody conjugated drug production facility,https://systimmune.com/news-biokin,No,,,No,,,No,,,No,,,No,,,No,,
artbio inc,2025-07-29 07:30:00,Yes,AB001,"PSMA, Prostate-Specific Membrane Antigen",oncology,other,Phase 1,Yes,PSMA-targeted small molecule radiolabeled with Pb212,https://www.prnewswire.com/news-releases/artbio-announces-fda-clearance-of-ind-application-for-lead-alpha-radioligand-therapy-ab001-302549360.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,alpha radioligand therapies (ARTs),https://artbio.com/
cyteir therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='neurodex.co', port=443):",No,CYT-0851,Not specified,oncology,other,Phase 1/2,Yes,investigational monocarboxylate transporter inhibitor,https://www.nasdaq.com/articles/cyteir-therapeutics-to-discontinue-cyt-0851-development-program-dissolve-company,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
reunion neuroscience inc,2025-10-17 12:30:26,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,proprietary serotonin receptor agonist compounds,https://public.com/stocks/reun,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,next-generation psychedelic-inspired therapeutic solutions,https://www.globenewswire.com/news-release/2025/09/16/3150672/0/en/Reunion-Neuroscience-Announces-Final-Closing-of-its-Series-A-Financing-and-Plans-to-Advance-RE104-into-Clinical-Development-for-the-Treatment-of-Generalized-Anxiety-Disorder-GAD.html
imago biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.iposcoop.com', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
otonomy inc (inactive),Error: Connection failed - HTTPSConnectionPool(host='www.sandiegouniontribune,Yes,SPT-2101; OTO-104; OTO-510; OTO-413,Brain-Derived Neurotrophic Factor (BDNF); Ménière's disease,inner ear disorders; hearing loss; balance disorders,cytokine; other,Phase 2,Yes,"OTO-104 (OTIVIDEX), a sustained-exposure formulation of dexamethasone",https://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-otonomy-assets-to-boost-inner-ear-disorders-pipeline-and-appoints-industry-leaders-to-board-301782910.html,No,,,Yes,"OTO-413, a sustained-exposure formulation of Brain-Derived Neurotrophic Factor (BNDF)",https://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-otonomy-assets-to-boost-inner-ear-disorders-pipeline-and-appoints-industry-leaders-to-board-301782910.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea",https://www.prnewswire.com/news-releases/spiral-therapeutics-acquires-otonomy-assets-to-boost-inner-ear-disorders-pipeline-and-appoints-industry-leaders-to-board-301782910.html
disarm therapeutics inc,2020-10-15 09:20:00,Yes,DSRM-3716; Unnamed Molecule 1; Unnamed Molecule 2; Unnamed Molecule 3,"SARM1, Sterile Alpha and toll / Interleukin-1 Receptor Motif-Containing 1",neurological disorders; neurodegenerative disorders,enzyme,Preclinical,Yes,"novel, potent SARM1 inhibitors",https://www.prnewswire.com/news-releases/lilly-announces-agreement-to-acquire-disarm-therapeutics-301153277.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
jade pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,JADE101,"APRIL, A Proliferation-Inducing Ligand",autoimmune diseases; nephrology,cytokine,Phase 1,No,,,No,,,No,,,Yes,monoclonal antibody designed to target BAFF-R,https://www.linkedin.com/company/jade-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,
monopar therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,MNPR-101; MNPR-101-Zr; MNPR-101-Lu; ALXN1840,"uPAR, Urokinase Plasminogen Activator Receptor; Wilson Disease",oncology; rare diseases,enzyme; other,Phase 1; Phase 2,Yes,"ALXN1840, a late-stage therapy for Wilson disease",https://www.linkedin.com/company/monopar-therapeutics-inc,No,,,No,,,Yes,MNPR-101 radiopharmaceutical program targeting advanced cancers,https://www.linkedin.com/company/monopar-therapeutics-inc,Yes,MNPR-101-Zr and MNPR-101-Lu in advanced cancers,https://www.stocktitan.net/news/MNPR/,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceutical pipeline targeting advanced cancers,https://www.linkedin.com/company/monopar-therapeutics-inc
heronova pharmaceuticals,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.m,No,SUSTOL; CINVANTI; ZYNRELEF; APONVIE,Chemotherapy-Induced Nausea and Vomiting; Postoperative Pain; Postoperative Nausea and Vomiting,oncology; acute care,Not specified,Approved,No,,,No,,,No,,,No,,,No,,,No,,,Yes,miRNA Molecular Diagnostic,https://www.linkedin.com/company/heranova-lifesciences,No,,,No,,,No,,,No,,
splice bio sl,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,No,SB-007,"ABCA4, ATP-Binding Cassette Subfamily A Member 4",ophthalmology,enzyme,Phase 1/2,No,,,No,,,Yes,Protein Splicing,https://www.prnewswire.com/news-releases/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines-302477915.html,No,,,No,,,No,,,No,,,Yes,AAV gene therapy,https://www.prnewswire.com/news-releases/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines-302477915.html,No,,,No,,,No,,
adcendo aps,2024-11-25 07:00:54,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,antibody-drug conjugates (ADCs),https://www.prnewswire.com/news-releases/adcendo-aps-announces-first-patient-dosed-in-phase-iii-adcelerate1-trial-of-adce-d01-302475071.html,Yes,antibody-drug conjugates (ADCs),https://www.prnewswire.com/news-releases/adcendo-aps-announces-first-patient-dosed-in-phase-iii-adcelerate1-trial-of-adce-d01-302475071.html,No,,,No,,,No,,,No,,,No,,,No,,
hemab aps,2023-02-21 00:00:00,No,Sutacimig; HMB-002,"Factor VIIa, Coagulation Factor VIIa; TLT-1, Triggering Receptor Expressed on Myeloid Cells-Like Transcript 1; VWF, Von Willebrand Factor",rare diseases; hematology,enzyme; other,Phase 2; Phase 1,No,,,No,,,No,,,Yes,monoclonal and bispecific antibody-based therapeutics,https://www.prnewswire.com/news-releases/hemab-therapeutics-announces-135m-series-b-financing-to-advance-first-prophylactic-treatments-for-underserved-bleeding-and-thrombotic-disorders-301750293.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vividion therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,VVD-214; VVD-037; VVD-642,"WRN, Werner Helicase; KEAP1, Kelch-like ECH-associated protein 1; RAS-PIK3CA, RAS-dependent PIK3CA oncogenic signaling",oncology; immunology,enzyme; other; other,Phase 1,Yes,creation of highly selective small molecule medicines that drug traditionally inaccessible targets,https://www.linkedin.com/company/vividion-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,chemoproteomics platform allows us to identify and pursue novel strategies to target pathways,https://vividion.com/
encoded therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,ETX101; ETX201,"SCN1A, Sodium Voltage-Gated Channel Alpha Subunit 1; UBE3A-ATS, UBE3A Antisense Transcript",CNS; rare diseases,ion channels; other,Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Non-opioid AAV9-miRNA Gene Therapy to Silence SCN9A,https://www.linkedin.com/company/encodedtherapeutics,Yes,"creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders",https://www.linkedin.com/company/encodedtherapeutics,No,,,No,,,No,,
shanghai haihe biopharma co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.haihepharma.com', po",No,Glumetinib,"c-Met, Mesenchymal-Epithelial Transition Factor",oncology,kinases,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
velosbio inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,Not specified,Not specified,oncology,Not specified,Not specified,No,,,No,,,No,,,Yes,an antibody from Oncternal now in human trials,https://www.biopharmadive.com/news/merck-velosbio-antibody-drug-conjugate-deal/588452/,Yes,"experimental antibody-drug conjugates, led by a treatment called VLS-101",https://www.biopharmadive.com/news/merck-velosbio-antibody-drug-conjugate-deal/588452/,No,,,No,,,No,,,No,,,No,,,No,,
amolyt pharma,2023-02-06 00:00:00,Yes,eneboparatide; AZP-3601; AZP-3813,"PTH1, Parathyroid Hormone 1 Receptor; Growth Hormone Receptor",rare diseases; endocrine diseases,gpcr; other,Phase 2,No,,,Yes,Advancing peptides for the treatment of rare endocrine and related diseases,https://www.linkedin.com/company/amolytpharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tubulis gmbh,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,TUB-040,Disease Name,oncology,Not specified,Phase 1,No,,,No,,,No,,,Yes,antibody and chemical assets,https://de.linkedin.com/company/tubulis,Yes,Antibody Drug Conjugates (ADCs),https://de.linkedin.com/company/tubulis,No,,,No,,,No,,,No,,,No,,,No,,
genequantum healthcare suzhou co ltd,"Error: Connection failed - HTTPSConnectionPool(host='convention.bio.org', por",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,standard antibody production,https://www.linkedin.com/company/genequantum,Yes,ADC drug development platform,https://www.linkedin.com/company/genequantum,No,,,No,,,No,,,No,,,No,,,No,,
imaginab inc,No timestamp found,Yes,CD8 ImmunoPET; Optical PSMA; DLL3; integrin αvβ6,"CD8, CD8 receptor; PSMA, Prostate-Specific Membrane Antigen; DLL3, Delta-like ligand 3; integrin αvβ6",oncology; autoimmune diseases,immune checkpoint; other; other; other,Phase 2; Phase 2; Preclinical; Preclinical,No,,,No,,,No,,,Yes,engineered antibodies that maintain the specificity of full-length antibodies,https://www.prnewswire.com/news-releases/imaginab-inc-innovative-biologics-technology-platform-acquired-by-telix-to-enable-next-generation-therapeutic-assets-discovery-302357691.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms,https://www.linkedin.com/company/imaginab
cocrystal pharma inc,2025-09-15 20:30:00,Yes,Not specified,Not specified,infectious diseases,Not specified,Not specified,Yes,small molecule therapeutics,https://www.linkedin.com/company/cocrystal-pharma-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
outlook therapeutics inc,2025-10-15 13:13:35,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,bevacizumab,https://www.linkedin.com/company/outlook-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
taiga biotechnologies inc (inactive),2020-09-10 00:00:00,No,TBX-2400,Not specified,oncology,other,Phase 1,No,,,No,,,Yes,fusion protein,https://www.linkedin.com/company/taiga-biotechnologies,No,,,No,,,Yes,fusion protein,https://www.linkedin.com/company/taiga-biotechnologies,No,,,Yes,"Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient’s own immune cells",https://www.linkedin.com/company/taiga-biotechnologies,No,,,No,,,No,,
hangzhou synrx therapeutics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
mercator medsystems inc,Error: Connection failed - 404 Client Error: Not Found for url: https://www.l,No,Not specified,Not specified,cardiovascular,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Exosome-based therapeutics, Oncolytic viruses, Scaffold proteins (DARPins, Affibodies), Immune cell engagers (BiTEs), Nanoparticles for drug delivery",https://www.linkedin.com/company/mercator-medsystems-inc.
scancell holdings plc,2025-10-13 14:35:16,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,highly tumour specific monoclonal antibodies that redirect immune cells or drugs,https://uk.linkedin.com/company/scancell-limited,No,,,No,,,Yes,"DNA immunotherapies, which have a targeted dual-action approach",https://uk.linkedin.com/company/scancell-limited,No,,,Yes,We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses,https://uk.linkedin.com/company/scancell-limited,No,,,No,,
chelsea therapeutics international ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Northera; droxidopa,Norepinephrine,CNS; rare diseases,other,Phase 3,Yes,Northera™ (droxidopa),https://www.linkedin.com/company/chelsea-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
intervexion therapeutics llc,"Error: Connection failed - HTTPSConnectionPool(host='news.uams.edu', port=443",Yes,IXT-m200,Methamphetamine,CNS,other,Phase 2,No,,,No,,,No,,,Yes,Our lead product is a monoclonal antibody against methamphetamine,https://pmc.ncbi.nlm.nih.gov/articles/PMC5404366/,No,,,No,,,No,,,No,,,Yes,Our most advanced follow-on program is a vaccine against methamphetamine which is currently in late preclinical development,https://pmc.ncbi.nlm.nih.gov/articles/PMC5404366/,No,,,No,,
cessation therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,development of immunotherapy for substance abuse,https://www.linkedin.com/company/cessation-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
avistone biotechnology co ltd,2025-05-31 19:06:39,Yes,PLB1001; PLB1004; ANS03,"MET, MET Tyrosine Kinase; EGFR, Epidermal Growth Factor Receptor; ROS1, ROS Proto-Oncogene 1; NTRK, Neurotrophic Tyrosine Receptor Kinase",oncology,kinases,Phase 2; Phase 1; Preclinical,Yes,"PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity",https://www.linkedin.com/company/avistone-biotechnology-co-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
keros therapeutics inc,2025-08-20 15:59:04,No,Elritercept; Cibotercept; KER-065,Activin A and B proteins,hematologic cancers; pulmonary arterial hypertension; cardiovascular disorders; neuromuscular diseases,cytokine,Phase 2; Phase 3; Preclinical,No,,,No,,,Yes,protein therapeutics,https://www.globenewswire.com/news-release/2025/10/15/3166903/0/en/Keros-Therapeutics-Announces-Plan-for-Return-of-375-Million-in-Excess-Capital.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
xoma corp,"Error: Connection failed - HTTPSConnectionPool(host='xoma.com', port=443): Ma",No,TIDAL-01; mezagitamab; seralutinib,Not specified,oncology; autoimmune diseases; cardiovascular,other; immune checkpoint; kinases,Phase 1; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,norovirus vaccine programs,https://www.linkedin.com/company/xoma,No,,,No,,
capsida biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,CAP-002; CAP-003,"STXBP1, Syntaxin-binding protein 1; GBA, Glucocerebrosidase",CNS; neurodegenerative diseases,enzyme,Phase 1/2,No,,,No,,,Yes,functional frataxin protein,https://capsida.com/,No,,,No,,,No,,,No,,,Yes,Engineering novel AAVs and developing the next generation of gene therapies,https://www.linkedin.com/company/capsida-biotherapeutics,No,,,No,,,No,,
draig therapeutics ltd,Error: Connection failed - HTTPSConnectionPool(host='www.pharmaceutical-techn,Yes,DT-101,"AMPA, Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor",CNS; neuropsychiatric conditions,ion channels,Phase 2,Yes,next-generation AMPA modulator,https://uk.linkedin.com/company/draigtherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rvac medicines pte ltd,2022-05-26 00:00:00,Yes,RVM-V001,"Disease Name, COVID-19",infectious diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,mRNA therapeutics,https://edbi.com/rvac-medicines-a-cbc-incubated-mrna-platform-company-raises-us140-million-to-expand-rd-and-manufacturing-capacity-2/,No,,,Yes,"mRNA vaccines targeting infectious diseases such as COVID-19, RSV, and Clostridioides difficile",https://www.probiocdmo.com/genscript-probio-and-rvac-medicines-announce-strategic-partnership-for-gmp-plasmid-dna-manufacturing-for-mrna-covid-19-vaccine-candidate.html,No,,,No,,
abdera therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,Yes,targeted radiation therapies,https://www.linkedin.com/company/abdera-therapeutics,No,,,No,,,No,,,No,,,No,,,Yes,radioisotopes to selectively destroy tumor cells,https://www.linkedin.com/company/abdera-therapeutics
verve therapeutics inc,2025-06-17 10:50:56,Yes,Kisunla; Zepbound; Mounjaro; MORF-057; STX-478; PNT2002; PNT2001; Omvoh; orforglipron,"PCSK9, Proprotein Convertase Subtilisin/Kexin Type 9; α4β7 integrin; GLP-1, Glucagon-Like Peptide-1; PI3Kα, Phosphoinositide 3-Kinase Alpha; PSMA, Prostate-Specific Membrane Antigen; IL-23p19, Interleukin-23 Subunit p19",neurodegeneration; obesity; diabetes; inflammatory bowel disease; oncology; cardiovascular,enzyme; other; gpcr; kinases; immune checkpoint; cytokine,Phase 3; Phase 2; Approved; Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene editing medicines,https://www.linkedin.com/company/verve-therapeutics-inc,No,,,No,,,No,,
river vision development corp (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Econazole; Miconazole; Sulconazole; Sertaconazole; Clotrimazole; Itraconazole; Suloctidil; Pimozide; Butamben; Clemizole; Proroxan; Saccharin; Ritonavir; Nifenazone; Levonordefrin; Tafenoquine; Primaquine; Apomorphine,"Sterol 14-demethylase; K+ VGIC; DRD2, Dopamine Receptor D2; DRD3, Dopamine Receptor D3; ADRA2, Alpha-2 Adrenergic Receptor; HADH2, Hydroxyacyl-CoA Dehydrogenase; TF HIF1A, Hypoxia-Inducible Factor 1-alpha; ALOX12, Arachidonate 12-Lipoxygenase; ALOX15, Arachidonate 15-Lipoxygenase; HIV Protease; CYP3A, Cytochrome P450 3A; SLC47, Multidrug and Toxin Extrusion Protein 1",infectious diseases; neglected tropical diseases,enzyme; ion channels; gpcr; nuclear receptors; other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
azafaros bv,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,pipeline of oral small molecules with disease-modifying potential,https://nl.linkedin.com/company/azafaros-b-v,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pulmocide ltd,2022-12-06 00:00:00,No,Opelconazole,"Disease Name, Invasive Pulmonary Aspergillosis",infectious diseases,other,Phase 3,Yes,novel triazole antifungal,https://www.ipgroupplc.com/news-and-events/portfolio-news/2022/2022-12-06,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
noema pharma ag,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cervomed inc,2025-10-14 18:03:00,No,Neflamapimod,"p38 MAPK alpha, Mitogen-Activated Protein Kinase Alpha",CNS,kinases,Phase 2,Yes,"neflamapimod, an investigational, orally administered small molecule brain penetrant",https://www.cnbc.com/quotes/CRVO,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
la jolla pharmaceutical company,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Not specified,Not specified,oncology; immunology; allergy; nephrology; CNS; rare diseases,Not specified,Preclinical,Yes,XERAVA® (eravacycline),https://www.linkedin.com/company/la-jolla-pharmaceutical-company,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medivation inc (inactive),2016-08-22 00:00:00,No,XTANDI; Talazoparib; Pidilizumab,Androgen Receptor; BRCA-mutated; Not specified,oncology,nuclear receptors; enzyme; immune checkpoint,Phase 3; Phase 2; Marketed,Yes,focused on developing and commercializing small molecules for oncology,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-medivation,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
exact therapeutics as,2020-11-25 00:00:00,No,Folfirinox; Ps101,Locally Advanced Pancreatic Adenocarcinoma; Colorectal Cancer; Solid Tumor,oncology,other,Phase II; Phase I,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bailisi kang biomedicine (hangzhou) co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.moomoo.com', port=44",No,BB-1701,"HER2, Human Epidermal Growth Factor Receptor-2",oncology,other,Phase 2,No,,,No,,,No,,,Yes,anti-HER2 antibody,https://www.marketscreener.com/quote/stock/EISAI-CO-LTD-6492461/news/Bliss-Biopharmaceuticals-Bailisi-Kang-and-Eisai-reached-a-clinical-trial-cooperation-agreement-on-43777753/,Yes,antibody drug conjugates (ADCs),https://www.marketscreener.com/quote/stock/EISAI-CO-LTD-6492461/news/Bliss-Biopharmaceuticals-Bailisi-Kang-and-Eisai-reached-a-clinical-trial-cooperation-agreement-on-43777753/,No,,,No,,,No,,,No,,,No,,,No,,
neurovia inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='globalventuring.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cytosinlab therapeutics co ltd,2025-01-03 09:45:42,Yes,CX-2051; CX-801,"EpCAM, Epithelial Cell Adhesion Molecule; IFN-α2b, Interferon alpha-2b",oncology,enzyme; cytokine,Phase 1,Yes,developing innovative drugs with new mechanisms of action (MOA),"https://www.ventureradar.com/organisation/CytosinLab%20Therapeutics%20Co_%5Bdot%5D_,%20Ltd_%5Bdot%5D_/325ed662-6983-4e9a-8468-d58e7f85698f",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
junhemeng biopharmaceutical (tonghua) co ltd,2024-05-17 09:10:08,No,Ultra-Rapid Insulin CI; BioChaperone Lispro; THDB0206,Diabetes; Type 2 Diabetes,metabolic diseases,enzyme,Phase 3,No,,,No,,,Yes,developer of recombinant protein drugs,https://www.linkedin.com/pulse/newsletter-chinas-life-science-industry-may-oiqjc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
qurebio ltd,2025-06-05 09:02:52,No,Q-1802; Q-1801; PD-1 Antibody-Cytokine Fusion Candidate,"Claudin18.2, Claudin-18 isoform 2; PD-L1, Programmed Death-Ligand 1; SIRPα, Signal Regulatory Protein Alpha; PD-1, Programmed Cell Death Protein 1",oncology; autoimmune diseases; inflammatory disorders,immune checkpoint; other; cytokine,Phase 3; Phase 1; Preclinical,No,,,No,,,Yes,protein therapeutics,https://www.prnewswire.com/news-releases/qurebio-ltd-completes-nearly-cny-100-million-series-c1-financing-led-by-efung-capital-accelerating-clinical-progress-in-global-competition-for-core-pipelines-302473108.html,Yes,bispecific and multispecific antibody,https://www.prnewswire.com/news-releases/qurebio-ltd-completes-nearly-cny-100-million-series-c1-financing-led-by-efung-capital-accelerating-clinical-progress-in-global-competition-for-core-pipelines-302473108.html,No,,,Yes,fusion protein with dual functions as a PD-1 checkpoint inhibitor and a cytokine modulator,https://www.prnewswire.com/news-releases/qurebio-ltd-completes-nearly-cny-100-million-series-c1-financing-led-by-efung-capital-accelerating-clinical-progress-in-global-competition-for-core-pipelines-302473108.html,No,,,No,,,No,,,No,,,Yes,T-cell engager and NK-cell engager platforms,https://www.prnewswire.com/news-releases/qurebio-ltd-completes-nearly-cny-100-million-series-c1-financing-led-by-efung-capital-accelerating-clinical-progress-in-global-competition-for-core-pipelines-302473108.html
pulmovant inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biocentury.com', por",No,mosliciguat,"Disease Name, Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)",rare diseases; respiratory,other,Approved,Yes,"mosliciguat is a novel, potential first-in-class, sGC activator",https://www.linkedin.com/company/pulmovant,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pelican therapeutics inc,Error: Connection failed - HTTPSConnectionPool(host='ir.scorpiusbiologics.com,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rege nephro co ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Tamibarotene; RN-014,"RAR, Retinoic Acid Receptor",renal diseases,nuclear receptors,Phase 2,Yes,small molecule for autosomal dominant polycystic kidney disease (ADPKD),https://www.linkedin.com/company/rege-nephro/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell therapy for chronic kidney disease with nephron progenitor cells derived from iPS cells,https://www.linkedin.com/company/rege-nephro/,No,,,No,,,Yes,development of a human kidney chip utilizing nephron progenitor cells,https://www.linkedin.com/company/rege-nephro/
xiangxue life sciences,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",Yes,TAEST16001,"NY-ESO-1, New York Esophageal Squamous Cell Carcinoma 1",oncology,immune checkpoint,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,TCR-based therapies for cancer,https://www.linkedin.com/company/guangdong-xiangxue-life-sciences-ltd,No,,,No,,,No,,
tiumbio co ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Merigolix; TU2670; DW4902; TU2218; TU7710,"GnRH, Gonadotropin-Releasing Hormone; TGF-β, Transforming Growth Factor Beta; VEGF, Vascular Endothelial Growth Factor",gynecology; oncology; hematology,gpcr; cytokine; other,Phase 2,Yes,Small molecules,https://www.linkedin.com/company/tiumbio,Yes,non-peptide GnRH antagonist,https://www.linkedin.com/company/tiumbio,Yes,단백질의약품 연구 개발,https://www.linkedin.com/company/tiumbio,Yes,치료용 항체 개발,https://www.linkedin.com/company/tiumbio,No,,,No,,,No,,,No,,,No,,,No,,,No,,
oryzon genomics sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,iadademstat; vafidemstat,"LSD1, Lysine-Specific Demethylase-1",oncology; CNS,enzyme,Phase 2,Yes,"iadademstat, a highly potent and selective LSD1 inhibitor",https://www.linkedin.com/company/oryzon,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nuvectis pharma inc,2025-10-16 12:05:58,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1.",https://www.linkedin.com/company/nuvectis,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
capella bioscience ltd (inactive),Error: Connection failed - 403 Client Error: Forbidden for url: https://www.f,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
airway therapeutics inc,2025-10-16 21:06:20,Yes,Zelpultide Alfa; AT-100,"SP-D, Surfactant Protein D",respiratory diseases; inflammatory diseases; infectious diseases,cytokine,Phase 2; Phase 3,No,,,No,,,Yes,protein development for applications in the lungs and pediatrics,https://www.linkedin.com/company/airway-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medimmune llc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.nytimes.com', port=4",No,Serplulimab; Vobramitamab duocarmazine; RYZ101,"PD-1, Programmed Cell Death Protein 1; B7-H3, B7 Homolog 3; SSTR2, Somatostatin Receptor Type 2",oncology,immune checkpoint; other; other,Phase 3; Phase 2; Phase 1,Yes,to supplement its small molecule portfolio with biologic drugs,https://insights.citeline.com/SC124675/Farewell-To-MedImmune-AstraZeneca-Will-Combine-Large-And-Small-Molecule-Research/,No,,,Yes,biological medicines,https://www.cnbc.com/2007/04/23/astrazeneca-to-buy-medimmune-for-15-billion.html,Yes,"Cambridge Antibody Technology, a smaller, UK-based biotech firm",https://www.cnbc.com/2007/04/23/astrazeneca-to-buy-medimmune-for-15-billion.html,No,,,No,,,No,,,No,,,Yes,best known as the maker of the nasal spray flu vaccine FluMist,https://www.cnbc.com/2007/04/23/astrazeneca-to-buy-medimmune-for-15-billion.html,No,,,No,,
aevi genomic medicine inc (inactive),1-12-02 23:50:39,Yes,AVTX-002; AVTX-008; AEVI-002; AEVI-006; AEVI-007,"LIGHT, Lymphotoxin-like exhibits Inducible expression and competes with HSV Glycoprotein D for HVEM receptor; PI3Kα, Phosphoinositide 3-kinase alpha; IL-18, Interleukin-18; mTORC1/2, Mammalian Target of Rapamycin Complex 1/2",immunology; inflammation; rare diseases; pediatric diseases,cytokine; enzyme; other,Phase 2; Phase 1; Phase 1b/2a,Yes,AEVI-006 (OSI-027),https://www.smartbusinessdealmakers.com/articles/topic/cerecor-buys-aevi-genomic-medicine/,No,,,No,,,Yes,Phase 2-Ready Fully Human Monoclonal Antibody That Targets Interleukin 18 (IL-18),https://www.marketscreener.com/quote/stock/AEVI-GENOMIC-MEDICINE-INC-32526460/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rinri therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Rincell-1,Not specified,CNS; sensorineural hearing loss,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,regenerative cell therapy,https://www.bioindustry.org/member/rinri-therapeutics/,No,,,No,,,No,,
suzhou genhouse pharmaceutical co ltd,"Error: Connection failed - HTTPSConnectionPool(host='bouncewatch.com', port=4",Yes,GH55,"ERK1/2, Extracellular Signal-Regulated Kinase 1/2",oncology,kinases,Preclinical,Yes,small molecule anti-tumor drugs,https://bouncewatch.com/explore/startup/suzhou-genhouse-pharmaceutical-coltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
suzhou regend therapeutics co ltd,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,REGEND001,"Disease Name, Chronic Obstructive Pulmonary Disease (COPD)",respiratory diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,progenitor cell-based regenerative medicine,https://informaconnect.com/bioeurope/sponsors/regend-therapeutics/,No,,,No,,,No,,
calimmune inc,2015-06-27 00:00:00,Yes,Not specified,"HIV, Human Immunodeficiency Virus; Sickle Cell Disease; Beta Thalassemia",infectious diseases; rare diseases,other,Phase 1/Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ex vivo hematopoietic stem cell (HSC) gene therapy,https://www.prnewswire.com/news-releases/csl-behring-to-acquire-biotech-company-calimmune-and-its-proprietary-stem-cell-gene-therapy-platform-300510086.html,No,,,No,,,No,,
graphite bio inc,2021-04-15 00:00:00,No,nula-cel; GPH-101; GPH-102,"Beta-globin gene mutation; Disease Name, Sickle Cell Disease; Disease Name, Beta-Thalassemia",rare diseases; hematology,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene editing, gene therapy, CRISPR, UltraHDR™ gene editing platform","https://www.linkedin.com/company/graphitebio#:~:text=Graphite%20Bio%20is%20a%20clinical,serious%20and%20life%2Dthreatening%20diseases.",No,,,No,,,No,,
throne biotechnologies inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Stem Cell Educator Therapy,"Disease Name, Type 1 Diabetes",metabolic diseases; autoimmune diseases,other,Phase II/III,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Stem Cell Educator therapy,https://www.linkedin.com/company/throne-biotechnologies,No,,,No,,,No,,
rocket pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='www.globaldata.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy cures,https://www.linkedin.com/company/rocket-pharmaceuticals-ltd,No,,,No,,,No,,
atsena therapeutics inc,2025-04-02 11:30:18,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,ocular gene therapy programs; preclinical programs to treat inherited retinal diseases; novel spreading AAV.SPR capsid; adeno-associated virus (AAV) technology,https://www.globenewswire.com/news-release/2025/04/02/3054152/0/en/Atsena-Therapeutics-Announces-Oversubscribed-150-Million-Series-C-Financing-to-Further-Advance-Ocular-Gene-Therapy-Programs.html,No,,,No,,,No,,
peloton therapeutics inc,2023-02-11 20:58:48,Yes,PT2977; PT2567; PT2385,"HIF-2α, Hypoxia-inducible factor-2 alpha",oncology; non-oncology,other,Phase 2,Yes,"first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities",https://www.foresitecapital.com/portfolio/peloton-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biocon biologics ltd,2025-10-17 04:50:21,No,Jobevne; Yesintek,"VEGF, Vascular Endothelial Growth Factor; IL-12, Interleukin-12; IL-23, Interleukin-23",oncology; autoimmune diseases,cytokine,Approved,No,,,No,,,Yes,Biocon Biologics will manufacture and supply insulin glargine,https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-biologics-expands-collaboration-with-civica-to-supply-affordable-insulin-in-us/articleshow/124634808.cms,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kashiv biosciences llc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,ADL-018; AVT23,"IgE, Immunoglobulin E",immunology; respiratory diseases; allergic conditions,other,Phase 3,Yes,small and large molecules,https://www.linkedin.com/company/kashiv-pharma,Yes,peptides,https://www.linkedin.com/company/kashiv-pharma,Yes,proteins,https://www.linkedin.com/company/kashiv-pharma,Yes,monoclonal antibodies,https://www.linkedin.com/company/kashiv-pharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,
gh research plc,2025-06-20 17:04:25,No,GH001; GH002,Treatment-Resistant Depression,CNS,other,Phase 2,Yes,"5-Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT)",https://www.cnbc.com/quotes/GHRS,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rednvia co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,DA-1229; Metformin,Not specified,cardiovascular,Not specified,Phase 2; Phase 2/3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
regenxbio inc,2025-10-14 12:06:05,No,ABBV-RGX-314; RGX-202,"VEGF, Vascular Endothelial Growth Factor; DMD, Dystrophin Gene",retinal diseases; neuromuscular diseases,cytokine; other,Phase 2; Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"AAV Therapeutics, an innovative class of gene therapy medicines",https://www.linkedin.com/company/regenx,No,,,No,,,No,,
allakos inc,2022-10-19 00:00:00,No,AK006,Not specified,immunology,Not specified,Phase 2,No,,,No,,,No,,,Yes,monoclonal antibodies that target immunomodulatory receptors,https://www.jitta.com/stock/NASDAQ:ALLK,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arcus biosciences inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,"TIGIT, T cell immunoreceptor with Ig and ITIM domains",oncology,immune checkpoint,Phase 2,Yes,small-molecule CD73 inhibitor,https://www.businesswire.com/news/home/20200527005478/en/,No,,,Yes,protein-based therapeutics,https://www.foresitecapital.com/portfolio/arcus-biosciences/,Yes,anti-TIGIT monoclonal antibody,https://www.businesswire.com/news/home/20200527005478/en/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rapt therapeutics inc,2025-10-16 17:52:21,Yes,RPT904,"IgE, Immunoglobulin E",allergic diseases,other,Phase 2b,No,,,No,,,No,,,Yes,"RPT904, a novel, half-life extended monoclonal antibody designed to bind free IgE",https://www.linkedin.com/company/rapt,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alpine immune sciences inc,2023-12-06 00:00:00,No,Povetacicept; ALPN-303,"BAFF, B cell activating factor; APRIL, A proliferation inducing ligand",autoimmune diseases; kidney diseases,cytokine,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arcutis biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,best molecules to bear against validated physiologic targets,https://www.linkedin.com/company/arcutis-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kura oncology inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Ziftomenib; KO-2806; Tipifarnib,"Menin; HRAS, Harvey Rat Sarcoma Viral Oncogene; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha",oncology; hematologic malignancies; solid tumors,enzyme; kinases; other,Phase 2; Phase 1,Yes,Our small-molecule drug candidates target signaling pathways and other drivers of cancer,https://www.linkedin.com/company/kura-oncology-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
compass pathways plc,2025-10-14 13:34:50,No,CTX-009; CTX-471; CTX-8371; CTX-10726; MM120; MM402,"DLL4, Delta-like ligand 4; VEGF-A, Vascular endothelial growth factor A; CD137, Tumor necrosis factor receptor superfamily member 9; PD-1, Programmed cell death protein 1; PD-L1, Programmed death-ligand 1",oncology; CNS; mental health; anxiety; depression; autism spectrum disorder,other; immune checkpoint; cytokine,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,COMP360 psilocybin treatment,https://uk.linkedin.com/company/compass-pathways
maze therapeutics inc,2025-10-14 18:03:54,Yes,MZE001,"GYS1, Glycogen Synthase 1",rare diseases,enzyme,Phase 1,Yes,small molecule precision medicines,https://www.linkedin.com/company/mazetx,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clasp therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,CLSP-1025,"p53R175H, Tumor-Specific Mutation in p53 Protein",oncology,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations,https://www.linkedin.com/company/clasp-therapeutics,No,,,No,,,Yes,next-generation T cell engagers (TCEs),https://www.linkedin.com/company/clasp-therapeutics
exegenesis bio inc,2024-12-03 15:25:42,No,EXG001-307,"SMN1, Survival Motor Neuron 1",rare diseases; neurology,other,Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs",https://www.linkedin.com/company/exegenesis,No,,,No,,,No,,
latigo biotherapeutics inc,2025-03-17 05:00:00,No,LTG-001; LTG-305,"NaV1.8, Voltage-Gated Sodium Channel",pain management,ion channels,Phase 1,Yes,Nav1.8 inhibitor,https://www.prnewswire.com/news-releases/latigo-biotherapeutics-closes-150-million-in-series-b-financing-to-advance-non-opioid-pain-therapeutics-302397457.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
catalym gmbh,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,Yes,visugromab,"GDF-15, Growth Differentiation Factor-15",oncology,cytokine,Phase 3,No,,,No,,,No,,,Yes,"anti-GDF-15 antibody, visugromab",https://de.linkedin.com/company/catalym,Yes,combining our clinical-stage antibody visugromab with antibody-drug conjugates (ADCs),https://de.linkedin.com/company/catalym,No,,,No,,,No,,,No,,,No,,,Yes,new class of immunotherapies that neutralize GDF-15,https://de.linkedin.com/company/catalym
carmot therapeutics inc,2023-06-25 00:00:00,Yes,CT-388; CT-868; CT-996; Petrelintide,"GLP-1, Glucagon-Like Peptide-1 Receptor; GIP, Glucose-Dependent Insulinotropic Polypeptide Receptor; Amylin, Amylin Analog",obesity; diabetes; metabolic diseases,gpcr; other,Phase 3; Phase 2; Phase 1,Yes,"CT-996, a once-daily oral small molecule GLP-1 receptor agonist",https://www.gene.com/carmot,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
lumen bioscience inc,"Error: Connection failed - HTTPSConnectionPool(host='www.lumen.bio', port=443",No,LMN-201,Clostridioides difficile infection,infectious diseases,other,Phase 2,No,,,No,,,Yes,spirulina-based GMP manufacturing,https://www.prnewswire.com/news-releases/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics-302577688.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"spirulina-based drug discovery, manufacturing, and delivery platform",https://www.prnewswire.com/news-releases/lumen-bioscience-expands-board-and-leadership-team-to-advance-clinical-pipeline-of-novel-oral-biologics-302577688.html
sirius therapeutics inc,No timestamp found,No,SRSD107,"FXI, Factor XI",cardiovascular; coagulation disorders,enzyme,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,siRNA technology,https://www.linkedin.com/company/sirius-therapeutics-inc,No,,,No,,,No,,,No,,
artios pharma ltd,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,ART0380; ART4215,"ATR, Ataxia Telangiectasia and Rad3-related protein; Polθ, DNA Polymerase Theta",oncology,kinases; enzyme,Phase 1,Yes,selective small-molecule ATR inhibitor,https://www.linkedin.com/company/artios-pharma-ltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
arthrosi therapeutics inc,2025-10-08 08:00:00,No,pozdeutinurad; AR882,"URAT1, Uric Acid Transporter 1",metabolic diseases,enzyme,Phase 3,Yes,highly potent and selective next generation URAT1 inhibitor,https://www.prnewswire.com/news-releases/arthrosi-secures-153-million-in-series-e-financing-to-complete-pivotal-development-of-pozdeutinurad-for-the-treatment-of-gout-and-tophaceous-gout-302578248.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
nmd pharma as,"Error: Connection failed - HTTPSConnectionPool(host='international.au.dk', po",No,NMD670,Not specified,Genetic disorders; rare diseases,Not specified,Not specified,Yes,ClC-1 Cl- ion channel inhibitors,https://www.linkedin.com/company/nmdpharma/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hongyun huaning (hangzhou) biopharmaceutical co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.bioworld.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,The World's First ETa-specific Monoclonal Antibody: Gmax Biopharm's GMA131 Approved by the US FDA for Clinical Study on (DKD) Diabetic Kidney Disease,https://enmobile.prnasia.com/mediaroom/?company_id=16265,Yes,"ACR246, a best-in-class ADC developed by Hangzhou Adcoris and potentially first to market, targets the 5T4 fetal antigen and utilizes a patented topoisomerase I inhibitor.",https://medium.com/@wuhanmabnus/the-target-of-endothelin-1-receptor-ednra-f7974d1f741d,No,,,No,,,No,,,No,,,No,,,No,,
iteos therapeutics sa,2025-05-28 12:10:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,Small molecule immunomodulators,https://www.linkedin.com/company/iteos-therapeutics-sa,No,,,No,,,Yes,anti-TREM2 antibody,https://www.linkedin.com/company/iteos-therapeutics-sa,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"T Cell Engagers, BiTEs",https://www.linkedin.com/company/iteos-therapeutics-sa
cytomx therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='seekingalpha.com', port=",Yes,CX-2051; CX-801,"EpCAM, Epithelial Cell Adhesion Molecule; IFN-α2b, Interferon Alpha-2b",oncology,enzyme; cytokine,Phase 1,No,,,No,,,No,,,No,,,Yes,EpCAM antibody drug conjugate (CX-2051),https://www.linkedin.com/company/cytomx-therapeutics,No,,,No,,,No,,,No,,,No,,,Yes,immune modulators,https://www.cnbc.com/quotes/CTMX
neurolixis inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,NLX-112; NLX-101; NLX-204,"5-HT1A, Serotonin 5-HT1A receptor",CNS; rare diseases; movement disorders; Parkinson's disease; autism spectrum disorders; depression,gpcr,Phase 2,Yes,discovery and development of novel drugs,https://www.linkedin.com/company/neurolixis-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tengion inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Neo-Urinary Conduit; Neo-Kidney Augment; Neo-Bladder Augment,Bladder dysfunction; Kidney failure; Neurogenic bladder,oncology; nephrology; urology,other,Phase 1; Preclinical; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Neo-Kidney Augment™, Neo-Urinary Conduit™, regenerative medicine, cellular therapies",https://www.prnewswire.com/news-releases/tengion-announces-transactions-totaling-336-million-to-advance-its-organ-regeneration-platform-213872451.html,No,,,No,,,Yes,"Organ Regeneration Platform™, regenerative medicine",https://www.prnewswire.com/news-releases/tengion-announces-transactions-totaling-336-million-to-advance-its-organ-regeneration-platform-213872451.html
vitaeris inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,clazakizumab; garadacimab; SAB-185; CSL112; CSL200,"IL-6, Interleukin-6; Factor XIIa; SARS-CoV-2; ApoA-1, Apolipoprotein A-1; Disease Name",immunology; respiratory; cardiovascular; transplant; rare diseases,cytokine; enzyme; other; enzyme; other,Phase 3; Phase 2; Early Phase; Phase 3; Phase 1,No,,,No,,,Yes,recombinant proteins,https://biomelbourne.org/csl-to-acquire-biotech-company-vitaeris/,Yes,monoclonal antibody (MAB),https://newsroom.csl.com/2020-06-08-CSL-Behring-to-Acquire-Biotech-Company-Vitaeris,No,,,No,,,No,,,No,,,No,,,No,,,No,,
hybridon inc,2000-06-30 00:00:00,Yes,Aducanumab; AGB101; AR1001; AVP-786; AXS-05; Blarcamesine; BPDO-1603; Brexpiprazole; Caffeine; Donanemab; Donepezil; E2814; Fosgonimeton; Gantenerumab; Guanfacine; Hydralazine hydrochloride; Icosapent ethyl,"Aβ, Amyloid Beta; SV2A, Synaptic Vesicle Glycoprotein 2A; Neurotransmitter receptors; NMDA, N-Methyl-D-Aspartate receptor; Sigma-1 receptor; M2 autoreceptor; Tau, Microtubule-associated protein tau; HGF/MET receptor system; Alpha-2 adrenergic receptor; Free radicals; Omega-3 fatty acids",neurology; Alzheimer's disease; cognitive disorders,other; other; gpcr; gpcr; gpcr; other; other; gpcr; gpcr; other; gpcr; other; other; other; gpcr; other; other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"antisense drugs, novel immune stimulatory CpG DNA, functional genomics",https://www.bioprocessonline.com/doc/hybridon-sells-dna-manufacturing-business-0002,No,,,No,,,No,,,No,,
novan inc,2023-07-17 00:00:00,No,ZELSUVMI; berdazimer,Molluscum contagiosum,dermatology; infectious diseases,other,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,NITRICIL™ drug delivery technology,https://investor.ligand.com/news-and-events/press-releases/news-details/2023/Ligand-Offers-15-Million-To-Acquire-Assets-Of-Novan-Inc/default.aspx
freeline therapeutics holdings plc,No timestamp found,No,TLN-121; KRAS inhibitor; EZH2 inhibitor,"BCL6, B-cell lymphoma 6; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; EZH2, Enhancer of Zeste Homolog 2",oncology,enzyme; other; enzyme,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing transformative adeno-associated virus (AAV) vector-mediated gene therapies,https://www.marketscreener.com/quote/stock/FREELINE-THERAPEUTICS-HOL-110594703/company/,No,,,No,,,No,,
mina therapeutics ltd,2021-08-06 00:00:00,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA therapeutics,https://uk.linkedin.com/company/mina-therapeutics,Yes,Harnessing an innate mechanism of gene activation,https://uk.linkedin.com/company/mina-therapeutics,No,,,No,,,No,,
eicosis llc,Error: can't compare offset-naive and offset-aware dateti,No,Not specified,"sEH, Soluble Epoxide Hydrolase",pain; inflammation,enzyme,Phase 1,Yes,lead compounds developed by Hammock were licensed exclusively to EicOsis,https://research.ucdavis.edu/eicosis-receives-15m-to-help-fund-human-clinical-trials-of-non-opioid-pain-therapy/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
achaogen inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.nature.com', port=44",No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,antibiotic—plazomicin,https://www.idsociety.org/news--publications-new/articles/2019/Drug-Company-Closing/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kiora pharmaceuticals inc,2025-10-16 16:26:56,No,KIO-301; KIO-104,"Disease Name, Inherited Retinal Degenerations; DHODH, Dihydroorotate Dehydrogenase",ophthalmology; inflammatory conditions,other; enzyme,Phase 2,Yes,small molecule,https://at.linkedin.com/company/kiorapharma,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,molecular photoswitch,https://at.linkedin.com/company/kiorapharma
lyra therapeutics inc,Error: can't compare offset-naive and offset-aware dateti,Yes,LYR-210; LYR-220,Chronic Rhinosinusitis,respiratory diseases,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy",https://www.linkedin.com/company/lyra-therapeutics
mabion sa,"Error: Connection failed - HTTPSConnectionPool(host='www.mabion.eu', port=443",Yes,NVG-222,"ROR1, Receptor Tyrosine Kinase-like Orphan Receptor 1; CD3, Cluster of Differentiation 3",oncology,kinases; immune checkpoint,Phase 1,No,,,No,,,Yes,clinical and commercial manufacture of recombinant protein therapeutics,https://pl.linkedin.com/company/mabion,Yes,"Antibodies Development, Monoclonal Antibody Production",https://pl.linkedin.com/company/mabion,No,,,No,,,No,,,No,,,Yes,commercial production of the antigen for their COVID-19 vaccine,https://pl.linkedin.com/company/mabion,No,,,No,,
cohbar inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,IFx-Hu2.0; IFx-Hu3.0,"emm55, Immunogenic Bacterial Protein; CD22",oncology; immunology,immune checkpoint; other,Phase 2/3; Preclinical,No,,,Yes,peptides encoded in its genome,https://www.linkedin.com/company/cohbar-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bolt biotherapeutics inc,2025-08-14 20:09:37,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,agonist antibody now in Phase 1 testing,https://www.biopharmadive.com/news/bolt-biotherapeutics-layoffs-ceo-change-restructuring-pipeline/716165/,Yes,"immune-stimulating antibody conjugate, or ISAC",https://www.biopharmadive.com/news/bolt-biotherapeutics-layoffs-ceo-change-restructuring-pipeline/716165/,No,,,No,,,No,,,No,,,No,,,Yes,"immune-stimulating antibody conjugate, or ISAC",https://www.biopharmadive.com/news/bolt-biotherapeutics-layoffs-ceo-change-restructuring-pipeline/716165/
edesa biotech inc,2025-09-03 18:51:15,No,EB06; EB05; EB01,"CXCL10, C-X-C Motif Chemokine Ligand 10; TLR4, Toll-Like Receptor 4",dermatology; respiratory; immunology,cytokine; immune checkpoint,Phase 2; Phase 3,No,,,No,,,No,,,Yes,monoclonal antibody,https://www.globenewswire.com/news-release/2025/08/08/3130401/0/en/Edesa-Biotech-Reports-Fiscal-3rd-Quarter-2025-Results.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
clearside biomedical inc,2025-08-26 12:13:00,Yes,CLS-AX; XIPERE,"VEGF, Vascular Endothelial Growth Factor; Uveitic Macular Edema",ophthalmology,kinases; other,Phase 3; Marketed,Yes,Clearside is evaluating various small molecules for a range of retinal diseases with high unmet medical need.,https://www.globenewswire.com/news-release/2025/07/17/3117105/0/en/Clearside-Biomedical-Announces-Plan-to-Explore-Strategic-Alternatives-to-Advance-its-Proprietary-Suprachoroidal-Space-SCS-Delivery-Platform-and-Promising-Ophthalmology-Pipeline.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Clearside strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic agents including gene therapies.,https://www.globenewswire.com/news-release/2025/07/17/3117105/0/en/Clearside-Biomedical-Announces-Plan-to-Explore-Strategic-Alternatives-to-Advance-its-Proprietary-Suprachoroidal-Space-SCS-Delivery-Platform-and-Promising-Ophthalmology-Pipeline.html,No,,,No,,,No,,
durect corp,2025-09-12 14:46:25,No,Larsucosterol,"DNA methyltransferases, Epigenetic enzymes",hepatology,enzyme,Phase 3,Yes,"larsucosterol, a novel epigenetic modulator",https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tern therapeutics llc,2025-09-17 15:27:09,Yes,TTX-381; TTX-181,"TPP1, Tripeptidyl Peptidase 1",rare diseases; neurodegenerative disorders; ophthalmology,enzyme,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy targeting vision loss in children with CLN2 Batten disease,https://www.prnewswire.com/news-releases/andelyn-biosciences-and-tern-therapeutics-partner-for-late-stage-process-performance-qualification-ppq-manufacturing-of-aav-gene-therapy-for-the-treatment-of-cln2-batten-disease-302545046.html,No,,,No,,,No,,
alessa therapeutics inc,2025-10-17 13:44:32,No,Enolen; Biolen,Prostate Cancer; Not specified,oncology,other,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,localized drug delivery technology,https://innovation.ucsf.edu/news/alessa-therapeutics-announces-closing-15m-seed-financing
mabspace international ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.lavfund.com', port=4",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,antibody-based therapeutics for cancer and other diseases,https://www.prnewswire.com/news-releases/hjb-merges-with-mabspace-biosciences-to-form-transcenta-holding-a-fully-integrated-leading-global-biotherapeutics-company-300771676.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bioxodes sa,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",No,BIOX-101,"Factors XIa and XIIa, Intrinsic Coagulation Pathway; Neutrophils; NETs, Neutrophil Extracellular Traps",neurology; thrombo-inflammatory diseases; stroke,enzyme; other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs).",https://bioxodes.com/
serda therapeutics bv,2025-07-04 22:15:25,No,SN514,Not specified,wound care,enzyme,Phase 1,No,,,No,,,Yes,Utilizing a proprietary proteolytic enzyme,https://nl.linkedin.com/company/serda-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
baoyuan biopharmaceuticals technology hangzhou co ltd,2019-09-25 06:35:00,Yes,AB-106; DS-6051b,"ROS1, ROS proto-oncogene 1; NTRK, Neurotrophic Tyrosine Receptor Kinase",oncology,kinases,Phase 2,Yes,ROS1/NTRK dual inhibitor,https://www.prnewswire.com/news-releases/preclincal-results-of-baoyuans-next-generation-ros1ntrk-inhibitor-ab-106-published-in-nature-communications-300925036.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
yourchoice therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,YCT-529; GPHR-529,"RAR-α, Retinoic Acid Receptor Alpha",reproductive health,nuclear receptors,Phase 2,Yes,YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor,https://www.pharmacy.umn.edu/news/yourchoice-therapeutics-begins-first-human-trial-male-birth-control-pill,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
malaghan institute of medical research,2025-10-18 01:32:42,Yes,CAR T-cell therapy,Disease Name,oncology,immune checkpoint,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,New Zealand's first CAR T-cell clinical trial,https://www.malaghan.org.nz/,Yes,clinical trials of new vaccines,https://nz.linkedin.com/company/malaghan-institute-of-medical-research,No,,,No,,
metagen therapeutics inc,2025-10-08 00:00:00,Yes,MVT-201,Not specified,infectious diseases,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,oral FMT therapeutic for ulcerative colitis,https://www.linkedin.com/company/metagentx/
thryv therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,THRV-1268,"SGK1, Serum/Glucocorticoid-Regulated Kinase 1",cardiovascular; rare diseases,kinases,Phase 2/3,Yes,potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1),https://ca.linkedin.com/company/thryv-therapeutics-inc,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
recode therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,RCT2100,Cystic Fibrosis,rare diseases; respiratory diseases,Not specified,Phase 2,No,,,No,,,Yes,CFTR protein,https://www.linkedin.com/company/recode-therapeutics,No,,,No,,,No,,,Yes,"mRNA therapeutics, Antisense oligonucleotides (ASOs)",https://www.linkedin.com/company/recode-therapeutics,Yes,gene correction therapeutics,https://www.linkedin.com/company/recode-therapeutics,No,,,No,,,Yes,Non-Viral Lipid Nanoparticles,https://www.linkedin.com/company/recode-therapeutics
highlight therapeutics sl,2025-10-14 08:37:03,Yes,BO-112; BO-110; BO-212,Not specified,oncology; dermato-oncology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNA-based therapy,https://www.highlighttherapeutics.com/,No,,,No,,,No,,,No,,
tract therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,TRK-001,Not specified,transplant medicine; autoimmune diseases,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,autologous regulatory T cell product,https://www.linkedin.com/company/tract-therapeutics,No,,,No,,,No,,
pharmazz inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Sovateltide; Centhaquine,Disease Name,neurology; critical care,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spikimm sas,"Error: Connection failed - HTTPSConnectionPool(host='www.pasteur.fr', port=44",No,AZD3152; VYD222; REGN-17092; AER-800,"Spike Glycoprotein, Coronavirus",infectious diseases,other,Not specified,No,,,No,,,No,,,Yes,prophylactic mAbs against severe viral diseases,https://www.linkedin.com/company/spikimm/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
canadian immunization research network,"Error: Connection failed - HTTPSConnectionPool(host='research.mcmaster.ca', p",No,Not specified,Not specified,oncology; infectious diseases,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,focus on late-stage vaccine evaluation of program implementation,https://ca.linkedin.com/showcase/cirn-rcri/,No,,,No,,
7tm pharma a/s (inactive),2009-01-21 00:00:00,Yes,TM30339; TM38837,"Y4, Y4 receptor; CB1, Cannabinoid receptor type 1",metabolic diseases; obesity,gpcr; gpcr,Preclinical; Phase 1,Yes,Ar231453 was kindly provided by Lisbeth Elster (7TM Pharma).,https://pmc.ncbi.nlm.nih.gov/articles/PMC2823539/,Yes,"The ghrelin and substance P peptides were purchased from Bachem (Bubendorf, Switzerland).",https://pmc.ncbi.nlm.nih.gov/articles/PMC2823539/,Yes,"Receptors/Membrane, Signal Transduction/Adenylate Cyclase, Signal Transduction/G-proteins, Signal Transduction/Inositol Phosphates",https://pmc.ncbi.nlm.nih.gov/articles/PMC2823539/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
braxia scientific corp,2020-02-06 00:00:00,No,PCN-101; RL-007; DMT-1002; GRX-917; KUR-101; EMP-01; RLS-01; NN-101; VLS-01; COMP360; 18-MC; LSD; R(-)-MDMA; DMT; Psilocybin; Mescaline; CYB001; CYB003; CYB004; CYB005; SPL026; SPL028; SPL029; SPL801B; BMB-101; MYCO-001; MYCO-003; PLZ-1013; AP-188; TD-0148A; MSP-1014; EV101; MEAI; MYND-778; MYND-604,Treatment-Resistant Depression; Generalized Anxiety Disorder; Mild-Traumatic Brain Injury; Opioid Use Disorder; Post-Traumatic Stress Disorder; Nicotine Use Disorder; Autism Spectrum Disorder; Alcohol Use Disorder; Eating Disorders; Depression; Anxiety; Dyskinesia; Cancer-Related Stress,CNS; psychiatry; mental health; substance use disorders; oncology; rare diseases; infectious diseases,other,Phase 1; Phase 2; Phase 3; Preclinical,Yes,discovering and commercializing novel drugs,https://thecse.com/listings/braxia-scientific-corp/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,delivery methods,https://thecse.com/listings/braxia-scientific-corp/
marker therapeutics inc,2025-10-06 11:56:38,No,MT-401-OTS; MT-601,"Survivin, Apoptosis Inhibitor; PRAME, Preferentially Expressed Antigen in Melanoma; NY-ESO-1, Cancer/Testis Antigen; WT-1, Wilms Tumor 1",oncology; hematological malignancies; solid tumors,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,development of next-generation T cell-based immunotherapies,https://www.linkedin.com/company/marker-therapeutics,No,,,No,,,No,,
salarius pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='salariuspharma.com', por",No,seclidemstat; SP-3164,Not specified,oncology; hematologic cancers; gastroenterology oncology; respiratory infectious diseases,other,Phase 1/2; IND-stage,Yes,"SP-3164, an oral small molecule targeted protein degrader",https://www.linkedin.com/company/salarius-pharmaceuticals,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"SP-3164, an oral small molecule targeted protein degrader",https://www.linkedin.com/company/salarius-pharmaceuticals,No,,
epsilogen ltd,Error: Connection failed - HTTPSConnectionPool(host='european-biotechnology.c,No,MOv18 Ig; EPS 401,"FOLR1, Folate Receptor Alpha; EGFR, Epidermal Growth Factor Receptor",oncology,other,Phase 1,No,,,No,,,No,,,Yes,development of immunoglobulin (IgE) antibodies to treat cancer,https://uk.linkedin.com/company/epsilogen-ltd,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rigel pharmaceuticals inc,2025-10-09 19:09:14,Yes,Olutasidenib; Ly3871801; R906289; Fostamatinib,"IDH1, Isocitrate Dehydrogenase 1; Disease Name; SYK, Spleen Tyrosine Kinase",oncology; immunology; rare diseases,enzyme; other; kinases,Phase 2; Phase 2; Phase 1/2; Phase 3,Yes,"dedicated to discovering, developing and providing novel small molecule drugs",https://www.linkedin.com/company/rigel,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pentixapharm gmbh,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,Yes,Y90-PentixaTher is a y ttrium-90 (Y-90) radiolabeled peptide therapeutic,https://www.auntminnie.com/clinical-news/molecular-imaging/nuclear-medicine/news/15743946/eckert-ziegler-signs-manufacturing-deal-with-pentixapharm,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor",https://www.eu-startups.com/directory/pentixapharm/
oculis sa,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,Privosegtor; OCS-01; Licaminlimab,"SGK-2, Serum-Glucocorticoid Kinase-2; TNF-alpha, Tumor Necrosis Factor-alpha",neuro-ophthalmology; ophthalmology; diabetes,kinases; cytokine,Phase 3,Yes,"Privosegtor, a new peptoid small molecule candidate",https://www.linkedin.com/company/oculis-sa,No,,,No,,,Yes,"Licaminlimab, a topical biologic anti-TNFα eye drop candidate",https://www.linkedin.com/company/oculis-sa,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dermavant sciences inc,2025-01-16 18:00:02,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,promising compounds that address unmet therapeutic needs,https://www.linkedin.com/company/dermavant-sciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
krystal biotech inc,2025-10-06 13:00:31,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,COL7 protein,https://www.marketscreener.com/news/bofa-securities-adjusts-krystal-biotech-price-target-to-255-from-182-maintains-buy-rating-ce7d5adddd8dff22,No,,,No,,,No,,,No,,,Yes,genetic medicines to treat diseases with high unmet medical needs,https://www.linkedin.com/company/krystal-biotech-inc,No,,,No,,,No,,
genor biopharma co ltd,"Error: Connection failed - HTTPSConnectionPool(host='dealstreetasia.com', por",No,GB491; GB261; GB263T; GB268; GBD218; GBD201; GBD209; GB226; GB492,"CDK4/6, Cyclin-Dependent Kinase 4/6; CD20/CD3; EGFR/cMET/cMET; PD-1/CTLA-4/VEGF; BCMA/GPRC5D; CCR8/CTLA-4",oncology; autoimmune diseases,kinases; immune checkpoint; other; immune checkpoint; other; immune checkpoint,Phase 3; Phase 1/2; Phase 1/2; Preclinical; Preclinical; Preclinical; Preclinical; Marketed; Preclinical,Yes,highly selective oral CDK4/6 inhibitor,https://www.genorbio.com/,No,,,No,,,Yes,Antibodies,"https://www.ventureradar.com/organisation/Genor%20Biopharma%20Co_%5Bdot%5D_,%20Ltd_%5Bdot%5D_/1a6b4a2d-c62b-4ef5-8f20-7bf726bde42f",No,,,No,,,No,,,No,,,No,,,No,,,No,,
rayzebio inc,2025-06-20 18:46:57,No,Not specified,Not specified,immunology,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceuticals,https://www.linkedin.com/company/rayzebio
f-star therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,VGA039,Protein S,hematology,enzyme,Phase 3,No,,,No,,,No,,,Yes,bispecific antibodies,https://uk.linkedin.com/company/f-star,No,,,No,,,No,,,No,,,No,,,No,,,No,,
spark therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,SPK-8011; SPK-3006; SPK-8016,Factor VIII,rare diseases; hematology,enzyme,Phase 3; Early Development,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,unlock the power of gene therapy to accelerate healthcare transformation,https://www.linkedin.com/company/roche-spark-therapeutics-inc,No,,,No,,,No,,
nuvig therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,No,NVG-2089,"FcγRIIb, Type II Fc receptor",autoimmune diseases; chronic inflammatory diseases,other,Phase 2,No,,,No,,,Yes,recombinant Fc-fusion protein,https://www.linkedin.com/company/nuvig-therapeutics-inc,No,,,No,,,Yes,recombinant Fc-fusion protein,https://www.linkedin.com/company/nuvig-therapeutics-inc,No,,,No,,,No,,,No,,,No,,
keryx biopharmaceuticals inc,2018-06-28 09:16:34,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,small commercial presence on the renal market,https://www.biopharmadive.com/news/akebia-keryx-to-merge-creating-1b-kidney-disease-company/526761/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
third arc bio inc,2024-07-23 07:00:00,Yes,ARC101,"CLDN6, Claudin 6",oncology; immunology,other,Phase 1,No,,,No,,,No,,,Yes,multifunctional antibodies,https://thirdarcbio.com/,Yes,antibody drug conjugates (ADCs),https://www.prnewswire.com/news-releases/third-arc-bio-launches-with-oversubscribed-165-million-series-a-financing-to-deliver-superior-biologics-for-solid-tumors-and-inflammatory--immunology-ii-diseases-302201952.html,No,,,No,,,No,,,No,,,No,,,No,,
bicara therapeutics inc,2025-10-15 18:31:39,No,Ficerafusp alfa,"EGFR, Epidermal Growth Factor Receptor; TGF-β, Transforming Growth Factor-beta",oncology,other,Phase 2/3,No,,,No,,,No,,,Yes,bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody,https://www.marketbeat.com/instant-alerts/insider-selling-bicara-therapeutics-nasdaqbcax-ceo-sells-13289-shares-of-stock-2025-10-15/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Dual-action antibodies bringing together the precision of targeted therapies and the power of tumor modulators,https://www.linkedin.com/company/bicara-therapeutics
artiva biotherapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.iposcoop.com', port=",Yes,AlloNK; AB-101,B cells,autoimmune diseases; oncology,other,Phase 1,No,,,No,,,No,,,Yes,B-cell targeted monoclonal antibodies (mAbs),https://www.marketscreener.com/news/wedbush-adjusts-price-target-on-artiva-biotherapeutics-to-23-from-18-maintains-outperform-rating-ce7d5addda8af527,No,,,No,,,No,,,Yes,natural killer (NK) cell-based therapies,https://www.marketscreener.com/news/wedbush-adjusts-price-target-on-artiva-biotherapeutics-to-23-from-18-maintains-outperform-rating-ce7d5addda8af527,No,,,No,,,No,,
epigenetix inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",Yes,ATX-559; ATX-295,"DHX9, RNA and DNA/RNA Helicase; KIF18A, Mitotic Kinesin Motor Protein",oncology,enzyme; other,Phase 1/2,Yes,first-in-class oral cancer drug,https://www.linkedin.com/company/epigenetix,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"epigenetic drugs, such as EZH2 inhibitors",https://www.linkedin.com/company/epigenetix
ji xing pharmaceuticals ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.cbinsights.com', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kadimastem ltd,2025-09-30 11:29:52,Yes,IsletRx; iTOL102,"Disease Name, Type 1 Diabetes",endocrinology; diabetes,other,Preclinical,Yes,Add NLS’s expertise in CNS small molecules to create a uniquely diversified pipeline.,https://www.linkedin.com/company/kadimastem/,No,,,No,,,No,,,No,,,No,,,No,,,Yes,stem cell-derived insulin-producing cells,https://www.linkedin.com/company/kadimastem/,No,,,No,,,No,,
vaccitech plc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
viela bio inc,2020-06-27 00:00:00,Yes,Inebilizumab,"CD19, Cluster of Differentiation 19",immunology; neurology; rare diseases,cytokine,Approved,No,,,No,,,No,,,Yes,"Monoclonal antibodies (e.g., Uplizna, VIB7734, VIB4920)",https://www.biopharmadive.com/news/horizon-acquires-astrazeneca-spinout-viela-bio/594265/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
biogencell ltd,2024-07-11 08:29:52,Yes,BGC101,Not specified,cardiovascular,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,BioGenCell pioneers revolutionary cell therapy for microvascular disease,https://www.calcalistech.com/ctechnews/article/hki11xl2wa,No,,,No,,,No,,
vessl therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.globes.co.il', port=4",Yes,ATEV; Symvess,Not specified,vascular diseases; renal diseases,other,Approved; Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell- and gene-based proprietary technologies,https://vessltherapy.com/,No,,,No,,,Yes,regenerative medicine solutions based on proprietary cell and gene technology,https://vessltherapy.com/
agenus inc,2025-10-17 18:58:51,No,Botensilimab; Balstilimab; Zalifrelimab,"CTLA-4, Cytotoxic T-Lymphocyte-Associated Protein 4; PD-1, Programmed Cell Death Protein 1",oncology,immune checkpoint,Phase 2,No,,,No,,,No,,,Yes,broad repertoire of antibody therapeutics,https://www.linkedin.com/company/agenus,No,,,No,,,No,,,Yes,adoptive cell therapies (via MiNK Therapeutics),https://www.linkedin.com/company/agenus,Yes,"vaccine adjuvants (via SaponiQx, Inc.)",https://www.linkedin.com/company/agenus,No,,,No,,
verastem inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Avutometinib; Defactinib,"KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; RAF, Rapidly Accelerated Fibrosarcoma; MEK, Mitogen-Activated Protein Kinase Kinase; FAK, Focal Adhesion Kinase",oncology; gynecological cancers,kinases,Approved,Yes,novel small molecule drugs that inhibit critical signaling pathways in cancer,https://www.linkedin.com/company/verastemoncology,No,,,No,,,Yes,antibody drug discovery,https://www.linkedin.com/company/verastemoncology,No,,,No,,,No,,,No,,,No,,,No,,,No,,
versantis ag,"Error: Connection failed - HTTPSConnectionPool(host='www.venturekick.ch', por",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
elysium therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.linkedin.com', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,new chemical entities that are comprised of FDA-approved drugs,https://www.linkedin.com/company/elysium-therapeutics-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
dialectic therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.dtsciences.com', por",No,DT2216,"BCL-XL, B-cell lymphoma extra large",oncology,enzyme,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
longeveron inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Laromestrocel,Not specified,rare diseases; cardiovascular; CNS,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,developing cellular therapies for life-threatening and chronic aging-related conditions,https://www.linkedin.com/company/longeveron-inc,No,,,No,,,Yes,regenerative medicine solutions,https://www.linkedin.com/company/longeveron-inc
lycera corp (inactive),2018-06-29 03:10:07,Yes,LYC-30937; ELC-301; ELC-401; ELC-201; ELC-100,"RORgamma, Retinoic Acid Receptor-related Orphan Receptor Gamma; CD20; IL13Ra2, Interleukin-13 Receptor Subunit Alpha-2; 4-1BBL, Tumor Necrosis Factor Receptor Superfamily Member 9 Ligand; Neuroendocrine Tumors",oncology; immunology; inflammatory bowel disease; CNS; rare diseases,nuclear receptors; other; other; immune checkpoint; other,Phase 1; Phase 1/IIa; Preclinical; Preclinical; Phase 1/II,Yes,small molecule therapies for autoimmune disorders,https://www.prnewswire.com/news-releases/lycera-and-celgene-announce-an-exclusive-strategic-collaboration-to-advance-novel-immune-modulators-300095984.html,No,,,No,,,No,,,No,,,No,,,No,,,Yes,adoptive T-cell therapy,https://www.prnewswire.com/news-releases/lycera-and-celgene-announce-an-exclusive-strategic-collaboration-to-advance-novel-immune-modulators-300095984.html,No,,,No,,,No,,
4sc ag,"Error: Connection failed - HTTPSConnectionPool(host='imux.com', port=443): Ma",Yes,Resminostat; Domatinostat; 4SC-202,Not specified,oncology,Not specified,Phase II,Yes,develops small-molecule drugs,"https://www.cnbc.com/quotes/VSC-FF#:~:text=4Sc%20AG%20is%20a%20Germany,of%20preclinical%20and%20clinical%20development.",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
erytech pharma sa,"Error: Connection failed - HTTPSConnectionPool(host='live.euronext.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
plus therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,REYOBIQ; Doceplus; Doxoplus,High-Grade Glioma; Ependymoma; CNS Tumors; Recurrent Glioblastoma; Leptomeningeal Metastases,oncology; CNS; rare diseases,other,Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers",https://www.marketbeat.com/instant-alerts/plus-therapeutics-inc-nasdaqpstv-short-interest-update-2025-10-18/
ubix therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,UBX-303-1; UBX-103,"Disease Name, B-cell lymphoma; Disease Name, Prostate cancer",oncology,other,Phase 1; Licensed,No,,,No,,,No,,,No,,,Yes,degrader-antibody conjugates,https://www.linkedin.com/company/ubix-therapeutics,No,,,No,,,No,,,No,,,Yes,targeted protein degradation (TPD) therapeutics,https://www.linkedin.com/company/ubix-therapeutics,No,,
beacon therapeutics ltd,2024-07-03 08:00:00,Yes,laru-zova; Undisclosed asset; CDHR1,"RPGR, Retinitis Pigmentosa GTPase Regulator; Disease Name; CDHR1, Cadherin Related Family Member 1",ophthalmology; rare diseases,other; Not specified; other,Phase 3; Preclinical; Preclinical,No,,,No,,,Yes,"target generation technology platform that will identify, screen, and search secreted proteins",https://www.prnewswire.com/news-releases/beacon-therapeutics-raises-170-million-in-series-b-funding-to-advance-development-of-ophthalmic-gene-therapies-302188599.html,No,,,No,,,No,,,No,,,Yes,ophthalmic gene therapy company,https://www.linkedin.com/company/beacon-therapeutics,No,,,No,,,No,,
sutro biopharma inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,STRO-004; STRO-006; STRO-003,"Tissue Factor; ITGB6, Integrin Beta-6; ROR1, Receptor Tyrosine Kinase-like Orphan Receptor 1",oncology,enzyme; other; kinases,Preclinical,No,,,No,,,No,,,Yes,antibody drug conjugates (ADCs),https://www.linkedin.com/company/sutro-biopharma-inc-,Yes,antibody drug conjugates (ADCs),https://www.linkedin.com/company/sutro-biopharma-inc-,No,,,No,,,No,,,No,,,No,,,No,,
bavarian nordic as,2025-10-16 06:21:34,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,innovative vaccines,https://www.linkedin.com/company/bavariannordic,No,,,Yes,Virus-Like Particles (VLP),https://www.linkedin.com/company/bavariannordic
prothena corp plc,2025-10-08 19:59:36,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,protein dysregulation,https://www.linkedin.com/company/prothena_biosciences_inc,Yes,clinical pipeline of antibody-based product candidates,https://www.home.saxo/markets/stocks/prta-xnas,No,,,No,,,No,,,No,,,No,,,No,,,No,,
tourmaline bio inc,2025-10-17 13:15:03,No,Pacibekitug,"IL-6, Interleukin-6",cardiovascular,cytokine,Phase 2,No,,,No,,,No,,,Yes,anti-IL-6 mAb,https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd,No,,,No,,,No,,,No,,,No,,,No,,,No,,
burnet institute,No timestamp found,No,Omega-3 fatty acid; aspirin; vaginal progesterone; oral progesterone; L-arginine; selenium; nicorandil; isosorbide dinitrate; nicardipine; celecoxib; pravastatin; lactoferrin; glyceryl trinitrate; retosiban; relcovaptan; human chorionic gonadotropin; Bryophyllum pinnatum extract; vitamin D; allylestrenol; dalteparin; tadalafil; UNIMMAP,Preterm birth; Preterm labor; Fetal growth restriction,maternal health; pregnancy complications,Not specified,Phase 3; Phase 2; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
akcea therapeutics inc,2020-10-12 09:00:00,No,Vupanorsen; Vutrisiran; AKCEA-TTR-LRx,"ANGPTL3, Angiopoietin-like 3; TTR, Transthyretin",cardiovascular; rare diseases,other,Phase 3; Phase 2; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,Yes,antisense therapy,https://www.pfizer.com/news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx,No,,,No,,,No,,,No,,
gemini therapeutics inc,No timestamp found,No,GMT001; Bitopertin; DISC-0974,"Disease, Age-related Macular Degeneration; Disease, Erythropoietic Protoporphyria; Disease, Chronic Kidney Disease and Anemia",ocular diseases; rare diseases; hematology,other,Phase 2; NDA Submission; Phase 1,Yes,aldoxorubicin,https://www.geminithera.com/,No,,,Yes,"GEM103, a recombinant form of the human complement factor H protein",https://www.jitta.com/stock/NASDAQ:GMTX,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
propella therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='www.tracxn.com', port=44",No,PRL-02,"CYP17, Cytochrome P450 17A1",oncology; urology,enzyme,Phase 1,Yes,"PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor",https://www.prnewswire.com/news-releases/astellas-completes-acquisition-of-propella-therapeutics-302021329.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sab bio,2025-09-16 16:01:09,No,SAB-142; SAB-176; SAB-185,Type 1 Diabetes; Type A and Type B Influenza Viruses; SARS-CoV-2,immunology; infectious diseases,cytokine; other,Phase 2; Preclinical,No,,,No,,,No,,,Yes,fully-human anti-thymocyte immunoglobulin (hIgG),https://www.linkedin.com/company/sab-biotherapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
assembly biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,ABI-5366; ABI-1179,HSV helicase-primase complex,infectious diseases,enzyme,Phase 1,Yes,innovative small molecule antiviral therapeutics,"https://www.linkedin.com/company/assembly-bio#:~:text=Assembly%20Biosciences%20is%20a%20biotechnology,the%20lives%20of%20patients%20worldwide.",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
rhythm pharmaceuticals inc,2025-10-16 13:00:24,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,preclinical suite of small molecules for the treatment of congenital hyperinsulinism,https://www.linkedin.com/company/rhythm-pharmaceuticals-inc-,Yes,peptides,https://www.linkedin.com/company/rhythm-pharmaceuticals-inc-,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sab biotherapeutics inc,2025-09-16 16:01:09,No,SAB-142; SAB-176,Type 1 Diabetes; Type A and Type B Influenza viruses,metabolic diseases; infectious diseases,other; cytokine,Preclinical; Preclinical,No,,,No,,,No,,,Yes,"human, multi-targeted, high-potency immunoglobulins (IgGs)",https://www.news-medical.net/suppliers/SAb-Biotherapeutics-Inc.aspx,No,,,No,,,No,,,No,,,No,,,No,,,No,,
day one biopharmaceuticals holding co llc,2025-10-07 15:10:02,No,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,"Targeted Therapies, MAPK",https://www.linkedin.com/company/dayonebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
day one biopharmaceuticals inc,2025-10-07 15:10:02,No,MTX-13; DAY301; OJEMDA,"PTK7, Protein-Tyrosine Kinase 7",oncology; pediatric cancers,kinases,Phase 1,Yes,Targeted Therapies,https://www.linkedin.com/company/dayonebio,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
ovid therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.cnn.com', port=443):",Yes,OV329; OV350; OV4071,"GABA-AT, Gamma-Aminobutyric Acid Aminotransferase; KCC2, Potassium-Chloride Cotransporter 2",CNS; epilepsy; neuropsychiatric disorders; neurodevelopmental disorders; neurodegenerative disorders,enzyme; ion channels,Phase 1; Preclinical,Yes,developing a next generation of targeted small molecule therapies,https://ovidrx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aktis oncology inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,AKY-1189,"Nectin-4, Nectin Cell Adhesion Molecule 4",oncology,other,Phase 1,No,,,No,,,Yes,miniprotein radioconjugate,https://www.prnewswire.com/news-releases/aktis-oncology-announces-175-million-oversubscribed-series-b-financing-to-further-advance-its-proprietary-radiopharmaceutical-pipeline-302261656.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,radiopharmaceuticals,https://www.prnewswire.com/news-releases/aktis-oncology-announces-175-million-oversubscribed-series-b-financing-to-further-advance-its-proprietary-radiopharmaceutical-pipeline-302261656.html
can-fite biopharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Namodenoson; Piclidenoson; CF602,"A3AR, A3 Adenosine Receptor",oncology; liver diseases; inflammatory diseases,gpcr,Phase 3,Yes,developing orally bioavailable small molecule therapeutic products,https://www.cnbc.com/quotes/CANF,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases",https://www.cnbc.com/quotes/CANF
chiasma inc,2021-05-05 11:00:00,No,Oleogel-S10; Mycapssa; AP103,Dystrophic Epidermolysis Bullosa; Acromegaly; Neuroendocrine Tumors,rare diseases; genetic disorders; oncology,other,Preclinical; Approved; Marketed,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bird rock bio inc,"Error: Connection failed - HTTPSConnectionPool(host='ir.skyebioscience.com', ",Yes,Nimacimab; Namacizumab; Gerilimzumab,"IL-6, Interleukin-6",renal diseases; diabetic kidney disease; fatty liver disease; rheumatoid arthritis,cytokine,Phase 2,Yes,"Previous small molecule inverse agonists to the CB1 receptor demonstrated significant benefits in inflammation, metabolism and fibrosis",https://www.prnewswire.com/news-releases/bird-rock-bio-announces-corporate-name-change-from-ruiyi-inc-300192745.html,No,,,No,,,Yes,RYI-018 is a first in class inverse agonist antibody to the CB1 receptor; gerilimzumab is a novel anti-IL-6 antibody,https://www.prnewswire.com/news-releases/bird-rock-bio-announces-corporate-name-change-from-ruiyi-inc-300192745.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,
captor therapeutics sa,2025-10-10 07:23:39,Yes,Everolimus; Ct-01,Disease Name,oncology,Not specified,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,targeted protein degradation,https://ch.linkedin.com/company/captortherapeutics,No,,
emtora biosciences,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,eRapa,"mTOR, Mammalian Target Of Rapamycin",oncology; rare diseases,kinases,Phase 3,Yes,"rapamycin, eRapa™",https://www.linkedin.com/company/emtora-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
transition therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
innate pharma sa,Error: Connection failed - 403 Client Error: Forbidden for url: https://pitch,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates,https://www.linkedin.com/company/innate-pharma,No,,,No,,,No,,,Yes,Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology,https://www.linkedin.com/company/innate-pharma,No,,,No,,,Yes,"Innate has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering",https://www.linkedin.com/company/innate-pharma
ankasa regenerative therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.o,Yes,ALETA-001; AUTO1/22; AUTO6NG; AVC-201; TAC101-CLDN18.2; AlloNK; BST02; IDP-023; AMTAGVI; OPC1; CASGEVY,"CD19; CD22; GD2; CD123; CLDN18.2; CD20; FSHR, Follicle-Stimulating Hormone Receptor; Lupus Nephritis; Liver Cancer; Non-Hodgkin's Lymphoma; Multiple Myeloma; PD-1, Programmed Cell Death Protein 1; BCL11A, B-Cell Lymphoma/Leukemia 11A",oncology; hematologic malignancies; solid tumors; autoimmune diseases; rare diseases; CNS; regenerative medicine,immune checkpoint; cytokine; other,Phase 1; Phase 2; Phase 3; Approved,No,,,No,,,Yes,Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans,https://ankasaregenerativetherapeutics.com/,No,,,No,,,No,,,No,,,Yes,Developing novel protein-based stem cell activation therapies to improve tissue repair and regeneration,https://ankasaregenerativetherapeutics.com/,No,,,No,,,No,,
iterion therapeutics inc,2025-10-16 12:30:04,Yes,Tegavivint,"TBL1, Transducin Beta-like Protein One",oncology,other,Phase 1/2a,Yes,developing novel small-molecule therapies that target the Wnt/β-catenin signaling pathway,https://www.linkedin.com/company/iterion-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
xwpharma ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.xwpharma.com', port=",Yes,Valiloxybate,"GABA-B, Gamma-Aminobutyric Acid Type B Receptor",CNS; sleep disorders,gpcr,Preclinical,Yes,small molecule drug candidates,https://www.linkedin.com/company/xwlabs,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
vaderis therapeutics ag,No timestamp found,No,VAD044,"AKT, Protein Kinase B",rare diseases; vascular malformations,kinases,Phase 2,Yes,"oral, once-daily allosteric AKT-inhibitor",https://curehht.org/press-release-vaderis-receives-fda-fast-track-designation-for-treatment-of-hht/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
onconano medicine inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,therapeutic payloads directly to the tumor site... various payloads from small molecules to large biologics,https://www.linkedin.com/company/onconano-medicine,No,,,Yes,various payloads from small molecules to large biologics,https://www.linkedin.com/company/onconano-medicine,No,,,Yes,polymer drug conjugates (PDCs)...transform cancer treatment beyond today's antibody-drug conjugates,https://www.linkedin.com/company/onconano-medicine,No,,,No,,,No,,,No,,,No,,,Yes,nanotechnology platform...precisely deliver anti-cancer payloads to the tumor microenvironment,https://www.linkedin.com/company/onconano-medicine
epion therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.newworldangels.com',",No,EpiSmart,"Disease Name, Keratoconus",Ophthalmology,other,Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
anwita biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='anwitabio.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,Yes,"improved cytokines (Exenokines, Mableukins etc)",https://www.linkedin.com/company/anwitabio,Yes,tumor-targeting antibody drug conjugates,https://www.linkedin.com/company/anwitabio,Yes,tumor-targeting antibody drug conjugates,https://www.linkedin.com/company/anwitabio,No,,,No,,,No,,,No,,,No,,,No,,
tachyon therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.biospace.com', port=",Yes,Zavondemstat; TACH101,"KDM4, Histone Lysine Demethylase 4",oncology,enzyme,Phase 1,Yes,first-in-class compounds,https://www.linkedin.com/company/tachyon-therapeutics,No,,,No,,,Yes,collaboration with AbCellera to develop novel antibody therapeutic targeting TGF-β Superfamily Member,https://tachyontx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
medeor therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,MDR-101,Not specified,transplantation,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,chimerism would provide significant clinical benefit,https://www.linkedin.com/company/medeor-therapeutics,No,,,No,,,No,,
beam therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"mRNA therapeutics, RNA, DNA",https://www.linkedin.com/company/beamtx,Yes,"gene therapy, gene editing, CRISPR, CRISPR Cas9, AAV vectors, ex vivo, in vivo, cell therapy",https://www.linkedin.com/company/beamtx,No,,,No,,,Yes,"lipid nanoparticles, LNP, viral delivery, nanoparticles formulation",https://www.linkedin.com/company/beamtx
minovia therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",Yes,MNV-201,Not specified,rare diseases; age-related diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Mitochondrial Augmentation Technology (MAT) is a cell therapy platform,https://www.linkedin.com/company/minoviatherapeutics,No,,,No,,,Yes,developing robust analytical methods to measure cellular mitochondrial function,https://www.linkedin.com/company/minoviatherapeutics
oruka therapeutics inc,2025-09-18 15:34:29,No,ORKA-001; ORKA-002,"IL-23p19, Interleukin-23 p19 subunit; IL-17A/F, Interleukin-17A and Interleukin-17F",dermatology; immunology,cytokine,Phase 1,No,,,No,,,No,,,Yes,long-acting anti-IL-23p19 antibody,https://www.linkedin.com/company/oruka-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,
keymed biosciences inc,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,CM313,"CD38, Cluster of Differentiation 38",autoimmune disorders; oncology,immune checkpoint,Phase 3,No,,,No,,,No,,,Yes,anti-IL-4Rα monoclonal antibody,https://www.linkedin.com/company/keymed-biosciences,No,,,No,,,No,,,No,,,No,,,No,,,No,,
numab therapeutics ag,2025-01-13 00:00:00,Yes,Not specified,Not specified,oncology; immunology,immune checkpoint,Not specified,No,,,No,,,No,,,Yes,multi-specific antibodies in immunology and cancer,https://www.bakermckenzie.com/en/newsroom/2025/01/numab-therapeutics-in-series-c-financing-round,No,,,No,,,No,,,No,,,No,,,No,,,No,,
alentis therapeutics ag,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.b,Yes,ALE.P02,Not specified,oncology,Not specified,Phase 1,No,,,No,,,No,,,Yes,specific antibodies against Claudin-1,https://www.swissbiotech.org/listing/alentis-therapeutics-ag/,Yes,antibody-drug conjugates (ADCs),https://www.linkedin.com/company/alentis-therapeutics/,No,,,No,,,No,,,No,,,No,,,No,,
beigene (suzhou) co ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Tislelizumab; Zanubrutinib; Sonrotoclax,"PD-1, Programmed Cell Death Protein 1; BTK, Bruton Tyrosine Kinase; BCL2, B-cell Lymphoma 2",oncology; hematologic malignancies; gastrointestinal cancers; lung cancers; other cancers,immune checkpoint; kinases; other,Approved; Phase 3,Yes,expanding pipeline of small molecule medicines and drug candidates,https://www.turnerandtownsend.com/outcomes/beigene-manufacturing-facility-china/,No,,,No,,,Yes,Phase 2 mAb Transfer from External Vendor,https://beonemedicines.com/about/manufacturing/,Yes,Antibody Drug Conjugates Pipeline,https://beonemedicines.com/,No,,,No,,,No,,,No,,,Yes,Pioneering Protein Degradation with CDACs,https://beonemedicines.com/about/manufacturing/,No,,
beigene ltd,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,BTK inhibitor,https://www.linkedin.com/company/beigene,No,,,No,,,Yes,PD-1 inhibitor,https://www.linkedin.com/company/beigene,Yes,Antibody Drug Conjugates,https://beonemedicines.com/,No,,,No,,,No,,,No,,,Yes,chimeric degradation activation compounds (CDACs),https://www.linkedin.com/company/beigene,No,,
bluejay therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.crunchbase.com', por",Yes,BJT-778; BJT-628; BJT-188,"HBsAg, Hepatitis B Surface Antigen",infectious diseases; liver diseases,other,Phase 3,Yes,liver-targeted fatty acid synthase (FASN) inhibitor,https://bluejaytx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
sionna therapeutics inc,2025-10-15 18:36:27,No,Not specified,"NBD1, Nucleotide Binding Domain 1 of CFTR; ICL4, Intracellular Loop 4 of CFTR; TMD1, Transmembrane Domain 1 of CFTR",rare diseases,other,Phase 1,Yes,advancing a pipeline of small molecules engineered to correct the defects caused by F508del,https://www.sionnatx.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
erasca inc,2025-09-30 16:53:49,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,Yes,pan-KRAS inhibitor ERAS-4001,https://www.linkedin.com/company/erasca,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
genfleet therapeutics (shanghai) inc,"Error: Connection failed - HTTPSConnectionPool(host='synapse.patsnap.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
kuur therapeutics ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.ppf.eu', port=443): ",Yes,KUR-501; KUR-502; KUR-503,"GD2; CD19; GPC3, Glypican-3",oncology,immune checkpoint,Phase 1; Phase 1; Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,off-the-shelf engineered CAR-NKT cell therapies,https://www.linkedin.com/company/kuurtx,No,,,No,,,No,,
tectonic therapeutic inc,2025-09-19 14:46:31,Yes,TX45,"RXFP1, Relaxin Family Peptide Receptor 1",cardiovascular,gpcr,Phase 1,No,,,No,,,Yes,discovery and development of therapeutic proteins,https://www.linkedin.com/company/tectonictx,Yes,discovery and development of therapeutic proteins and antibodies,https://www.linkedin.com/company/tectonictx,No,,,Yes,"lead asset, TX45, is an Fc-relaxin fusion molecule",https://www.nasdaq.com/events/tectonic-therapeutic-inc-rings-closing-bell,No,,,No,,,No,,,No,,,No,,
third harmonic bio inc,2025-04-14 11:55:05,No,THB335,"KIT, Mast/Stem Cell Growth Factor Receptor",immunology; dermatology; respiratory; gastrointestinal inflammatory diseases,kinases,Phase 1,Yes,oral mast cell inhibitor,https://www.biopharmadive.com/news/third-harmonic-bio-dissolution-strategic-alternatives/745263/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immunoact pvt ltd,Error: Connection failed - HTTPSConnectionPool(host='www.biospectrumasia.com',Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"Gene-modified Cell Therapies, CAR-T cell therapy, NexCAR19",https://in.linkedin.com/company/immunoact,No,,,No,,,No,,
nanobiotix sa,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,JNJ-1900; NBTXR3,Not specified,oncology,other,Phase 3; Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
purple biotech ltd,"Error: Connection failed - HTTPSConnectionPool(host='finance.yahoo.com', port",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
immune pharmaceuticals inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,CagriSema,"GLP-1, Glucagon-Like Peptide-1; Amylin",cardiometabolic; obesity,gpcr; other,Phase 3,No,,,No,,,No,,,Yes,fully human monoclonal antibody,https://www.linkedin.com/company/immune-pharmaceuticals-ltd-,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"NanoCyclo, a topical formulation of cyclosporine",https://www.linkedin.com/company/immune-pharmaceuticals-ltd-
panolos bioscience,2021-06-17 00:00:00,Yes,PB101; PKB01; PB203,"VEGF, Vascular Endothelial Growth Factor; Immune checkpoint molecules",oncology; immunology,cytokine; immune checkpoint,Phase 1,No,,,No,,,Yes,multi-specific therapeutic proteins development,https://www.prnewswire.com/news-releases/chime-biologics-announced-global-strategic-cooperation-with-panolos-bioscience-to-advance-multi-specific-therapeutic-proteins-development-301935948.html,Yes,mono- or multi-specific antibody therapeutics,https://www.linkedin.com/company/panolos-bioscience/,No,,,No,,,No,,,No,,,No,,,No,,,No,,
proviva therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
aravive inc,2024-01-17 16:09:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
opsona therapeutics ltd (inactive),"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",Yes,Not specified,"TLRs, Toll-Like Receptors; Inflammasome Signalling",immunology; oncology; infectious diseases,other,Not specified,Yes,small molecules,https://www.irishtimes.com/business/health-pharma/biopharma-start-up-co-founded-by-tcd-professor-raises-30m-1.3658569,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,proteolysis targeting chimera,https://www.irishtimes.com/business/health-pharma/biopharma-start-up-co-founded-by-tcd-professor-raises-30m-1.3658569,No,,
silenseed ltd,2023-06-21 07:18:58,Yes,CPI-613; Masitinib; EndoTAG-1; SM-88; Pamrevlumab; Eryaspase; AVB-500,Not specified,oncology,Not specified,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,Yes,RNAi-based treatments and therapeutics,https://en.tgt.co.il/project-35/silenseed/,No,,,No,,,No,,,Yes,Targeted Drug Delivery,https://silexion.com/
synairgen plc,2025-01-16 16:17:28,No,Not specified,Not specified,infectious diseases,Not specified,Not specified,No,,,No,,,Yes,investigative inhaled IFN-β candidate,https://uk.linkedin.com/company/synairgen,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pikralida sp zoo,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",Yes,PKL-021; TRX-03; TRX-06; TRX-12,"MMP, Matrix Metalloprotease; Inflammation; Blood-Brain Barrier Disruption; Neuronal Loss",neurology; toxicology; veterinary medicine,enzyme; other,Phase 2,Yes,"PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor",https://pl.linkedin.com/company/pikralida,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,Snakebite envenoming – innovative pre-hospital treatment solutions,https://pl.linkedin.com/company/pikralida
pharmain corp,"Error: Connection failed - HTTPSConnectionPool(host='www.sbir.gov', port=443)",No,PHIN-214,Not specified,liver diseases; oncology,other,Phase 1,No,,,Yes,peptide engineering,https://pharmain.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
omeicos therapeutics gmbh,2018-12-02 00:00:00,No,OMT-28,"AMPK/SIRT-1/PGC1-alpha, AMP-activated protein kinase/Sirtuin-1/Peroxisome proliferator-activated receptor gamma coactivator 1-alpha",rare diseases; metabolic diseases,enzyme,Phase 2,Yes,OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts.,https://www.linkedin.com/company/omeicos-therapeutics-gmbh,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
pentixapharm holding ag,2025-10-18 00:00:00,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
bharat biotech ltd,No timestamp found,No,altSonflex1-2-3,"Disease Name, Shigellosis",infectious diseases,other,Phase 2,No,,,No,,,Yes,"India’s first recombinant Epidermal Growth Factor (REGEN-D®) to combat diabetic foot ulcers, burns",https://in.linkedin.com/company/bharat-biotechil,No,,,No,,,No,,,No,,,No,,,Yes,"Typhoid Conjugate vaccine, Rotavirus vaccine, Hepatitis B vaccine, Rabies vaccine, Influenza A(H1N1) vaccine, Japanese Encephalitis (JE) vaccine, Polio vaccine, innovative vaccine, COVAXIN",https://in.linkedin.com/company/bharat-biotechil,No,,,No,,
u.s. stem cell inc,2021-03-22 00:00:00,No,Omisirge; GDA-201,"Disease Name, Hematologic Malignancies; Disease Name, Non-Hodgkin Lymphoma",oncology; hematology,other; cytokine,Approved; Phase 1/2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,autologous cell therapies for the treatment of chronic and acute heart damage,https://www.cnbc.com/quotes/USRM,No,,,No,,,Yes,regenerative medicine solutions for their patients,https://us-stemcell.com/
ascentage pharma group inc,2025-10-07 16:18:05,Yes,olverembatinib; lisaftoclax; APG-2449; APG-5918; alrizomadlin,"BCR-ABL, Breakpoint Cluster Region-Abelson Tyrosine Kinase; Bcl-2, B-cell Lymphoma 2; FAK, Focal Adhesion Kinase; ALK, Anaplastic Lymphoma Kinase; ROS1, ROS Proto-Oncogene 1; SDH, Succinate Dehydrogenase",oncology; hematologic malignancies; solid tumors,kinases; enzyme; other,Approved; Phase 3,Yes,first- and best-in-class small molecule therapies,https://biotuesdays.com,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
epizyme inc,"Error: Connection failed - HTTPSConnectionPool(host='www.ipsen.com', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
inmune bio inc,"Error: Connection failed - HTTPSConnectionPool(host='www.reddit.com', port=44",No,XPro; INKmune; CORDStrom,"sTNF, Soluble Tumor Necrosis Factor; NK Cells; Disease Name",CNS; oncology; rare diseases,cytokine; other; other,Phase 2; Phase 1/2; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.",https://www.linkedin.com/company/inmune-bio-inc,No,,,No,,,No,,
avecho biotechnology ltd,2025-08-25 22:33:34,No,Suvorexant; Daridorexant; YZJ-1139; Escitalopram Oxalate,Not specified,CNS,Not specified,Phase 3; Phase 2; Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,drug delivery system called Tocopheryl Phosphate Mixture (TPM®),https://au.linkedin.com/company/avecholtd
lygenesis inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,regenerative cell therapy,https://www.prnewswire.com/news-releases/lygenesis-announces-first-patient-dosed-in-its-phase-2a-clinical-trial-of-a-first-in-class-regenerative-cell-therapy-for-patients-with-end-stage-liver-disease-302105734.html,No,,,No,,,Yes,organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs,https://www.linkedin.com/company/lygenesis
syndesi therapeutics sa,"Error: Connection failed - HTTPSConnectionPool(host='www.pearceip.law', port=",Yes,SDI-118,"SV2A, Synaptic Vesicle Protein 2A",CNS; neuropsychiatric disorders; neurodegenerative disorders,other,Phase 1,Yes,"The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies","https://news.abbvie.com/2022-03-01-AbbVie-Acquires-Syndesi-Therapeutics,-Strengthening-Neuroscience-Portfolio",No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
multitude therapeutics inc,2024-08-20 03:30:00,No,ADCE-T02; AMT-562,"TF, Tissue Factor; HER3, Human Epidermal Growth Factor Receptor 3",oncology,enzyme; other,Phase 1,No,,,No,,,No,,,Yes,novel cancer and immune cell surface targets discovered by monoclonal antibody arrays,https://www.linkedin.com/company/multitude-therapeutics,Yes,antibody-drug conjugates (ADCs),https://www.multitudetherapeutics.info/,No,,,No,,,Yes,CAR-Ts and immuno-oncology antibodies for solid and hematological tumors,https://www.linkedin.com/company/multitude-therapeutics,No,,,No,,,No,,
multitude therapeutics inc (inactive),"Error: Connection failed - HTTPSConnectionPool(host='adcendo.com', port=443):",Yes,ADCE-T02,"TF, Tissue Factor",oncology,enzyme,Phase 1,No,,,No,,,No,,,Yes,antibody discovery capability for cancer immunotherapy,https://www.linkedin.com/company/multitude-therapeutics,Yes,developing novel antibody-drug conjugates (ADC),https://www.linkedin.com/company/multitude-therapeutics,No,,,No,,,Yes,developing novel CAR-Ts,https://www.linkedin.com/company/multitude-therapeutics,No,,,No,,,Yes,immuno-oncology antibodies for solid and hematological tumors,https://www.linkedin.com/company/multitude-therapeutics
intarcia therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='not%20found', port=443):",No,ITCA 650,"GLP-1, Glucagon-Like Peptide-1",metabolic diseases,gpcr,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,drug-eluting implant,https://www.biopharmadive.com/news/intarcia-i2o-diabetes-fda-series-a-kurt-graves/692286/
hdt bio corp,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,Yes,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,Yes,create antibodies and T-cells that fight cancer and infectious diseases,https://www.linkedin.com/company/hdt-bio,No,,,No,,,Yes,advancing RNA therapeutics and immunology,https://www.linkedin.com/company/hdt-bio,No,,,Yes,develop vaccines and therapies for infectious diseases and cancer,https://www.linkedin.com/company/hdt-bio,No,,,Yes,"LION™ nanocarriers, HDT's proprietary platform",https://www.linkedin.com/company/hdt-bio
esperare foundation,2025-09-25 11:52:16,Yes,Not specified,Not specified,rare diseases; pediatric-onset rare diseases,Not specified,Preclinical,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,EspeRare focuses on rescuing and repositioning discontinued therapies with high potential to address severe and currently neglected therapeutic needs of children affected by rare genetic diseases.,https://ch.linkedin.com/company/esperare-foundation
armgo pharma inc,"Error: Connection failed - HTTPSConnectionPool(host='www.mda.org', port=443):",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
asklepios biopharmaceutical inc,"Error: Connection failed - HTTPSConnectionPool(host='www.bayer.com', port=443",Yes,AB-1003,"Disease Name, Limb-Girdle Muscular Dystrophy 2I/R9",neuromuscular diseases,other,Phase 1; Phase 2,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,gene therapy platform includes an industry-leading proprietary cell line manufacturing process called Pro10™ and an extensive adeno-associated virus (AAV) capsid and promoter library,https://www.bayer.com/media/en-us/bayer-acquires-asklepios-biopharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy/,No,,,No,,,No,,
xiamen tebao biological engineering co ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.yicaiglobal.com', po",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
logicbio therapeutics inc,"Error: Connection failed - HTTPSConnectionPool(host='www.astrazeneca-us.com',",Yes,LB-001,"Disease Name, Methylmalonic Acidemia (MMA)",rare diseases,other,Phase 1/2,No,,,No,,,Yes,therapeutic protein expression levels,https://www.marketscreener.com/quote/stock/LOGICBIO-THERAPEUTICS-INC-46676834/,No,,,No,,,No,,,No,,,Yes,genome editing and gene delivery platforms,https://www.marketscreener.com/quote/stock/LOGICBIO-THERAPEUTICS-INC-46676834/,No,,,No,,,No,,
harvard apparatus regenerative technology inc,2025-08-14 00:00:00,No,Cellspan Esophageal Implant,Severe Esophageal Disease,gastrointestinal; rare diseases,other,Phase 1,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs,https://www.cnbc.com/quotes/HRGN,No,,,No,,,Yes,development of organ replacement therapies using cellular scaffolds and tissue engineering,https://www.linkedin.com/company/hregen-inc
tvax biomedical inc,2022-11-18 00:00:00,No,TVI-Brain-1,"Disease Name, Glioblastoma Multiforme (GBM)",oncology,other,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"T cell therapy, Vaccine-enhanced adoptive T cell immunotherapy",https://www.linkedin.com/company/tvax-biomedical-inc-,Yes,Vaccine-enhanced adoptive T cell immunotherapy,https://www.linkedin.com/company/tvax-biomedical-inc-,No,,,No,,
eloxx pharmaceuticals inc,2023-10-19 00:00:00,No,ELX-02; ZKN013,Collagen IV; Collagen VII/LAMB3; APC,rare diseases; genetic diseases; cystic fibrosis; kidney diseases; ocular genetic disorders,other,Phase 2; Preclinical,Yes,small molecule drug candidate,https://www.linkedin.com/company/eloxx-pharmaceuticals,No,,,Yes,restore production of full-length functional proteins,https://www.linkedin.com/company/eloxx-pharmaceuticals,No,,,No,,,No,,,Yes,RNA-modulating drug candidates,https://www.linkedin.com/company/eloxx-pharmaceuticals,No,,,No,,,No,,,No,,
cerrx inc,"Error: Connection failed - HTTPSConnectionPool(host='tracxn.com', port=443): ",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
treeway bv,"Error: Connection failed - HTTPSConnectionPool(host='www.alzdiscovery.org', p",Yes,Zolgensma,Disease Name,rare diseases; neurodegenerative disorders,Not specified,Approved,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,collaboration with uniQure to develop a gene therapy treatment for ALS,https://www.drugtargetreview.com/organisations/treeway-b-v/,No,,,No,,,No,,
allegheny-singer research institute,"Error: Connection failed - HTTPSConnectionPool(host='taggs.hhs.gov', port=443",No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
endocyte inc (inactive),2018-10-18 00:00:00,Yes,177Lu-PSMA-617,"PSMA, Prostate-Specific Membrane Antigen",oncology,enzyme,Phase 3,No,,,No,,,No,,,No,,,Yes,drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells,https://www.globenewswire.com/news-release/2018/10/18/1623094/14452/en/Endocyte-Enters-Into-Agreement-to-be-Acquired-by-Novartis-AG-for-2-1-Billion.html,No,,,No,,,Yes,Endocyte also expects to have an Investigational New Drug application submitted in the fourth quarter of 2018 for its adaptor-controlled CAR T-cell therapy,https://www.globenewswire.com/news-release/2018/10/18/1623094/14452/en/Endocyte-Enters-Into-Agreement-to-be-Acquired-by-Novartis-AG-for-2-1-Billion.html,No,,,No,,,Yes,Radiopharmaceuticals such as 177 Lu-PSMA-617 are innovative medicinal formulations containing radioisotopes that are used clinically for both diagnosis and therapy,https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms
angiocrine bioscience inc,2025-10-03 00:00:00,No,AB-205; E-CEL UVEC (AB-207),Not specified,oncology; immunology; regenerative medicine,other,Phase 1; Phase Ib/II,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,"engineered cellular therapies, genetically modified human endothelial cells, hematopoietic stem cell gene therapy",https://www.linkedin.com/company/angiocrine-bioscience-inc-,No,,,No,,,No,,
"facet solutions, inc. (inactive)",2010-05-22 00:00:00,No,Iberdomide; Mezigdomide,"CRBN, Cereblon E3 Ligase",oncology,enzyme,Phase 3,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
providence therapeutics inc,Error: Connection failed - 403 Client Error: Forbidden for url: https://www.c,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
amcure gmbh,2017-10-01 00:00:00,Yes,AMC303,"CD44v6, Splice Variant of CD44 Family of Transmembrane Glycoproteins",oncology,other,Phase 1,No,,,Yes,"allosteric inhibitor of CD44v6, AMC303",https://www.linkedin.com/company/amcure-gmbh,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
addex therapeutics ltd,2025-09-30 08:38:13,Yes,ADX71149; dipraglurant; GABAB PAM; mGlu7 NAM; M4 PAM; mGlu2 NAM,"mGlu2, Metabotropic Glutamate Receptor 2; mGlu5, Metabotropic Glutamate Receptor 5; GABAB, Gamma-Aminobutyric Acid Type B Receptor; mGlu7, Metabotropic Glutamate Receptor 7; M4, Muscarinic Acetylcholine Receptor 4",neurological disorders; epilepsy; post-stroke recovery; substance use disorder; chronic cough; stress related disorders; schizophrenia; psychosis; mild neurocognitive disorders; depression,gpcr,Phase 2; Preclinical,Yes,novel orally available small molecule drugs known as allosteric modulators,https://ch.linkedin.com/company/addex-therapeutics,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
helix biopharma corp,2025-10-16 14:28:25,Yes,L-DOS47; LEUMUNA; GEMCEDA,"CEACAM6, Carcinoembryonic Antigen-related Cell Adhesion Molecule 6",oncology,other,Phase 2,Yes,oral gemcitabine chemotherapy,https://ca.linkedin.com/company/helix-biopharma-corp,No,,,No,,,Yes,clinical-stage antibody-enzyme conjugate (AEC),https://ca.linkedin.com/company/helix-biopharma-corp,Yes,clinical-stage antibody-enzyme conjugate (AEC),https://ca.linkedin.com/company/helix-biopharma-corp,No,,,No,,,No,,,No,,,No,,,No,,
diffusion pharmaceuticals inc,"Error: Connection failed - HTTPSConnectionPool(host='en.wikipedia.org', port=",No,Neflamapimod,"p38MAPK alpha, p38 Mitogen-Activated Protein Kinase Alpha",CNS; neurodegenerative diseases,kinases,Phase 2,Yes,novel therapies that enhance the body’s ability to deliver oxygen,https://www.globenewswire.com/news-release/2023/08/15/2725889/0/en/Diffusion-Pharmaceuticals-Stockholders-Approve-Merger-with-EIP-Pharma.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
initiator pharma as,2022-05-13 00:00:00,Yes,IPED2015; IP2018; IPTN2021; IP2015; IP2016; IP2017,"DAT, Dopamine Transporter; NAT, Noradrenaline Transporter; SERT, Sodium-Dependent Serotonin Transporter",CNS; erectile dysfunction; neuropathic pain; female sexual dysfunction,other,Phase 2,Yes,unique monoamine reuptake inhibitors,https://www.initiatorpharma.com/,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
cannamore biotechs ltd,"Error: Connection failed - HTTPSConnectionPool(host='www.ivc-online.com', por",No,IcBD-01,"Disease Name, Ulcerative Colitis",gastroenterology,other,Phase 2,Yes,CBD-based patent protected formulation,https://www.prnewswire.com/il/news-releases/cannamore-biotechs-announces-successful-completion-of-phase-2a-clinical-trial-for-cannabidiol-based-treatment-for-ulcerative-colitis-302202525.html,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,Yes,cannabinoid-based pharmaceutical drugs,https://www.prnewswire.com/il/news-releases/cannamore-biotechs-announces-successful-completion-of-phase-2a-clinical-trial-for-cannabidiol-based-treatment-for-ulcerative-colitis-302202525.html
cost-bry pty ltd,Error: Connection failed - HTTPSConnectionPool(host='statedevelopment.sa.gov.,No,Not specified,Not specified,Not specified,Not specified,Not specified,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,,No,,
